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ABSTRACT 
 
 
 The first part (Chapter 1 and 2) of this dissertation presents a novel combination 
study of melanoma therapy. Acquired clinical resistance to vemurafenib, a selective 
BRAFV600E inhibitor, arises frequently after short term chemotherapy. Since the 
inhibitions of targets in the RAF-MEK-ERK pathway result in G0/G1 cell cycle arrest, 
vemurafenib-resistant cancer cells are expected to escape this cell cycle arrest and 
progress to subsequent G2/M phase. We hypothesized that a combined therapy using 
vemurafenib with a G2/M phase blocking agent will trap resistant cells and overcome 
vemurafenib resistance. To test this hypothesis, we first determined the combination 
index (CI) values of our novel tubulin inhibitor ABI-274 and vemurafenib on parental 
human A375 and MDA-MB-435 melanoma cell lines to be 0.32 and 0.1, respectively, 
suggesting strong synergy for the combination. We then developed an A375RF21 subline 
with significant acquired resistance to vemurafenib and confirmed the strong synergistic 
effect. Next we studied the potential mechanisms of overcoming vemurafenib resistance. 
Flow cytometry confirmed that the combination of ABI-274 and vemurafenib 
synergistically arrested cells in G1/G2/M phase, and significantly increased apoptosis in 
both parental A375 and the vemurafenib-resistant A375RF21 cells. Western blot analysis 
revealed that the combination treatment effectively reduced the level of phosphorylated 
and total AKT, activated the apoptosis cascade, and increased cleaved caspase-3 and 
cleaved PARP, but had no significant influence on the level of ERK phosphorylation. 
Finally, in vivo co-administration of vemurafenib with ABI-274 showed strong 
synergistic efficacy in the vemurafenib-resistant xenograft model in nude mice. Overall, 
these results offer a rational combination strategy to significantly enhance the therapeutic 
benefit in melanoma patients who inevitably become resistant to current BRAF inhibition 
therapy. 
 
 The second part (Chapter 3 to 5) of this dissertation focuses on the discovery of a 
series of small molecule survivin inhibitors. Inhibitors of apoptosis (IAP) proteins are 
widely considered as promising cancer drug targets, especially for drug-resistant tumors. 
Mimicking the IAP-binding motif of second mitochondria-derived activator of caspases 
(Smac) is a rational strategy to design potential IAP inhibitors. In this report, we used the 
bioactive conformation of AVPI tetrapeptide in the N-terminus of Smac as a template and 
performed a shape-based virtual screening against a drug-like compound library to 
identify novel IAP inhibitors. Top hits were subsequently docked to available IAP crystal 
structures as a secondary screening followed by validation using in vitro biological 
assays. Four novel hit compounds were identified that potently inhibited cell growth in 
two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) 
cancer cell lines. The best compound, UC-112, has IC50 values ranging from 0.7 to 3.4 
μM. UC-112 also potently inhibits the growth of P-glycoprotein (Pgp) overexpressed 
multidrug-resistant cancer cells, strongly activates capase-3/7 and caspase-9 activities, 
and selectively down-regulates survivin level at a concentration as low as 1 μM. Co-
incubation of UC-112 with a known proteasome inhibitor (MG132) rescued survivin 
inhibition, consistent with the anticipated mechanism of action for UC-112. As a single 
agent, UC-112 strongly inhibits tumor growth and reduces both XIAP and survivin levels 
 v 
in an A375 human melanoma xenograft model in vivo. Three analogs generated from 
UC-112 structural modification along with template compound UC-112 were submitted 
to NCI-60 cancer cell line screening. The results indicated that structural modification of 
UC-112 to give our best compound MX106 has improved activity by four fold (2.2 μM 
for UC-112 vs. 0.5 μM for MX106, average GI50 values over all cancer cell lines in the 
NCI-60 panel).Western blot analyses demonstrated the new compounds maintained high 
selectivity for survivin inhibition over other members in the inhibitiors of apoptosis 
protein family. When tested in an A375 human melanoma xenograft model, the most 
active compound MX106 effectively suppressed tumor growth and strongly induced 
cancer cell apoptosis in tumor tissues. Taken together, this novel scaffold is promising for 
the development of selective survivin inhibitors as potential anticancer agents. 
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CHAPTER 1.    EMERGING DRUG COMBINATION APPROACHES IN 
MELANOMA THERAPY* 
 
 
1.1 Introduction 
 
The FDA approvals of ipilimumab targeting the cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), pembrolizumab targeting the programmed cell death 
protein 1 (PD-1), BRAF inhibitors vemurafenib and dabrafenib, and MEK inhibitor 
trametinib represent significant milestones in more effective treatment of advanced 
melanoma. However, it is clear that the use of these single-agent therapies have limitation 
clinically. For example, ipilimumab only showed 4.5% objective response rate when used 
alone in a Phase II clinical trial (1). The efficacy of vemurafenib lasts only 6.7 months 
before the disease relapses especially in patients with metastatic melanoma (2). 
Therefore, rational combination approaches are strongly preferred in order to improve the 
overall patient progression-free survival (PFS), overcome or delay the development of 
multi-drug resistance and reduce the incidents of side effects (3-6). 
 
In this chapter, we will summarize the emerging combination therapy approaches 
from both clinical trial and preclinical research in the past five years (7). 
 
 
1.2 Combination of Kinase Inhibitors for Melanoma Treatment 
 
 
1.2.1 Combined Inhibitions Targeting Components within the Mitogen-activated 
Protein Kinase (MAPK) Signaling Pathway 
 
1.2.1.1 Targeting BRAF: mechanism of action, toxicity and drug resistance 
 
BRAF is a serine/threonine growth signal transduction protein kinase from RAF 
family which plays important roles in the RAS/RAF/MEK/ERK pathway and directs cell 
division, proliferation and secretion (8). BRAF inhibitors (BRAFi) are ATP-competitive 
ligands which inactivate the function of BRAF protein by either stabilizing the inactive 
form of kinase domain (sorafenib) or preferentially inhibit the active form of the kinase 
(vemurafenib, dabrafenib) (9, 10). Various mutations of BRAF gene have been identified 
in cancers including melanoma, colorectal and ovarian cancer. Around 60% of human 
melanoma adopted the T1799A transversion in exon 15, which lead to BRAFV600E 
mutation and the over-activated monomer phosphorylation for BRAFV600E (10, 11). The 
 
 
 
* Reprinted with permission. Wang J, Miller DD and Li W. Emerging Drug Combination 
Approaches in Melanoma Therapy, Melanoma - Current Clinical Management and 
Future Therapeutics, Prof. Mandi Murph (Ed.), 2015. ISBN: 978-953-51-2036-0, InTech, 
DOI: 10.5772/59360.  
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two FDA approved BRAFi (vemurafenib and dabrafenib) selectively and potently block 
the activation of BRAFV600E and thus inhibit the MAPK signaling pathway.  
 
These drugs show very high clinical efficacy in metastatic melanoma patients 
harboring the BRAFV600E mutation (12-14). Interestingly, in a clinical study which treated 
43 patients with any V600 BRAF mutation including the rare V600R variant, five out of 
the six melanoma patients having V600R mutation had clinical response to the therapy of 
vemurafenib or dabrafenib (response rate 86%) (15). 
 
However, wide type BRAF melanoma tumors do not respond to vemurafenib or 
dabrafenib inhibition, although they are sensitive to the MEK inhibitors (10). 
Paradoxically, in cells with RAS mutation and wild-type BRAF, treatment with 
vemurafenib or dabrafenib will promote the formation of BRAF-CRAF heterodimer and 
lead to the activation of subsequent MEK/ERK signaling and cell proliferation (5) as 
shown in Figure 1-1. This mechanism is used to explain the observation of typical 
clinical side effects associated with the use of vemurafenib: nearly 25% of patients 
developed skin lesions and even cutaneous squamous cell carcinoma (CSCC). In 
addition, in vitro study has revealed that vemurafenib inhibits multiple off-target kinases 
including c-Jun N-terminal kinase (JNK), suppresses JNK-dependent apoptosis, and 
generates CSCC toxicity (16).  
 
1.2.1.2 Mechanisms of resistance to BRAF inhibition 
 
In general, due to alternative pathway activations and inter- and intra-patients 
melanoma genetic heterogeneity, various mechanisms of resistance to BRAF inhibition 
have been identified (11, 17-20). As we mentioned before, melanoma tumors bearing 
wide type BRAF are intrinsically resistant to vemurafenib and dabrafenib. Tumor micro-
environment also contributes to the innate resistance to BRAF inhibition in melanoma. 
For example, stromal cells secrete hepatocyte growth factor (HGF), which activates the 
HGF-receptor MET, MAPK and PI3K-AKT pathways (21). 
 
Eventually, nearly all BRAF mutated melanoma tumors develop acquired drug 
resistance upon treatment with BRAF inhibitors. The disease progression arises as early 
as two-month continuous treatment (19, 20). The mechanisms of acquired resistance to 
BRAF inhibition can be generalized into two categories: BRAFV600E-bypass mechanisms 
and MAPK-bypass mechanisms.  
 
First, the BRAFV600E-bypass mechanisms reactivate MAPK signaling and lead to 
ERK-dependent tumor cell survival and proliferation (Figure 1-2A). COT, which is 
coded by gene MAP3K8, is a MEK kinase. The overexpression of COT or amplification 
of MAP3K8 directly activates MEK signaling without the participation of RAF protein 
(22). The mutant of MEK1C121S increases catalytic capability and circumvents BRAF to 
activate basal level of ERK phosphorylation (23). Before the treatment of vemurafenib or 
dabrafenib, melanoma cells with BRAFV600E mutation have over-activated monomer 
BRAF/MEK/ERK cascade which forms an ERK-dependent negative feedback loop. This 
negative feedback loop reduces the expression of the active RAS-GTP. In the presence of  
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Figure 1-1. The mechanisms of BRAF inhibitor vemurafenib (Vem) action, 
toxicity and the interaction between melanoma cells with T lymphocytes 
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Figure 1-2. The mechanisms of acquired resistance to BRAF inhibition 
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vemurafenib or dabrafenib, ERK phosphorylation level is rapidly reduced and the feed-
back suppression on RAS activation is abolished (Figure 1-1). Therefore, eventually the 
ERK cascade level is restored through RAS over-activation. NRAS mutants including 
NRASQ61K and NRASQ61R can drive ERK activation through ARAF or CRAF homo- or 
hetero-dimers which are alternative MEK activators (24). The combinations of BRAF 
inhibition plus MEK or ERK inhibition have showed efficacy of overcoming the 
resistance through these BRAF V600E-bypass mechanisms (25-27), leading to the recent 
FDA approval of dabrafenib plus trametinib combination therapy for advanced 
melanoma.  
 
Second, the MAPK-bypass mechanisms allow melanoma cells to escape from the 
cytotoxicity of BRAF or MEK inhibition through the activation of ERK-independent 
survival pathways (Figure 1-2B). The PI3K-AKT signaling pathway can be activated 
through the overexpression of receptor tyrosine kinases (RTKs), for example, insulin-like 
growth factor 1 (IGF-1) receptor (IGF-1R) and platelet-derived growth factor receptor 
beta (PDGFRβ) (28). The elevated levels of IGF-1R, PDGFRβ or HGF can also stimulate 
another receptor tyrosine kinase, MET, and increase the activity of PI3K. Phosphatase 
tensin (PTEN) is a negative regulator of PI3K. The PTEN loss-of-function mutation 
induces the resistance of BRAF inhibition and reduces the PFS of dabrafenib therapy in 
melanoma patients due to the PI3K activation (29). Moreover, the up-regulation of cyclin 
D1 can activate cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) and make melanoma 
cells less dependent on MAPK signaling in cell cycle progressing (30). 
 
Additionally, Jaehyuk Choi et al has reported a BRAFL505H mutation which 
changes an amino acid residue in BRAF-vemurafenib interface and causes the resistance 
to vemurafenib treatment in vitro (31). Since vemurafenib is a substrate of the ATP-
binding cassette sub-family G member 2 (ABCG2), the overexpression of ABCG2 in 
BRAFV600E melanoma cell lines has caused the increasing of vemurafenib efflux in vitro 
(32). The elucidation on the mechanism of acquired-resistance to BRAFi opens a door to 
rationally design and explore the proper combination strategies to overcome or delay the 
development of BRAFi resistance. 
 
1.2.1.3 Targeting MEK: mechanism of action, toxicity and resistance 
 
Trametinib, which was approved by FDA in May 2013 as a monotherapy agent 
against advanced melanoma with BRAFV600E and BRAFV600K mutations, is a first-in-
class, orally available, allosteric (non-ATP-competitive) MEK1/MEK2 inhibitor 
(MEKi)(33, 34). It selectively inhibits MEK, the down-stream kinase protein of RAF in 
the RAS-RAF-MEK-ERK pathway. As a result, melanoma cells with acquired resistance 
to BRAFi are commonly cross-resistant to MEKi such as trametinib or selumetinib, 
another selective allosteric MEKi (25, 35). This mechanism explains the clinical trial 
results in which trametinib monotherapy fails to significantly benefit patients who have 
already developed acquired BRAFi resistance (36). In contrast to the use of a BRAFi, no 
CSCC side effects are observed among the patients received trametinib treatment in 
clinical trials (14, 33). However, similar to the use of vemurafenib, disease progression 
occurs within 6-7 months in patients receiving single-agent trametinib treatment (37). 
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Nevertheless, a retrospective analysis of 23 patients, who were first treated with MEKi 
and upon progression with a selective BRAFi, shows that the median time to progression 
(TTP) has been prolonged to 8.9 months from 4.8 months using a single-agent MEKi or 
4.4 months for a single-agent BRAFi treatment, respectively (38). However, a recent 
clinical trial indicated that if melanoma patients were treated with a BRAFi first then 
MEKi therapy, no confirmed response was observed (36). This indicates that optimal 
treatment schedule and sequence is important for the melanoma therapy targeting the 
MAPK pathway. 
 
1.2.1.4 Drug combination targeting MAPK pathway: from lab bench to 
clinical practice 
 
Given that the mechanisms of tumor cells develop resistance to BRAFi partially 
by reactivating the ERK cascade and side effects such as CSCC are RAF-dependent, 
combining BRAFi with MEKi has attracted lots of research interest in order to further 
block the MAPK signaling pathway. In vitro and murine models first show the 
synergistic anti-proliferation and anti-tumor growth effects using the combined BRAFi 
and MEKi treatment (10, 28, 39, 40). Further, this combination overcomes the acquired 
resistance to BRAFi (28, 39) in both cellular based assay and mouse xenograft models. In 
addition, the combined inhibition of BRAF-MEK suppresses the paradoxical BRAFi-
induced MAPK signal elevation in melanoma cells and reduces the incidences of skin 
lesions in a rat model (10).  
 
When it comes to the clinical trial data, the combined inhibition of BRAF-MEK 
has presented significant improvements of major patient benefits (PFS and overall 
survival). A phase I/II trial (ClinicalTrials.gov, NCT1072175) investigated the 
combination of oral dabrafenib (150 mg twice per day) plus oral trametinib (1 or 2 mg 
daily) (combination 150/1 and 150/2) versus monotherapy of dabrafenib (150 mg twice 
per day) over 108 metastatic melanoma patients bearing either V600E (92 patients) or 
V600K (16 patients) BRAF mutation (13, 37). Median PFS in combination 150/2 group 
reached 9.4 months, compared to 5.8 months in the dabrafenib monotherapy group 
(hazard ratio 0.39, 95% confidence interval 0.25 to 0.62). The incidence of CSCC 
adverse events among combination 150/2 group is non-significantly lower than that 
among monotherapy group (7% versus 19%, P = 0.09). But more frequent cases of 
pyrexia which is not common in trametinib single treatment have been reported in 
combination 150/2 group (71%, with recurrent rate 79%), as compared with dabrafenib 
monotherapy group (26%) (41). These promising data lead to an accelerated FDA 
approval of the combination of dabrafenib (BRAFi) and trametinib (MEKi) for the 
treatment of unresectable or metastatic melanoma patients with BRAF V600E or V600K 
mutation, although further phase III studies with recruitment of more patients comparing 
the combination therapy with dabrafenib or vemurafenib single treatment 
(ClinicalTrials.gov, NCT01584648, NCT01597908) are still being assessed.  
 
In addition, several ongoing phase I/II clinical trials now have shown that 
generally the combination of other BRAFi and MEKi is well tolerated in patients with or 
without receiving BRAFi treatment before (ClinicalTrials.gov, NCT01271803 
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vemurafenib (BRAFi) + cobimetinib (MEKi), NCT01543698 LGX818 (BRAFi) + 
MEK162 (MEKi)) (42-44) and overall response rate has increased comparing to the 
monotherapy groups, although the anti-tumor efficacy data haven’t been released.  
 
 
1.2.2 Combination Targeted Therapy Using Phosphatidylinositol 3-kinase 
(PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Inhibitors 
 
The activation of PI3K/AKT/mTOR pathway have been widely proved to be one 
of the major mechanisms of intrinsic or acquired resistance to both DNA-methylation 
agents (e.g. dacarbazine) and targeted BRAF inhibitor therapy (Figure 1-1). Some cell 
lines that are cross-resistant to both BRAFi and MEKi, are still sensitive to the inhibition 
of AKT/mTOR(35). On the other hand, mechanistic study revealed evidences of a 
negative crosstalk between RAF/MEK/ERK and PI3K/AKT/mTOR pathways through 
RAS kinase. Therefore, when the downstream mTOR function is blocked, PI3K will be 
able to activate MAPK pathway via a switch of RAS (45, 46). These investigations 
suggest a promising combination strategy of targeting MAPK pathway together with 
PI3K/AKT/mTOR cascade. Several preclinical studies widely proved that in MAPK 
inhibition sensitive melanoma cell lines, co-targeting PI3K/AKT/mTOR effectively 
induces cancer cell apoptosis with down-regulated anti-apoptotic BCL-2 family proteins 
(35, 47-49). Such a co-targeting strategy can also postpone the emergence of acquired 
resistance to BRAFi dabrafenib mediated by PTEN mutation or disruption (50, 51). 
Further, the dual inhibition of two pathways has successfully overcome NRAS mutation 
mediated resistance to MAPK blockade in vitro and induced xenograft tumor regression 
in vivo (35, 39, 52). Finally, the combination of vemurafenib (BRAFi) or selumetinib 
(MEKi) with BEZ235 (dual PI3K and mTORc1/2 inhibitor) has been shown to overcome 
the PDGFRβ-driven resistance to MAPK pathway inhibition (53). 
 
A series of Phase I studies have evaluated the clinical relevance of the 
combination therapy which co- targets PI3K/AKT/mTOR and RAF/MEK/ERK pathways 
in terms of the incidence on severe side effect and anti-tumor efficacy in 236 patients. 
These patients have advanced cancers including melanoma, colorectal, pancreatic and 
non-small cell lung cancers. Results from three combination groups (AKTi MK2206 + 
MEKi selumetinib, NCT01021748; AKTi GSK2141795 + MEKi trametinib, 
NCT01138085; mTOR inhibitor everolimus + MEKi trametinib, NCT 00955773) are 
compared to the single treatment groups (54). Overall, the combination therapy did not 
provide significant increase of tumor control rate (64.6% for combination, 52.7% for 
monotherapy, P = 0.16), although all five colorectal patients with co-activation of both 
pathways in combination group achieved tumor regression to varied extent between 2% 
and 64%. However, this combination strategy causes significant higher rates of drug-
related grade III and above side effects (53.9% for combination, 18.1% for monotherapy, 
P < 0.001). Furthermore, two clinical trials which involve the combination therapy of 
BRAFi or MEKi with AKTi DNE3 recently have been terminated due to the safety 
concerns of the toxic properties of DNE3 (ClinicalTrials.gov, NCT02087254 and 
NCT02095652). Nevertheless, in another ongoing phase I/II trial which measures the 
safety and efficacy of a well-tolerated pan-PI3K inhibitor BKM120 combined with 
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vemurafenib therapy, preliminary data reveals that a vemurafenib-refractory melanoma 
patient with PTEN expression achieved a 35.9% reduction in target tumor 
(ClinicalTrials.gov, NCT01512251) (55). In general, drug-related toxicity is one of the 
major issues for this cross-pathway targeted combination therapy and patients genetic 
profiling is very important to achieve the maximum objective response. 
 
 
1.2.3 Combining Targeted Therapy with Anti-angiogenic Agents 
 
Melanoma is a vascular tumor. The abnormal expression of the epidermal growth 
factor (EGF) family protein and the up-regulation of EGFR-mediated alternative survival 
pathway have critically shaped the response of melanoma to the current chemotherapy 
agents (56-59). In a recent study by Sun et al, six out of sixteen melanoma cell lines 
display acquired EGFR expression after the development of resistance to BRAFi and 
MEKi (60). Even before the FDA approval of BRAFi and MEKi, the combination of 
bevacizumab, a recombinant human monoclonal antibody VEGF inhibitor, with a 
specific chemotherapy agent (for example, fluorouracil (61) or fotemustine (62)), has 
become a first-line treatment for metastatic melanoma patients. Clinical trials that study 
the combination of anti-angiogenic agents with cytotoxic agents have achieved promising 
anti-tumor activity, although tolerability issues exist (63). VEGF blockage has been 
shown to enhance the efficacy of a GM-CSF-secreting immunotherapy in vitro (64). In 
addition, a VEGF receptor-2 inhibitor, semaxanib, prolonged both the complete and 
partial response time of an immunomodulatory drug, thalidomide, over 10 recurrent 
metastasis melanoma patients without showing significant drug-drug interaction toxicity 
in a phase II trial (65). 
 
Along with the rapid development of targeted melanoma therapeutics, the 
combined inhibition of VEGFR plus PDGFR or mTOR has shown synergy anti-tumor 
effects on mouse models of B16 metastatic melanoma without increasing toxicity (66, 
67). A large-scale, unbiased drug screening study, which aims to discover effective 
genotype selective combinatorial therapeutics of vemurafenib-resistant BRAF and RAS 
mutant melanoma, identifies a triple BRAF+EGFR+AKT inhibition as highly effective 
approach (3). In the year of 2010, combination of bevacizumab with an mTOR inhibitor, 
everolimus, was evaluated in a phase II trial for patients with metastatic melanoma (68). 
The treatment was well tolerated in most patients. Seven out of fifty-seven patients (12%) 
receiving combination therapy have shown major responses, although the median PFS 
was only 4 months. This year (2014), in a phase II trial that combines bevacizumab and 
sorafenib, which is an inhibitor of both RAF kinase and VEGFR-2/PDGFR-β signaling, 
no objective tumor responses are seen in all the fourteen patients receiving treatment (69, 
70). Interestingly, the median TTP of patients with low VEGF (<300 pg/ml) was longer 
than that of patients with high VEGF (50 weeks versus 15 weeks, P =0.02). Therefore, 
the levels of VEGF in patients do influence the tumor progression profile 
(ClinicalTrials.gov, NCT00387751).  
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1.2.4 Combination Therapy Using Targeted Therapy with Versatile Chemotherapy 
Agents 
 
Since the abnormally activated (phosphorylation) of ERK and AKT constitutively 
exist in melanoma cells and promote the disease progression especially metastasis, 
blocking ERK or AKT pathway can sensitize the metastatic melanoma to the apoptosis 
induced by chemotherapeutic agents including cisplatin, temozolomide, DTIC and 
arsenite (71-73). With the understanding of tumor biology about the programmed cell 
apoptosis and the rapid development of agents that can trigger the cell death process in 
melanoma, the combination of a MAPK inhibitor with a BCL-2 inhibitor (ABT-737 (74) 
or navitoclax (75)), or a MDM2 antagonist nutlin-3 (76), has synergistically induced 
apoptosis of melanoma in vitro and suppressed xenograft tumor growth in vivo.  A 
comparative analysis on the samples collected from patients receiving vemurafenib or 
dabrafenib/trametinib combination treatment showed that BCL-2 expression level is 
closely related to the onset of MAPK inhibition resistance (75). Clinical trials are being 
conducted to investigate the combination of BCL-2 inhibitor (BH3 mimetics) navitoclax 
and vemurafenib (75). 
 
Due to the heterogenetic characteristics of melanoma disease, Vultur A et al (77) 
recently report that MEK or BRAF inhibition can potentially strengthen the invasion 
property of human melanoma cells by about 20%. As a result, co-inhibiting kinases that 
are actively involved in cell invasion process, such as RTK, STAT3 and Src, together 
with MEK inhibition has effectively abolished the invasive phenotype and further caused 
the tumor cell death in a 3D matrix model.  
 
Metformin, a biguanide oral anti-diabetic drug, has been discovered with 
antitumor activity in various cancer types including melanoma. Although the exact 
mechanisms remain to be elucidated, accumulating data suggest that metformin can 
activate AMP-activated protein kinase (AMPK) and thus increase the activities of VEGF 
and ERK in BRAFV600E mutated melanoma cells (78). AMPK negatively regulates 
malignant cell proliferation and viability (79). The combination of vemurafenib and 
metformin has shown synergistic anti-proliferative effects on six out of eleven tested 
BRAFV600E melanoma cell lines (80). Pilot clinical studies that evaluate the safety and 
efficacy of metformin combination therapies (plus dabrafenib or trametinib) are now 
recruiting patients (ClinicalTrials.gov, NCT0184000, NCT02143050). 
 
Unlike the cutaneous melanoma, over-activation of MAPK pathway in uveal 
melanoma is associated GNAQ or GNA11 mutations instead of BRAF or RAS mutations 
(81). Protein kinase C (PKC) inhibitors such as enzastaurin or AEB071 induce apoptosis 
in GNAQ-mutant but not in GNAQ wild type uveal melanoma cells (82). The level of 
ERK phosphorylation also decreases in these cells when they are treated using PKC 
inhibitors (82). Chen et al. has recently confirmed the synergy of the combination using a 
PKC inhibitor with a MEKi (PD0325901 or MEK162) in GNAQ/11 mutant uveal 
melanoma cells (83). 
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Understanding the mechanisms of resistance to MAPK inhibition in melanoma 
can lead to rational combination designs in order to overcome acquired drug resistance to 
BRAF inhibitors. For example, our lab recently identified a synergistic combination in 
which a novel tubulin inhibitor ABI-274 combined with vemurafenib could overcome the 
acquired vemurafenib-resistance (84). This combination treatment effectively arrested the 
vemurafenib-resistant melanoma cells in both G0/G1 and G2/M phases and induced strong 
apoptosis through the down-regulation of AKT phosphorylation. In addition, the 
combination of a MEKi (TAK-733) with an Hsp90 inhibitor (ganetespib) induces tumor 
regressions in vemurafenib-resistant xenograft models also through the depletion of AKT 
signaling (85). With the finding that up-regulated cyclin D1 expression is critical for the 
survival of vemurafenib-resistant cells, a selective inhibitor of cyclin dependent kinase 
(CDK) 4/6, LY2835219, has been reported to overcome the reactivation of MAPK 
signaling in vemurafenib-resistant BRAFV600E melanoma (86). 
 
 
1.3 Combinations Involving Immunotherapy in Melanoma Treatment 
 
 
1.3.1 Combined Blockade of Immuno-checkpoints 
 
Given the unsatisfactory results of cytokine-based melanoma immunotherapy 
(recombinant interferon-α 2b and high dose interleukin-2) in the past decade, the 
development and approval of ipilimumab (anti-cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) monoclonal antibody) in 2013 have marked a breakthrough of 
immune-checkpoints blockade therapy (87). CTLA-4 (CD152) expresses on the surface 
of active T-lymphocytes and inhibits the initial T-cell proliferation and migration to the 
tumor tissue (88). CTLA-4 antibodies preferentially target the suppressive regulatory T 
cells and prevent them from being hijacked by tumors (89). In a double-blinded phase III 
study in 676 patients with pretreated and refractory metastatic melanoma, ipilimumab at 
the dose of 3 mg/kg achieved a median OS of 10 months (87). In a meta-Kaplan-Meier-
analysis of data collected from 1,861 melanoma patients in a clinical trial, a plateau of 
survival curve starts from around 3 years after ipilimumab treatment with follow-up 
extends as long as ten years, indicating a long-term survival benefits of ipilimumab 
therapy (ClinicalTrials.gov, NCT01844505). In addition, ipilimumab showed good 
tolerance and efficacy in several other clinical trials in which it was combined with a 
standard chemotherapy agent such as dacarbazine, fotemustine or temozolomide (90).  
 
Another success of immune-check point blockade strategy is the development of 
anti-programmed death-1 (PD-1) antibodies, represented by pembrolizumab (MK-3475) 
and nivolumab (91, 92). Pembrolizumab, as the first-in-class PD-1 inhibitor, has obtained 
FDA approval in September 2014 for patients with advanced or unresectable melanoma. 
The cDNA of PD-1 (CD279) is first cloned in programmed death T cells although PD-1 
itself does not directly induce apoptosis. PD-1 is over-expressed on the surface of 
dysfunctional activated T-cells and contributes to the maintenance of T cell dysfunction 
(exhaust) phenotype and proliferation disability in the tumor site (93). Two counter 
receptors of PD-1 have been identified: PD-L1 and PD-L2. PD-L1 is more frequently and 
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exclusively expressed in various tumor cells; therefore, antibodies targeting PD-L1 
(MPDL3280A and BMS-936559) also have anti-tumor activity in advanced cancer 
including melanoma (92, 94). The PD-1-PD-L1 ligation retards the recognition and 
destroying of tumor cells by CD8+ cytotoxic T-lymphocytes (88). As a result, blocking 
PD-1 or PD-L1 will reverse the cancer cell immune escape. Because both CTLA-4 and 
PD-1 are key negative receptors that cooperatively modulate the adaptive immune 
response in tumor progression, their combination has been shown to be synergistic in B16 
melanoma tumors without overt toxicity (95).  
 
In a cohort phase I trial that studied the concurrent administration of ipilimumab 
and nivolumab to 53 patients with advanced, treatment-resistant melanoma, more than 
80% tumor reduction was observed in 30% patients after 12 weeks treatment at the 
maximum tolerated dose. Twenty-one out of fifty-three patients had objective responses 
and over 80% of these patients had tumor regression. Grade 3/4 adverse events are 
diagnosed in 53% patients but the toxicities are manageable with immune-suppressants 
(96). Consequential trials with more enrollment number of patients are necessary to 
further evaluate the safety and efficacy of this promising double immune-checkpoints 
blockage therapy comparing with each of its monotherapy regiments. 
 
Finally, combinatorial clinical trials using ipilimumab with other immunotherapy 
agents have shown some favorable therapeutic benefits. For example, combination of 
ipilimumab with peginterferon α-2b (pegylated interferon α-2b) in patients with 
unresectable melanoma both demonstrated significant increase of response rate and OS 
comparing with the monotherapy arm (97, 98) in recent phase I trials.  
 
 
1.3.2 Combined Therapy Inhibiting both Immuno-checkpoint and MAPK Signaling 
Pathway 
 
Checkpoint blockade immunotherapy and MAPK targeted chemotherapy have 
distinct clinical profiles. For example, targeted therapy has relative higher initial response 
rate (~60% for BRAFi) with rapid onset of effect, but its efficacy restrictively rely on the 
continuous treatment and the therapeutic response is usually not durable due to the quick 
development of acquired drug resistance. In contrast, immunotherapy has much a lower 
response rate (4.5% for ipilimumab), delayed onset of effect and difficulty in predicting 
patient outcome, but it has shown potentially durable responses and long-term survival 
benefit even off treatment. In addition, since the MAPK pathway is not required in the 
process of anti-tumor immune response, blocking MAPK signaling should not interfere 
with the efficacy of checkpoint blockade immunotherapy. Therefore, it seems very 
rational that the combination of a MAPKi and an immunotherapy agent such as 
ipilimumab or pembrolizumab can maximize the therapeutic benefits in advance 
melanoma. 
 
Interestingly, BRAF and MEK inhibition displayed an “endogenous vaccine-like” 
effects in melanoma cells (99). Cytotoxic agents like BRAFi induce tumor cell death and 
promote the uptake and presentation of tumor antigens to the effector immune cells (T 
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cells and B cells) through antigen-presenting cells (55). MEK inhibition, BRAFV600E 
RNA silencing or BRAF inhibition by PLX4720 increases the CD4+ and CD8+ 
lymphocytes mediated T-cell infiltration and reduce the level of immune-suppressants 
including IL-6, IL-10 or VEGF (100-102) in mice. The expression of PD-L1 is found to 
be elevated in BRAFi-resistant melanoma cells and it is mediated through the off-target 
activity of BRAFi in JUN and STAT3 signaling (103). However, Vella et al has 
published a paper in 2014 and stated that they have not found any impact of dabrafenib 
treatment on T lymphocytes. trametinib alone or in combination with dabrafenib has 
suppressed T lymphocyte proliferation, cytokine secretion and antigen-specific expansion 
in their isolated T lymphocyte and monocyte-derived dendritic cells. These findings 
should be carefully tested in vivo to evaluate the clinical relevance (104). 
 
As for the clinical practice, dose-limiting hepatotoxicity issues have led to the 
premature termination of the first phase I study on combination of ipilimumab with 
vemurafenib (ClinicalTrials.gov, NCT01400451). This signified the complexity of 
adverse effect in combined therapy of immune-regulating agents and kinase inhibitors. 
Another phase I study of ipilimumab plus dabrafenib, or ipilimumab plus the 
combination of dabrafenib with trametinib is still active and a phase II study is exploring 
the safety and efficacy of sequential administration of vemurafenib followed by 
ipilimumab (ClinicalTrials.gov, NCT01767454, NCT01673854). The data of these most 
recent trials will be released in the near future. 
 
 
1.4 Conclusion 
 
Extensive efforts and remarkable progresses have been made to discover and 
investigate rational approaches in combination melanoma therapy since the recent 
approval of MAPKi and immune checkpoints blockade antibodies. A number of new 
targeted or immune drugs for metastatic melanoma are currently under commercial 
development or late stage clinical trials, some of which will likely be approved in the 
next few years. Quality of life for many melanoma patients has been dramatically 
increased. However, significant challenges still remain. While some clinical evidence has 
really raised the expectation of survivals for patients with advanced melanoma, the 
benefits of combination therapy are usually accompanied by limitations. Comprehensive 
genetic profile and tailored patient matching is essential for targeted therapy, while 
biomarkers are critical to predict the patient immunotherapy response. Drug-related 
toxicity for combination treatment usually is not a simple one-plus-one situation, and 
potential drug-drug interactions, especially the combination of a targeted agent with an 
immunotherapeutic agent must be carefully evaluated in order to achieve both fast and 
durable responses. Adverse effects should be closely monitored and potential alternative 
dosing regiments is worth further exploration. Optimized dose schedule may help to 
delay the resistance development and reduce the frequency of adverse effect. For 
example, intermittent doses of BRAFi was able to enhance the tolerance in combination 
with immunotherapy, decrease the paradoxical MAPK activation, which might be the 
main cause of severe toxicity in clinical trial (105). Solid evidence of synergistic 
combination in preclinical research must be established before clinical trial conduction. 
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In fact, with the relatively large number of available targeted agents and 
immunotherapeutic agents for metastatic melanoma, the huge number of possible drug 
combinations coupled with dosing sequences or schedules already presents a significant 
challenge in designing proper clinical trials. To test all the possible drug combinations 
along with different dosing sequences clinically will not only have low benefits to 
patients, but is also a huge financial burden to the society. Carefully designed, predictive 
preclinical studies will be essential to provide critical supports for rational prioritization 
of clinical trials using drug combinations. Finally, clear understandings of various 
combination mechanisms and patient genetic profiles are critically important for the 
development of new combination approaches, prediction of expected therapy response 
and potential side effects. With the rapid advances in this field, it is likely that optimal 
combination treatments will greatly improve the management of advanced melanoma in 
cancer patients.   
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CHAPTER 2.    OVERCOMING ACQUIRED RESISTANCE TO BRAF 
INHIBITORS BY NOVEL SYNERGISTIC DRUG COMBINATION* 
 
 
2.1 Introduction 
 
The sustained clinical activity of vemurafenib in melanoma patients with 
BRAFV600E mutation is limited by the rapid development of acquired resistance (106-
108). Several mechanisms have been proposed in the literature (28, 109-111), including 
the amplification of the BRAF oncogene (112), the up-regulation of CRAF expression 
(113), oncogenic activation of NRAS (114), up-regulated EGFR-SFK-STAT3 pathway 
(115), gatekeeper mutations (116-118), up-regulation of growth factor receptors such as 
insulin-like growth factor 1 receptor (IGF1R) (46) or platelet-derived growth factor 
receptor (PDGFR) (114), and other resistance mechanisms (21, 119).  Several methods to 
maintain phosphorylated extracellular-signal-related kinase 1 and 2 (p-ERK1/2) levels in 
the presence of BRAF inhibitor drugs have been described, including ERK-kinase 1 
(MEK1) mutation, recruitment of alternative MEK1/2 activators, RAS mutation or up-
regulation of receptor tyrosine kinases (RTKs). Thus in many cases, vemurafenib-
resistant cells are cross-resistant to MEK inhibitors (35, 109, 120).  
 
Drug combinations using agents with distinct anti-cancer mechanisms can 
enhance tumor response and patient survival, especially in the treatment of advanced 
cancer patients (121-123). Combinations of vemurafenib with agents targeting the same 
mitogen-activated protein kinase (MAPK) pathway such as MEK or ERK inhibitors show 
clinical efficacy (28, 37, 39, 124), however they can only arrest cells in the G0/G1 phase. 
Such combination strategies are unlikely to be effective against resistant cells that can 
escape from this cell cycle arrest. Our preliminary study showed that the chronically 
selected vemurafenib-resistant human melanoma cells could not be blocked in the G0/G1 
phase by vemurafenib at the effective concentration to sensitive parental cell line, and the 
vemurafenib-resistant cells readily progressed into the G2/M phase. Thus, we 
hypothesized that a combination of vemurafenib with a compound that strongly induces 
the subsequent G2/M phase block should capture vemurafenib-resistant cells leaking from 
G0/G1 arrest, and thus produce a strong synergy.  
 
We recently discovered a novel class of anti-mitotic agents, represented by the 2-
aryl-4-benzoyl-imidazoles (ABIs) scaffold (125-128). ABI-231 and ABI-274 are among 
our most potent ABI compounds discovered to date with anti-proliferation IC50 values in 
the low nanomolar (nM) range in several melanoma cell lines. They bind to tubulin at the 
colchicine binding site (129).  
 
 
 
 
*Modified with permission. Wang J, Chen J, Miller DD, Li W. Synergistic combination 
of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired 
resistance in BRAFV600E melanoma. Mol Cancer Ther. 2014;13: 16-26. 
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Compared with many existing tubulin inhibitors such as paclitaxel and 
vinblastine, ABIs can effectively circumvent several clinically relevant multidrug 
resistant mechanisms, including drug resistance mediated by P-glycoprotein (Pgp), 
multidrug resistance-associated proteins (MRPs), and breast cancer resistant proteins 
(BCRP). An in vivo study indicated that ABIs significantly inhibited melanoma lung 
metastasis in mice (129). In the current study, we tested our hypothesis of synergistic cell 
cycle arrest by the combinations of vemurafenib with ABIs or docetaxel in a panel of 
BRAFV600E mutant parental melanoma cell lines and chronically selected vemurafenib-
resistant A375RF21 and MDA-MB-435 VemR sublines (28). The established 
vemurafenib-resistant A375RF21 cells were used in vitro and in vivo as the disease 
relapse model to test whether our proposed synergistic drug combination would be of 
potential therapy benefit in associated clinical vemurafenib resistance. 
 
 
2.2 Materials and Methods 
 
 
2.2.1 Reagents and Cell Lines 
 
Vemurafenib, selumetinib, trametinib, sunitinib (malate salt) and docetaxel were 
purchased from LC Laboratories (Woburn, MA). ABI-274 was synthesized as described 
(126). Human melanoma A375 cell line was acquired from ATCC (Manassas, VA). 
Human melanoma WM164 and MDA-MB-435 cells were obtained from Dr. Meenhard 
Herlyn (Wistar Institute, Philadelphia, PA), and Dr. Robert Clarke (Georgetown 
University, Washington, DC), respectively. MEK inhibition resistant 451LuMR and 
BRAF inhibition resistant WM983B BR cells were gifts from Dr. Meenhard Herlyn 
(Wistar Institute, Philadelphia, PA). All cell lines were authenticated prior to use for this 
study. A375, WM164 and MDA-MB-435 cells were cultured in DMEM medium 
(Mediatech, Inc., Manassas, VA), supplemented by 10% fetal bovine serum (FBS, 
Atlanta Biologicals, Lawrenceville, GA), 1% antibiotic/antimycotic mixture and 5 μg/mL 
bovine insulin (Sigma-Aldrich, St. Louis, MO). 451LuMR and WM983B BR cells were 
maintained in 5% FBS supplemented DMEM medium with 1 μM trametinib or 
vemurafenib, respectively. 
 
Vemurafenib-resistant melanoma cells were chronically selected by culturing 
A375 or MDA-MB-435 cells in increasing concentrations of vemurafenib following the 
reported method (28) for at least three months. A375RF21 and MDA-MB-435 VemR 
cells are maintained in full growth medium containing 2.5 μM vemurafenib. 
 
 
2.2.2 Cell Proliferation and In Vitro Combination Assay 
 
Cell proliferation was investigated using the MTS or SRB assay as described 
previously (125, 126, 129). An in vitro study of the combination of vemurafenib and the 
tubulin inhibitors was designed and conducted using CalcuSyn software (Biosoft, 
Ferguson, MO) with five duplicates of each treatment set. Drug concentrations were 
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selected based on the IC50 value of each drug tested from a pilot study. Synergism, 
additive activity or antagonism was determined through the Chou-Talalay method (130), 
showing a combination index (CI) as calculated in the software output. 
 
 
2.2.3 Cell Cycle Analysis 
 
Flow cytometry analysis was performed as described before (129). To determine 
cell cycle distributions in the G2 and M phases, cells were harvested with trypsin, stained 
using anti-phospho-histone H3 - AlexaFluor® 488 antibody on ice for one hour in the 
dark, followed by stained using PI/RNase solution for 30 minutes at room temperature in 
the dark per the manufacturer’s instructions (#FCCH025103, EMD Millipore 
Corporation, Ballerica, MA). Data were further processed and graphs were prepared 
using the Modfit 2.0 program (Verity Software House, Topsham, ME). 
 
 
2.2.4 Tubulin Polymerization Assay 
 
HTS-tubulin polymerization assay was performed as described previously (127) 
using a commercial kit following the manufacturer’s instructions (#BK004P, 
Cytoskeleton, Inc., Denver, CO). The absorbance at 340 nm was kinetically recorded 
every 1 min for 45 min at 37 °C by the SYNERGY HT micro-plate reader (Bio-Tek 
Instruments, Winooski, VT).  
 
 
2.2.5 Western Blot Analysis 
 
At the indicated time treatment, A375RF21, MDA-MB-435 VemR, A375, MDA-
MB-435 or WM164 cells were collected to investigate levels of relevant cascade protein 
or apoptosis markers by western blots. The following primary rabbit antibodies (Cell 
Signaling Technology, Inc., Danvers, MA) were used: anti-phospho-ERK1/2 
(Thr202/Tyr204; #9101), anti-p44/42 MAPRK (ERK1/2; #9102), anti-phospho-AKT 
(Ser473; #9271), anti-AKT (#9272), anti-cyclin D1 (#2978); anti-cleaved PARP (#9185), 
anti-cleaved caspase-3 (#9664), anti-RAS (#3339), anti-ARAF (#4432), anti-BRAF 
(#9433), anti-CRAF (#9422), phosphor-PI3 kinase p85 (Tyr458)/ p55 (Tyr199) (#4228), 
anti-PTEN (#9188), anti-PDGF receptor β (#3169), or anti-GAPDH (#3683). Target 
proteins were detected by incubating with 1× LumiGLO® reagent (Cell Signaling, #7003) 
for one minute and exposed to x-ray film. The films were scanned with grey scale and 
lane intensities were quantified with the ImageJ software (NIH, Bethesda, MD, USA). 
 
 
2.2.6 Apoptosis Detection 
 
A375RF21 cells were seeded in 6-well plates (1 × 106 per well) and treated with 
growth medium containing 0.5% DMSO, vemurafenib, ABI-274, docetaxel or the 
indicated combinations. After 48 hours of incubation, apoptosis analysis was performed 
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using the Annexin V-FITC Apoptosis Detection Kit (Abcam, Cambridge, MA) as per 
manufacturer’s instructions and analyzed by a BD LSR-II cytometer (BD Biosciences, 
San Jose, CA). 
 
 
2.2.7 Vemurafenib-resistant Tumor Xenograft and Treatment 
 
Seven to eight week old male nude mice were purchased from Charles River 
Laboratories International, Inc. (Wilmington, MA). A375RF21 cells were suspended in 
ice-cold phenol red-free and FBS-free DMEM medium and mixed with high 
concentration Matrigel (BD Biosciences, San Jose, CA) at a ratio of 1:1 right before use. 
100 μL of this mixture containing 3 × 106 cells was injected subcutaneously (s.c.) to the 
left-side dorsal flank of each mouse. One week after the inoculation, the mice were 
randomized into four groups (n = 7 for the initial low dose and n = 5 for subsequent high 
dose drug combination) and the treatments started. ABI-274 or vemurafenib was diluted 
in PEG300 (Sigma-Aldrich, St. Louis, MO) and administered through intraperitoneal 
(i.p.) injection once per day, 5 days per week for three continuous weeks. Vehicle control 
group was i.p. injected with same volume (100 μL) of PEG300 at the same dosing 
frequency. At the end of the experiments, mice were euthanized and tumor tissues were 
isolated, weighted and then fixed in 10% buffered formalin phosphate solution.  
Tumor volume and body weight of each mouse were evaluated three times a week.  
 
We calculated the tumor volume using formula a × b2 × 0.5, where a and b 
represented the larger and smaller tumor diameters (129). Data was showed as mean ± 
SD for each group and plotted as a function of time. Tumor growth inhibition (TGI) was 
calculated as 100 – 100 × [(T - T0)/(C - C0)], and tumor regression was calculated as (T-
T0)/ T0 × 100, where T, T0, C and C0 are the mean tumor volume for the specific group on 
the last day of treatment, mean tumor volume of the same group on the first day of 
treatment, mean tumor volume for the vehicle control group on the last day of treatment 
and mean tumor volume for the vehicle control group on the first day of treatment, 
respectively (28, 107).  
 
 
2.2.8 Pathology and Immunohistochemistry (IHC) Analysis 
 
Tumor tissues fixed in formalin buffer for over one week were stained with 
hematoxylin and eosin. For IHC analysis, the following primary antibodies were used: 
rabbit anti-Ki67, anti-phospho-AKT (Ser473), and anti-phospho-ERK1/2 
(Thr202/Tyr204) (#9027; #4060; #4376, Cell Signaling Technology).  Anti-S100 primary 
antibody was purchased from Abcam (#ab868, Abcam Inc., Cambridge, MA). Analyses 
were performed following manufacturer’s protocols. 
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2.2.9 Statistical Analysis  
 
Data were analyzed using Prism Software 5.0 (GraphPad Software, Inc., San 
Diego, CA). The statistical significance (P < 0.05) was evaluated by Mann-Whitney 
Rank Test, nonparametric t-test and one-way ANOVA for in vitro apoptosis detection 
and xenograft study. Treated groups were compared with the vehicle group and 
combination treatment groups were compared with the groups that received single agent 
treatment, accordingly.  
 
 
2.3 Results 
 
 
2.3.1 Combination of Vemurafenib with ABI Compound Showed Strong Synergies 
in Parental BRAFV600E Mutant Melanoma Cell Lines 
 
We started by testing ABI compounds (ABI-231 and ABI-274) to evaluate their 
combination effects with vemurafenib on parental human A375, MDA-MB-435 and 
WM164 cells which were all BRAFV600E mutant cell lines. Two well-known tubulin 
inhibitors, docetaxel and colchicine, were included for comparison (Table 2-1). We 
found that calculated CI values for combinations of ABI-231 or ABI-274 and 
vemurafenib was as low as 0.22 (in A375 cell line) and 0.10 (in MDA-MB-435 cell line) 
at ED50, showing the combination treatment had strong synergistic effects in vitro.  
 
 
2.3.2 Combination of ABI-231 and Vemurafenib Produced Synergistic Cell Cycle 
Arrests in Vemurafenib-sensitive A375 Cells 
 
ABI compounds as novel tubulin inhibitors arrest cancer cells including human 
melanoma A375 at G2/M phase, but vemurafenib as a BRAF inhibitor blocks cancer cell 
progressing from G1 phase. As shown in Figure 2-1, cell cycle distribution quantitative 
data revealed that single treatment of ABI-231 at 20 nM generated 43 ± 8% or 70 ± 2% 
of G2/M arresting after 12 h or 24 h incubation. And 60 ± 4% or 91 ± 1% cells were 
accumulated in G1 phase when they were treated by vemurafenib at 2 μM for 12 h or 24 
h. The combination of compound ABI-231 with vemurafenib displayed interesting 
“double” cycle cell arresting pattern at both G1 and G2/M phases in A375 cells from 12 h 
incubation, which contributed to the combined synergistic anti-proliferation effects. 
 
 
2.3.3 Combination of ABI-231 and Vemurafenib Affected Related Protein Levels in 
Vemurafenib-sensitive A375 Cells 
 
 To preliminarily investigate the mechanism of synergy combination, we 
performed western blotting to check the levels of related proteins in A375 cells after 
either single or combined treatment for 24 h, comparing with the DMSO vehicle control 
group. Representative results are shown in Figure 2-2. Since A375 is a vemurafenib- 
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Table 2-1. Combination of vemurafenib with tubulin inhibitors showed 
synergistic effect in the parental BRAFV600E melanoma cell lines as indicated by CI 
values determined at ED50 
 
Treatment 
+vemurafenib 
A375 MDA-MB-435 WM164 
ABI-231 0.22 0.23 0.66 
ABI-274 0.32 0.10 0.61 
Docetaxel 0.50 0.55 0.54 
Colchicine 0.47 0.78 1.28 
 
The combination index (CI) values at ED50 were calculated based on the results from cell 
viability MTS assay (n = 5). CI < 0.9 indicates synergism; 0.9 ≤ CI ≤ 1.1 indicates 
additive effect; CI > 1.1 indicates antagonism between the two tested drugs. 
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Figure 2-1. Cell cycle analysis of A375 cells incubated with single or combination 
treatment for 24 h (n = 3) 
A, representative flow cytometry diagram of cell cycle distribution. B, quantitative results 
of cell phase distribution. Data is presented by mean ± S.D. 
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Figure 2-2. Representative images of western blotting results for A375 cell 
incubated with either single or combination treatment for 24 h 
The densitometry data was measured by ImageJ software and normalized according to 
the reading from beta-actin loading control groups.  
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sensitive cell line, the treatment of vemurafenib or combination greatly reduced the level 
of pERK due to the inhibition of upstream BRAF activity. But ABI-231 single treatment 
did not affect the level of ERK phosphorylation. Interestingly, AKT phosphorylation 
level, which is critical in the regulation of cell survival and apoptosis, was reduced in 
both ABI-231 single treatment and combination treatment group. And the reduction of 
pAKT in these two groups accompanied with the decrease of total AKT level. This 
observation indicates that compound ABI-231 as a tubulin polymerization inhibitor exerts 
its anti-cancer activity partially through the interference of AKT pathway. And the co-
inhibition of both ERK and AKT phosphorylation generated synergistic anti-proliferation 
effect in vitro. 
 
 
2.3.4 Establishment of Vemurafenib-resistant A375RF21 Melanoma Subline  
 
Clinically melanoma tumors inevitably relapse only 3 to 6 months after receiving 
vemurafenib chemotherapy, and therefore we wanted to determine whether the observed 
synergy will remain effective in vemurafenib-resistant cells. Towards this goal, we 
established vemurafenib-resistant A375RF21 subline from the parental A375 human 
melanoma cells by chronic selection following literature reported procedures (28). The 
isolated resistant A375RF21 cell line steadily increased IC50 values for vemurafenib over 
50 fold (28.9 ± 0.6 μM in A375RF21 cells compare to 0.57 ± 0.03 μM in the parental 
A375 cells, Figure 2-3). 
 
We performed western blot analyses using both A375 and A375RF21 cells to 
determine differential protein activations known to result in vemurafenib resistance.  As 
shown in Figure 2-4A, the pERK level in A375RF21 in the presence of 2.5 μM 
vemurafenib (maintenance concentration of its culture medium) does not change, 
confirming the development of acquired vemurafenib resistance. 
 
The pMEK expression also remains active in A375RF21 cells, indicating their 
potential cross-resistance to MEK1/2 inhibitors. We confirmed this cross-resistance by 
incubating cells with two known MEK inhibitors (trametinib and selumetinib, Figure    
2-4B and C). The PI3K/AKT pathway was over-activated in A375RF21 cells while no 
significant changes of RAS, BRAF, ARAF, CRAF levels were observed.  These results 
are consistent with the report of Fei Su et al (28). Interestingly, we found that the level of 
PDGFRβ also increased significantly in A375RF21 cells in the presence or absence of the 
2.5 μM vemurafenib maintenance medium. Both resistant mechanisms that confer drug 
resistance in A375RF21 cells are well known to exist in vemurafenib-resistant patient 
tumors. 
 
 
2.3.5 Combination of Vemurafenib with ABI-274 Showed Strong Synergies in 
Vemurafenib-resistant A375RF21 Melanoma Cell Lines 
 
As shown in Table 2-2, the drug combination study when repeat using A375RF21 
cells produced calculated CI values for ABI-231 or ABI-274 in combination with  
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Figure 2-3. Establishment of vemurafenib-resistant A375 melanoma cell line 
A375RF21 from its parental A375 cell line using chronic selection over 3 months 
with increasing concentrations of vemurafenib 
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Figure 2-4. Major vemurafenib resistance mechanisms in A375RF21 cells are the 
over-expression of PDGFRβ and the activations of the PI3K-AKT pathway 
A, western blot analyses to compare the differential protein levels in the sensitive 
parental A375 and the vemurafenib-resistant A375RF21 cells, in the presence or absence 
of 2.5 μM vemurafenib (A375RF21 cell culture maintenance concentration). Cells were 
incubated with control vehicle or 2.5 μM vemurafenib for 24 h. Phospho-PI3K level was 
determined after 30 minutes stimulantion with 30 μM hydrogen peroxide. Graph showed 
representative results of three independent experiments. B, growth inhibition efficacy of 
kinase inhibitors determined in MTS assay (n = 4) on A375 and A375RF21 cells. 
Trametinib and selumenitib are MEK inhibitors while sunitinib (malate salt) is an RTK 
inhibitor. C, comparison of calculated IC50 values (showed as mean ± SD). 
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Table 2-2. Combination of vemurafenib with tubulin inhibitors showed 
synergistic effect in the vemurafenib-resistant A375RF21 melanoma cell lines 
 
Treatment 
+vemurafenib 
CI at ED50 CI at ED75 CI at ED90 
ABI-231 0.44 0.56 0.65 
ABI-274 0.53 0.59 0.70 
Docetaxel 0.63 0.80 0.90 
Colchicine 0.84 0.94 1.36 
 
The combination index (CI) values were calculated based on the results from cell 
viability MTS assay (n = 5). CI < 0.9 indicates synergism; 0.9 ≤ CI ≤ 1.1 indicates 
additive effect; CI > 1.1 indicates antagonism between the two tested drugs. 
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vemurafenib that were all less than 0.9 (range: 0.44-0.70), indicating strong synergy in all 
concentrations tested. At ED50, all tubulin inhibitors acted in a synergistic manner with 
vemurafenib. With an increase in drug concentration, the CI values for docetaxel or 
colchicine groups increased relatively quickly. At the dose of ED90, the combination of 
docetaxel with vemurafenib was almost additive (CI value as 0.90) while the combination 
effect of colchicine with vemurafenib has reversed to antagonism (CI value as 1.36). 
Compared with docetaxel or colchicine, ABI compounds showed greater synergy when 
combined with vemurafenib in the resistant A375RF21 cells. Dose –response curve in 
Figure 2-5 also clearly showed that in both A375 parental and vemurafenib-resistant 
A375RF21 subline, the combination of ABI-274 with vemurafenib dramatically 
increased the anti-proliferation activity comparing with the simple sum of the single 
treatment.  
 
 
2.3.6 Combination of ABI-274 and Vemurafenib Produced Synergistic Cell Cycle 
Arrests in A375RF21 Cells 
 
As a tubulin inhibitor binding to the colchicine site, ABI-274 effectively blocks 
the G2/M phase in the parent A375 cell line in a dose-dependent manner (129). To 
determine whether a combination of ABI-274 and vemurafenib will arrest vemurafenib-
resistant cells at different replication phases, we carried out cell cycle analysis in 
A375RF21 cells. After 24 h exposure to a compound solution at the indicated 
concentrations, data in Figure 2-6 clearly indicated synergistic cell cycle arrests. For 
DMSO controls, 50% of A375RF21 cells were distributed in G0/G1 phase and the 
percentage of cells in S or G2/M phase was 12% or 32%, correspondingly. For ABI-274 
single treated group at a concentration of 20 nM, the percentage of cell distributed in 
G2/M phase had accumulated up to 70%. Using vemurafenib as a single agent, to produce 
similar G0/G1 cell cycle arrest in the resistant A375RF21 cell line, the concentration of 
vemurafenib had to be increased to 30 μM or higher, compared with less than 1 μM in the 
parental A375 parental cells. As anticipated, the combination of vemurafenib and ABI-
274 strongly arrested A375RF21 cells in both G0/G1 (48%) and G2/M (43%) phase. In 
addition, this combination treatment generated much more cell debris which indicated an 
increase in cancer cell apoptosis. Treatment with the combination of vemurafenib and 
docetaxel produced similar synergistic effects. Flow cytometry analysis with anti-
phospho-histone H3 staining (Figure 2-7), which distinguishes the cells between G2 and 
M phase, confirmed the same pattern of synergistic cell cycle arrests due to the 
combination treatments.  
 
 
2.3.7 Combination Treatment Induced Significantly Increased Apoptotic and Cell 
Death in Vemurafenib-resistant Cells 
 
To understand more clearly the possible cell apoptosis induction effect of the 
combination treatment, we utilized Annexin V and Propidium Iodide co-staining flow 
cytometry to differentiate live and apoptotic cells in A375RF21. As expected, single  
 27 
 
 
Figure 2-5. In vitro dose-response curves (n = 5) of each combination in A375 and 
A375RF21 cells 
X-axis of each plot is the dose density regarding IC50 concentrations of drug A or B on 
A375 or A375RF21 cells in an A+B combination treatment. Figure A to C is the data 
from A375 cells and Figure D to F is the data from A375RF21 cells. 
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Figure 2-6. Cell cycle analysis for combination of ABI-274 with vemurafenib (n = 
4) 
A, A375 or A375RF21 cells treated with 1 μM vemurafenib for 24 h and compared with 
the DMSO control group. Vemurafenib at 1 μM effectively arrested A375 cells at G0/G1 
phases but could not arrest resistant A375RF21 cells. B, A375RF21 cells treated with 
DMSO, 30 μM vemurafenib, 20 nM ABI-274, 20 nM docetaxel and the combinations for 
24h. ABI-274 and docetaxel induced G2/M arrest in A375RF21 cells and their 
combinations with vemurafenib arrested cells in G1/G2/M phases. 
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Figure 2-7. Anti-phospho-histone H3 and PI (propidium iodide) bivariate staining 
cell cycle analysis on vemurafenib-resistant A375RF21 cells 
A, representative diagrams illustrated the cell distribution. The red lines were defined 
manually to show how the cell cycle phase distribution had been calculated accordingly. 
B, quantification data (mean ± S.D.) for cell cycle phases distribution. Ctrl: 5 ‰ DMSO; 
Vem: vemurafenib 30 μM; ABI: ABI-274 20 nM; Vem + ABI: vemurafeib 30 μM + 
ABI-274 20 nM; Doc: docetaxel 20 nM; Vem + Doc: vemurafeib 30 μM + docetaxel 20 
nM. 
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agent treatment produced only moderate effects on inducing cell apoptosis at tested 
concentrations; in contrast, the combination treatment groups significantly enhanced the 
apoptosis (Figure 2-8A). As shown in Figure 2-8B, in which we quantified the 
percentage sum of cell distributed in Q1 (early apoptosis), Q2 (apoptosis) and Q4 (dead 
cells), the combination of ABI-274 and vemurafenib resulted in 50 ± 7.6 % of counted 
cell apoptosis or death, which is much higher than the simple sum of apoptotic 
percentages in two single agent treatment groups (11.8 ± 3.0 % for ABI-274 and 11.9 ± 
3.5 % for vemurafenib). A similar synergy effect of apoptosis induction was also 
observed in the combination treatment group containing docetaxel (6.4 ± 3.0 % for 
docetaxel group, 38.1 ± 2.6 % for combination). 
 
 
2.3.8 Combination Mitigates Acquired Vemurafenib Resistance by Down-regulating 
pAKT or Total AKT and Activating Apoptosis Cascades 
 
It has been established that ABI-274 targets tubulin polymerization (125, 126) and 
vemurafenib targets BRAFV600E. As the first approach to understand responsible 
molecular mechanisms leading to this strong synergistic combination, we investigated 
whether the synergy is mediated through potentiation of the direct target of ABI-274 or 
vemurafenib. As shown in Figure 2-9 vemurafenib did not have any effect on tubulin 
polymerization, even at a high concentration of 20 μM. The addition of vemurafenib to 
ABI-274 at most marginally increased the inhibition of tubulin polymerization compared 
with the single agent ABI-274. The inhibition of tubulin polymerization in the 
combination treatment was exclusively contributed by ABI-274, suggesting the 
synergistic combination was not mediated through potentiation of the direct target 
inhibition for ABI-274.  
 
Next we determined using western blotting whether the combination has any 
effects on pERK, the hallmark of BRAFV600E inhibition by vemurafenib. Figure 2-10A 
revealed that either ABI-274 or the combination treatments had no obvious effect on 
pERK or total ERK level after 48h incubation with A375RF21 resistant cells. Replacing 
ABI-274 with another tubulin inhibitor, docetaxel, produced similar results in Figure     
2-10A). Therefore, the synergistic combination was unlikely through potentiation of the 
inhibition of BRAFV600E.  
 
Recently, Fei Su et al reported that pAKT levels were increased in A375 
vemurafenib-resistant clones compared with their parental vemurafenib-sensitive cells 
(28). Since A375RF21 cells also have strong pAKT activation (Figure 2-10A), we 
hypothesize that the combination treatment may produce its strong synergy through 
down-regulating activities in the AKT pathway in vemurafenib-resistant A375RF21 cells. 
As shown in Figure 2-10A, both pAKT and total AKT (tAKT) were greatly reduced  in 
single-agent ABI-274 or its combination treatment group after 48h incubation, suggesting 
that the synergistic anti-proliferation might be mediated by simultaneously targeting both 
ERK and AKT phosphorylation. Docetaxel also reduced the pAKT and tAKT expression 
and had similar effects in its combined treatment with vemurafenib. For example, in 
addition to the obvious reduction of tAKT levels, the combination of ABI-274 and  
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Figure 2-8. Combination of tubulin inhibitors with vemurafenib synergistically 
increased proportion of cell apoptosis or death in resistant A375RF21 cells 
A, representative quadrant diagrams illustrated the cell distribution in Q1 (early 
apoptosis), Q2 (apoptosis), Q3 (live), and Q4 (dead). Cell clusters with high-SSC (side 
scatter)/ low-FSC (forward scatter) cyto-morphological profiles were colored in black. 
There was no back-gating difference between grey and black populations. B, apoptosis 
fraction was calculated by adding distribution percentage in Q1, Q2 and Q4 together. 
Drug combinations induced significantly higher (*P < 0.05) portion of apoptosis 
compared with simple sum of apoptosis fraction in two single agent treatment groups. 
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Figure 2-9. Effect of single agent and combination treatment on purified-protein 
based tubulin polymerization assay (n = 3) 
Vemurafenib at 20 μM did not significantly influence tubulin polymerization compared 
with DMSO control group. The tubulin polymerization inhibition effect in the 
combination treated group was solely contributed by ABI-274. 
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Figure 2-10. Western blot analysis with indicated antibodies on lysate of 
A375RF21 (A), MDA-MB-435 and WM164 cells (B) after 48h treatment while 
GAPDH was used as a loading control 
A, while the indicated combination treatment only caused moderate decreasing of p-ERK 
level, they largely inhibited the AKT phosphorylation and increased the level of apoptotic 
markers including cleaved PARP and cleaved caspase-3. B, ABI-274 also displayed AKT 
knock-out effects in other two BRAFV600E mutant human melanoma cell lines, MDA-
MB-435 and WM164. 
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vemurafenib reduced the level of pAKT to 61% relative to tAKT (calculated from the 
quantified relative folds of lane density: 0.08/0.13×100%) while the single-agent 
treatment only reduced the levels of pAKT to 77% (ABI-274, 0.6/0.77×10%) and 70% 
(vemurafenib, 0.34/0.48×100%) relative to the corresponding levels of tAKT, 
respectively.  
 
The strong dose-dependent pAKT/tAKT inhibition effects of ABI-274 were 
further confirmed in other two BRAFV600E mutant cell lines, WM164 and MDA-MB-435 
(Figure 2-10B). Furthermore, since the highly phosphorylated AKT level is associated 
with upregulated PDGFRβ/PI3K in A375RF21 cells (Figure 2-4A), we continued to 
check the changes of PDGFRβ/PI3K levels in response to both single and combination 
treatment. Representative results in Figure 2-11 revealed that after 24hr incubation, ABI-
274 or docetaxel at the concentration of 20nM generally wiped out the PDGFβ and 
leaded to the down-regulation of PI3K level in A375RF21 cells. As a result, the AKT 
upstream PDGFRβ/PI3K levels were greatly reduced in combination treatment groups, 
although vemurafenib single treatment did not significantly affect the PDGFRβ/PI3K. 
Therefore, our data indicates that ABI-274 or docetaxel down-regulates pAKT/tAKT 
activity through the inhibition of PDGFRβ/PI3K pathway.  
 
In the vemurafenib-resistant cells (Figure 2-10A), decreased cyclin D1 levels in 
vemurafenib and the combination treatment groups indicated inhibitions on G0/G1 cell-
cycle progression. Apoptosis markers, cleaved PARP and caspase-3, were highly induced 
by tubulin inhibitors while vemurafenib slightly increased their expression. This result is 
consistent with our observation in apoptosis detection experiment.  
 
 
2.3.9 Combination of Vemurafenib and ABI-274 Synergistically Suppresses 
Vemurafenib-resistant Tumor Growth In Vivo 
 
To evaluate whether the strong synergy observed against A375RF21 cells in vitro 
could be transferred to vemurafenib-resistant tumors in vivo, we compared the effect of 
combination efficacy on tumor growth with single agent treatments. We previously 
established that ABI-274 is effective in suppressing parental A375 melanoma tumor 
growth in vivo at a dose of 25 mg/kg (129). A pilot study showed that vemurafenib-
resistant A375RF21 cells had similar growth kinetics to their parental A375 cells in the 
absence of drug treatment. We reduced the dose of ABI-274 to 10 mg/kg in the current 
study in order to avoid any potentially unexpected toxicity due to its combination with 
vemurafenib.  
 
As shown in Figure 2-12 and Table 2-3, vemurafenib (20 mg/kg) mono-therapy 
only achieved minimal (22.65%) TGI and ABI-274 (10 mg/kg) by itself resulted in 
slightly better TGI at 38.12% in this vemurafenib-resistant tumor model; in contrast, their 
combination treatment significantly enhanced tumor inhibition to 88.56% after 3-week 
treatment (Figure 2-12A, B and Table 2-3). Three out of the seven mice that received 
combination therapy were kept for additional 7 days without further treatment,  
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Figure 2-11. Western blotting analysis for cell lysates of A375RF21 incubated with 
indicated treatment for 24 h 
The densitometry data was measured by ImageJ software and normalized according to 
the reading from beta-actin loading control groups. 
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Figure 2-12. In vivo combination of vemurafenib and ABI-274 in the resistant 
A375RF21 xenograft model (n = 7) 
A, pictures of isolated tumor tissue. B, tumor volume growth curve. C, mice body weight 
versus time plot. D, representative immunohistochemistry images for H&E, Ki67, pAKT, 
pERK and S100 staining of xenograft tumor tissue sections after three weeks of single 
agent or combination treatment. The scale bar (yellow or blue) in each image represents 
100 μm. 
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Table 2-3. Tumor growth inhibition (TGI) and tumor weight comparison for in 
vivo combination of vemurafenib and ABI-274 in the resistant A375RF21 xenograft 
model (n = 7) 
 
Treatment group TGI (%) Tumor weight  
(gram) 
Vehicle - 2.48 ± 0.27 
ABI-274 10 mg/kg 38.12 ± 6.14 1.77 ± 0.11 
Vemurafenib 20 mg/kg 22.65 ± 8.31 2.05 ± 0.14 
Vemurafenib 20 mg/kg + ABI-274 
10mg/kg (after 3 weeks of treatment) 
88.56 ± 3.57* 0.77 ± 0.17 
Vemurafenib 20 mg/kg + ABI-274 
10mg/kg (additional 7 days without 
treatment) 
81.27 ± 5.52* 0.90 ± 0.11 
 
The combination of ABI-274 at 10 mg/kg and vemurafenib at 20 mg/kg achieved greater 
antitumor activity (TGI) compared with the simple sum of TGI in two single agent 
treatment groups (*P < 0.05). The synergistic tumor inhibition sustained after additional 
one week without further treatment (*P < 0.05). 
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and showed no significant (P = 0.2857) tumor relapse and maintained 81.27% tumor 
suppression. During the entire experiment, no mice in the four groups lost body weight 
by more than 10% (Figure 2-12C), indicating the absence of gross toxicity for these 
treatments. When mice were euthanized, major organs including brain, hearts, kidney, 
liver, spleen, and lungs were isolated and were submitted for pathological analysis. No 
abnormalities were observed on these organs. Collectively, these results strongly 
indicated that this combination treatment effectively helped overcoming the acquired 
resistance to vemurafenib in A375RF21 melanoma model and further confirmed the 
synergistic anti-proliferation effects observed in vitro.  
 
To determine whether the down-regulation of AKT signaling by combination 
treatment observed in vitro also functions in vivo, we performed immunohistochemistry 
analyses on tumor sections from all the experimental groups.  We also determined the 
activity in the ERK pathway and assessed the proliferation level indicated by cell marker 
Ki-67 in tumor sections. As shown in Figure 2-12E, the improved pathway and 
proliferation inhibition in the combination treatment groups corresponded well with 
overall tumor response TGI results. ERK and AKT phosphorylation together with Ki67 
expression levels in either nucleus or cytoplasm were largely reduced in the combination 
treatment group. Furthermore, wide area of background pink colored from Matrigel in 
H&E staining for tumor sections in the combination treatment group indicated that very 
few tumor cells, if any, remained after combination treatment. The significant reduction 
of melanoma cells in the combination treatment group was further confirmed by the 
reduced density in S100 immunostains (Figure 2-12D).  
 
Since the results presented in Figure 2-12 and Table 2-3 were promising but did 
not seem to result in tumor regression, we repeated the experiment by increasing the dose 
by 50% for both ABI-274 and vemurafenib. The results are shown in Figure 2-13 and 
Table 2-4. There is a slight increase of efficacy for vemurafenib (TGI of 22.65% at 20 
mg/kg vs. 28.10 % at 30 mg/kg), and there is substantial increase of efficacy for ABI-274 
(TGI of 38.12% at 10 mg/kg vs. 72.72 % at 15 mg/kg). Moderate tumor regression (44.9 
%) on the combination treatment group with the increase drug dose was apparent as 
shown in Figure 2-13B. Collectively, these data provided the first convincing evidence 
that the combinations of novel tubulin inhibitors, such as ABI-274 with vemurafenib, are 
likely to overcome the acquired resistance to vemurafenib for melanoma patients having 
BRAFV600E mutation. 
 
 
2.3.10 Establishment of Vemurafenib-resistant MDA-MB-435 VemR Melanoma 
Subline 
 
 To further expand the panel of vemurafenib-resistant cell model that can be used 
to evaluate the efficacy and mechanism of our combination treatment, we chronically 
selected one additional melanoma cell line with acquired resistance to vemurafenib, 
MDA-MB-435 VemR cells, following similar procedure that we used to generate 
A375RF21 cell line. 
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Figure 2-13. In vivo combination of high dose vemurafenib (30 mg/kg) and ABI-
274 (15 mg/kg) in the A375RF21 xenograft model (n = 5) 
A, pictures of isolated tumor tissue. B, tumor volume growth curve. C, mice body weight 
versus time plot. Combination of ABI-274 and vemurafenib at this dose achieved about 
45% of tumor regression. 
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Table 2-4. Tumor growth inhibition (TGI) and tumor weight comparison for in 
vivo combination of vemurafenib (30 mg/kg) and ABI-274 (15 mg/kg) in the resistant 
A375RF21 xenograft model (n = 5) 
 
Treatment group   TGI (%) Tumor weight 
(gram) 
Vehicle     - 1.60 ± 0.22 
Vemurafenib 30 mg/kg 28.10 ± 4.81 1.05 ± 0.21 
ABI-274 15 mg/kg 72.72 ± 8.29 0.51 ± 0.12 
Vemurafenib 30 mg/kg + ABI-274 
15 mg/kg 
103.38 ± 1.42 0.08 ± 0.03 
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As determined by MTS assay, the established MDA-MB-435 VemR subline is 
resistant to both vemurafenib and another recently approved BRAF inhibitor, dabrafenib.  
IC50 of vemurafenib increased over 14 folds, from 678 ± 24 nM in MDA-MB-435 cells to 
9.82 ± 0.04 μM in MDA-MB-435 VemR cells. And IC50 of dabrafenib increased over 50 
folds, from 4 ± 1 nM in MDA-MB-435 cells to 211 ± 13 nM in MDA-MB-435 VemR 
cells. However, as shown in Figure 2-14A, MDA-MB-435 VemR cell was not cross-
resistant to MEK inhibitors trametinib. This phenotype indicated that MDA-MB-435 
VemR had developed resistance to BRAF inhibitor through mechanism different from 
A375RF21 cells. In fact, western blotting analysis (Figure 2-14B) revealed that PDGFRβ 
level in MDA-MB-435 VemR cells was largely decreased comparing with that in MDA-
MB-435 parental cells, which is distinct from A375RF21 cells. Interestingly, although no 
significant activation of AKT/mTOR was observed in MDA-MB-435 VemR cells, MEK 
phosphorylation level maintained in the resistant cells when it was treated by 
vemurafenib. Therefore, MDA-MB-435 VemR adopted the resistance to BRAF inhibitor 
through MEK activation mediated mechanism. 
 
 
2.3.11 Combination of Tubulin Inhibitor with BRAF Inhibitor Showed Synergistic 
Anti-proliferation Effects in Expanded Panel of Vemurafenib or Trametinib 
Resistant Cell Lines 
 
 Due to the complexity of BRAF inhibition resistant mechanism and the 
heterogeneity of melanoma tumor, the efficacy of combination therapy need to be tested 
on expanded panel of BRAF resistant cell lines other than A375RF21. In our anti-
proliferation study, combination of tubulin inhibitor with BRAF inhibitor continuously 
displayed synergistic effect in MDA-MB-435 VemR, 451LuMR and WM983B BR cells. 
Among them, 451LuMR and WM983B BR cells were established by Dr. Mennhard 
Herlyn’s lab through chronical exposing BRAFV600E human melanoma 451Lu and 
WM983B cells to trametinib or vemurafenib, accordingly. These cells are found to cross 
resistant to vemurafenib, dabrafenib and trametinib(131). Combination index as shown in 
Table 2-5 indicated that ABI-274 combined with either vemurafenib or dabrafenib 
displayed strong in vitro synergistic effect in MDA-MB-435 VemR cells. In 451LuMR 
and WM983B BR cells, combination therapy of ABI-274 and vemurafenib showed 
sustained synergistic growth inhibition, while the combination of vemurafenib with 
trametinib only had additive anti-proliferation activity.  
 
 
2.4 Discussion 
 
Although vemurafenib, the first drug approved for melanoma patients harboring 
BRAFV600E mutation, showed remarkable responses in initial therapy, almost all patients 
taking this drug developed resistance to vemurafenib within a few months (132). 
Understanding the underlying mechanisms of either primary or acquired resistance and 
developing suitable combination strategies could provide more effective ways to 
overcome such resistance. There is a rich literature in both preclinical studies and clinical 
trials to search for effective combination of vemurafenib with other agents in order to  
 42 
 
 
Figure 2-14. Establishment of BRAF inhibitor resistant MDA-MB-435 VemR 
subline with chronically selection in vitro 
A, dose-growth inhibition curves of MDA-MB-435 VemR cells when treated by BRAF 
inhibitor, MEK inhibitor or tubulin inhibitor. Data was determined by MTS assay in vitro 
(n = 4). B, western blotting analysis revealed that MDA-MB-435 developed resistance to 
BRAF inhibitors through MEK activation mediated mechanism. 
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Table 2-5. Combination of BRAF inhibitors with ABI-274 showed synergistic 
effect in the expanded panel of vemurafenib-resistant melanoma cell lines 
 
Cell line BRAF 
inhibitor 
Tubulin 
inhibitor 
CI at ED50 CI at ED75 CI at ED90 
MDA-MB-
435 VemR 
Vemurafenib  ABI-274 0.59 0.55 0.52 
Docetaxel 0.55 0.94 1.03 
Vinblastine 0.79 0.95 1.13 
Dabrafenib ABI-274 0.37 0.43 0.51 
Docetaxel 0.84 0.84 0.85 
Vinblastine 0.44 0.44 0.47 
451LuMR Vemurafenib  ABI-274 0.96 0.74 0.68 
Docetaxel 0.44 0.60 0.82 
Trametinib 0.73 1.15 1.03 
WM983B 
BR 
Vemurafenib  ABI-274 0.29 0.39 0.74 
Docetaxel 0.24 0.49 1.04 
Trametinib 2.03 1.26 0.94 
 
The combination index (CI) values were calculated based on the results from cell 
viability MTS assay (n = 5). CI < 0.9 indicates synergism; 0.9 ≤ CI ≤ 1.1 indicates 
additive effect; CI > 1.1 indicates antagonism between the two tested drugs. 
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eliminate or reduce melanoma tumor resistances to BRAF or MEK1/2 inhibitors (28, 37, 
39, 80, 124, 133, 134). Inhibitors to the RAF/MEK/ERK pathway mainly produce G1 
cell-cycle arrest rather than melanoma tumor cell death. Thus a combination of agents 
targeting different components in the same pathway (e.g. combination of vemurafenib 
and MEK1/2 inhibitors), while effective initially (109), may not maintain long-lasting 
synergy against resistant cells that can escape from these G1 cell-cycle arrests.  
 
Activation of the PI3K/AKT/mTOR signaling pathway has been shown to 
contribute to the diminished sensitivity to ERK1/2 inhibition in human melanoma cell 
lines (135),  and several recent studies have clearly demonstrated the synergistic 
combination of an inhibitor targeting PI3K/AKT/mTOR pathway and a BRAF inhibitor 
or a MEK inhibitor (35, 39, 135, 136). Recently several novel classes of compounds were 
reported as inhibitors of tubulin polymerization and also showed strong inhibition of the 
AKT pathway (137-139). In addition, constitutively active PI3K/AKT pathway has been 
shown to lead to multidrug resistances to microtubule-targeted tubulin-polymerizing 
agents (MTPA) and inhibition of PI3K/AKT-mediated signaling pathway has been shown 
to sensitize cancer cells to MTPA-induced apoptosis (140). These studies indicate a close 
interplay between tubulin polymerization inhibitors and AKT down regulation in cancer 
cells. In addition, Nikolas K.H et al. has recently reported that MEK inhibitor AZD6244 
induced growth arrest in melanoma cells and tumor regression when combined with 
docetaxel (141). Interestingly, our current report is consistent with these studies. The in 
vivo studies presented here show an effective combination treatment in tumor cells that 
are already vemurafenib-resistant by using A375RF21 xenograft models. It is 
conceivable that if we used the combination before tumor cells became resistant to 
vemurafenib, tumor regression may be more enhanced and we could significantly delay 
or even prevent the development of resistant tumor cells. This could translate into at least 
a substantially longer progression-free time in patients, and/or enhanced disease 
regression. Collectively, our study offers the first direct evidence and a rationale for 
combining a potent tubulin inhibitor with an inhibitor targeting the RAF/MEK/ERK 
pathway for greatly improved therapy for melanoma patients.  
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CHAPTER 3.    LITERATURE REVIEW OF SURVIVIN AND ITS 
ANTAGONISTS  
 
 
3.1 The Structure and Tissue Distribution of Survivin 
 
Survivin (encoded by BIRC5), the smallest member of the inhibitor of apoptosis 
proteins (IAPs), is a 16.5kDa protein that consists of an N-terminal Zn2+-binding 
baculoviral inhibitor-of-apoptosis (IAP) repeat (BIR) domain and an amphipathic C-
terminal helix (142-144). Two molecules of human survivin form a homodimer through a 
hydrophobic interface, which locates in a region between the BIR domain and C-terminal 
alpha helix (145). 
 
Survivin is ubiquitously expressed in lung, breast, gastric, bladder, colon and 
prostate cancer, lymphoma, esophageal carcinoma and osteosarcoma cells but 
undetectable in finally differentiated adult normal tissues (146-149). And its tumor 
specific distribution pattern in human tissues has distinguished survivin from other 
members in IAP family (150, 151). Overexpression of survivin is positively correlated 
with tumor invasion, multiple drug resistance, and unfavorable prognosis with decreased 
patient survival rates (150, 152-156). Recent studies also revealed that there is a definite 
correlation between high levels of survivin and the over-activation of known oncogenic 
pathways (HIF-1α (157), HSP90 (158, 159) PI3K/AKT (160, 161), ERK (162), Bcl-2 
(14,15) and RAS pathways(163, 164)), but negatively correlate with tumor suppressor 
genes(165-167) (p53, PTEN). In addition, the presences of survivin in physiological 
fluids including urine, bronchial aspirate, pleural effusion and plasma make survivin as a 
useful biomarker to non-invasively monitor tumor relapse and metastasis(168, 169). 
 
 
3.2 The Expression and Regulation of Survivin 
 
Survivin expression dominantly peak in the G2/M phase, followed by a rapid 
degradation via the ubiquitin-proteasome pathway during G1 phase (161, 170). Studies 
have shown that this cell-cycle dependent pattern results from the reduced degradation of 
survivin rather than the up-regulated gene transcription in G2/M phase (171). The half-
life of survivin is as short as 30 min and its degradation is considered to be involved with 
the X-linked inhibitor of apoptosis (XIAP) – associated factor 1 (XAF1). The XAF1-
XIAP interaction activates the ubiquitin ligase activity of XIAP and thus degrades 
survivin (172). Meanwhile, heat shock protein 90 (Hsp90), one of the most important 
molecular chaperones in mammalian cells, binds to survivin BIR domain through ATPase 
domain of Hsp90 and protect survivin from the ubiquitin-mediated degradation (Figure 
3-1)(158). 
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Figure 3-1. The nodal functions of survivin and targets of survivin inhibitors 
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3.2.1 Control of Survivin Gene Expression by Transcription Factors 
 
Multiple upstream factors control the gene expression of survivin, including but 
not limiting to tumor suppressor p53, specificity protein 1 (Sp1), and Forkhead box O3 
(FOXO3).  
 
The interplay between p53 and survivin is mutual. In one hand, p53 can direct 
bind to and stimulate the DNA methyl-transferase (DNMT) 1(173), which methylates 
survivin promoter and leads to survivin gene repression. On the other hand, ectopic 
survivin decreases the mRNA level of p53 and Mdm2 in Adriamycin-treated MCF7 cells 
(174). In many cases, loss of wild-type p53 and survivin overexpression co-exist in 
cancer with elevated resistance to therapy. Also p53 gene mutant status is found to be 
highly associated with the expression of survivin and its anti-apoptotic splice variants, 
survivin-deltaEx3 and survivin-3B, in 163 breast carcinoma tissues (175).  
 
Chen et al (176) has shown that Sp1 can cooperate with Sp3 to regulate the basal 
expression level of survivin in Hela cells. Sp1 directly bind to the TATA-less regions of 
survivin promoter through the interaction with two Sp1 binding sites on that promoter 
(position -148 to -153; position -127 to -140). Furthermore, Sp1 is co-overexpressed with 
survivin in adenocarcinoma of lung cells A549 (177). In this model, Sp1 up-regulates 
survivin expression through direct binding with survivin promoter and lead to the 
deduction of caspase-9 activity (177). 
 
FOXO3 increases in cell response to high level of intracellular reactive oxygen 
species (ROS). The nuclear translocation of FOXO3 and activation of FOXO3/FKHRL1 
represses the survivin transcription in human neuroblastoma (NB) tumor and sensitize it 
to doxorubicin treatment (178). In fact, survivin induces mitochondria fragment, reduces 
mitochondrial respiration and thus protects NB cells from the FOXO3-mediated 
mitochondrial apoptosis (179).  
 
Other nuclear factors like kappa-light-chain-enhancer of activated B cells (NF-
κB) (180), signal transducer and activator of transcription-3 (STAT3) (181), Wingless-
type MTV integration site family member (Wnt) (182) have been reported to increase the 
mRNA level of survivin. And insulin-like growth factor (IGF) can promote the 
translation of survivin and prostate cancer cell survival through activating 
phosphoinositide 3-kinase (PI3K)/ AKT/ mammalian target of rapamycin (mTOR) 
signaling pathway (183). 
 
 
3.2.2 Post-translational Modification of Survivin 
 
Besides the mRNA-level regulation of survivin, post-translational modification 
determines the survivin function and its distribution among nuclear, cytoplasm and 
mitochondria. Generally, two major types of post-translational modification survivin are 
reported in the literature: phosphorylation and acetylation (Figure 3-1). 
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Survivin can be phosphorylated at several sites that shape its molecular functions, 
including Thr34, 53 and 117 plus Ser20. Thr34 of survivin is phosphorylated by cyclin 
dependent kinase (CDK)/p34cdc2-cyclcin B1 and this process results in “activated” 
survivin that is able to bind with caspase-9 in Hela cells (184). Ser20 of survivin can be 
phosphorylated by protein kinase A (PKA) or polo-like kinase 1 (PLK1) but evidences 
exist that they contribute to different molecular function of survivin. The phosphorylation 
of survivin through PKA-mediated mechanism specifically occurs in cytosol rather than 
mitochondria and leads to the stabilization of XIAP and subsequently anti-apoptosis 
effect (185). Interestingly, in cytosol PLK1-mediated phosphorylation of survivin at 
Ser20 is discovered to activate Aurora B and promote the formation of chromosomal 
passenger complex (CPC) in nucleus. In this way, PLK1 regulates cell mitosis (186). 
 
Next, the acetylation of survivin at residue Lys129 is regulated by factors like 
CREB binding protein (CBP) and histone deacetylase 6 (HDAC6). CBP directly 
acetylates survivin and catalyzes its homo-dimerization and accumulation in nucleus. 
Subsequently, the acetylated survivin binds to the N-terminal of STAT3 and decreases 
STAT3 oncogene activity (187). HDAC6 de-acetylates survivin and promotes the nuclear 
export of survivin in MCF7 breast cancer cells (188). 
 
 
3.3 The Nodal Functions of Survivin 
 
Functionally, nuclear survivin is a component of CPC (189), which regulates 
chromosomal segregation during cell division (190). Cytoplasmic and mitochondrial 
survivin inhibits the cell apoptosis both directly and indirectly through caspases-mediated 
mechanisms (Figure 3-1) (150, 154, 155). 
 
 
3.3.1 Apoptosis 
 
Survivin interferes the apoptosis process in both caspases-dependent and 
caspases-independent mechanisms. As indicated above, Thr34 phosphorylated survivin in 
mitochondria can bind directly with caspase-9 and thus prevent caspase-9 activation. 
Also the formation of survivin-XIAP complex protects ubiquitin-mediated degradation of 
XIAP and thus indirectly inhibits caspase-9 activation (172). Interestingly, survivin is 
found to bind with caspase-3 and caspase-7 with high affinity in vitro under cell-free 
condition (191). Meanwhile, the anti-apoptotic effect of survivin relies on the direct 
interaction between survivin and a mitochondria protein, Smac/DIABLO (second 
mitochondria-derived activator of caspases). In this case, survivin sequesters 
Smac/DIABLO away from XIAP binding and inhibits Smac/DIABLO releasing from 
mitochondria (144, 192, 193). Structure analysis showed that Smac/DIAOBLO 
competitively binds with survivin BIR domain through N-terminal Ala-Val-Pro-Ile 
(AVPI) tetra-peptide motif like it does with other IAP proteins (144, 194). Additionally, 
survivin induces the translocation of mitochondrial apoptosis-inducing-factor (AIF) from 
cytoplasm to nucleus and promote caspase-independent pathway with DNA-
fragmentation (195). 
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3.3.2 Mitotic 
 
CPC consists of two distinct units: an enzymatic complex contains Aurora B and 
C-terminal fragment of the inner centromere protein (INCENP), and a chromosomal 
localization complex contains N-terminal fragment of INCENP, survivin and Borealin 
(196). BIR domain of survivin interacts with phosphorylated Thr3 on histone H3 
(H3T3ph) through N-terminal Ala1 (194) and activates the kinase function of Aurora B 
(197). The formation of CPC and recognition of survivin BIR domain with Aurora B are 
crucial for both the proper chromosomal alignment and mitotic spindle assembling (189).  
 
 
3.3.3 DNA Repair and Autophagy 
 
The mechanism of survivin interfering with DNA-repair and autophagy has not 
been studied as clear as its function involves apoptosis and cell division. Current 
evidences show that nucleus survivin interacts with or regulates the level of various 
DNA-damage/repair-associated modules like Ku70 (a DNA-damage molecular sensor) 
(198) and DNA-dependent protein kinase catalytic subunit (DNA-PKCs) (199). Silencing 
survivin may induce autophagy-dependent apoptosis in hepatocellular carcinoma cells 
(200). And the down-regulation of survivin through knock-out of Beclin 1, an important 
autophagy regulator, sensitizes glioma cells to TRAIL-induced apoptosis (201).  
 
 
3.4 Current Antagonists of Survivin as Anti-tumor Agents 
 
 
3.4.1 Small Molecule Inhibitors 
 
Survivin is not enzymatic protein and doesn’t occupy common “druggable” 
binding site on its surface. Therefore, it makes the discovery of small molecule survivin 
antagonist fairly difficult. Generally, small molecule agents under current development 
antagonize survivin function in three distinct mechanisms.  
 
The first category is survivin expression modulator, which blocks either survivin 
gene promoter or transcriptional factor. For example, YM155, which is under Phase II 
clinical investigation, selectively suppresses the gene expression of survivin over the 
other IAPs and induces caspase or autophagy-mediated apoptosis in various cancer type 
(202-206). In xenograft models, YM155 can lead to tumor regression and sensitize the 
tumor to the treatment of commonly used chemotherapy agents (206, 207). Another 
example is FL118, which binds to survivin gene promoter region at low nano-molar 
concentration in a p53-independent manner and shows great anti-tumor efficacy in 
xenograft models (208, 209). Terameprocol (EM1421) inhibits Sp1 and subsequently 
reduces transcription of survivin, CDK1 and VEGF(210). Its administration as vaginal 
ointment is well tolerated in PhaseI/II trials in women with HPV-linked cervical 
squamous intraepithelial neoplasia but limited systemic absorption (211). However, in a 
more recent Phase I study, where terameprocol is co-currently administered with enzyme-
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inducing antiseizure drugs (EIASDs) intravenously for 5 consecutive days each month in 
high-grade glioma, the combination therapy is well tolerated without alteration of 
terameprocol pharmacokinetic profile and myelosuppression side effects (212). 
 
The second type of small molecule survivin inhibitor interferes with the 
interaction between survivin and other proteins like Hsp90 and Smac/DIABLO. A 
peptidomimetic of survivin sequence K79 to L87, shepherdin, can bind to ATP pocket on 
Hsp90 N-terminus and then destabilize survivin together with other Hsp90 client proteins 
like AKT, CDK6 and telomerase (213, 214). Shepherdin induces both apoptotic and non-
apoptotic massive cancer cell death and is well tolerated in mice model. The non-peptidic 
5-aminoimidazole-4-carboxamide-1-b-D-ribofuranoside (AICAR) directly binds to 
chaperone through hydrogen bonds between ribose ring of AICAR and Asp93 of Hsp90 
protein. And it destabilizes survivin and exerts anti-cancer activity through mechanisms 
similar to shepherdin (215). Oikawa et al. has reported the identification of a 5-dezaflavin 
analog that selectively inhibits the interaction of survivin-Smac/DIABLO but not 
survivin-INCENP through high through-put system. This compound sensitizes the lung 
carcinoma A549 cells to doxorubicin-induced DNA damage and synergistically enhances 
the apoptotic cell death (193). 
 
Some other small molecule survivin inhibitors regulate the post-translational 
modification of survivin mainly through the inhibition of CDK-mediated phosphorylation 
of survivin Thr34. Reported compounds in this category include flavopiridol (216), 
NU6140(217) and purvalanol A (218, 219). But usually their anti-cancer effect is not 
solely based on the inhibition of survivin phosphorylation. Among them, flavopiridol, as 
a flavonoid alkaloid pan-CDK inhibitor and the first CDK inhibitor to enter the clinic was 
approved as an orphan drug for treatment of chronic lymphocytic leukemia and is 
currently undergoing phase II studies as monotherapy and also as in combination regimes 
with traditional chemotherapy agents (220, 221). 
 
 
3.4.2 Survivin Antisense Oligonucleotides (ASOs) 
 
ASOs are developed as to specifically hybridize with complimentary survivin 
mRNA and lead to destruction of survivin mRNA by RNAse H (222). Gataparsen (or 
LY2181308) is the most advanced survivin ASO and it has an 18-mer 2’-O-
methoxyethyl-(MOE) modified structure, which protects it from the nuclease 
degradation. Upon binding to translational initiation condo of survivin, gataparsen 
activates caspase-3 apoptosis cascade in tumor cells without affecting other proteins and 
it is in Phase II clinical study. The maximum tolerable dose of gataparsen is determined 
as 750 mg in patients with various solid malignancies and its accumulation in tumor 
tissue and survivin-deregulation effect is confirmed in a Phase I study (223). However, 
data revealed from a Phase II study in patients with castration-resistant prostate cancer 
(CRPC) shows that the combination therapy using gataparsen together with standard 
treatment docetaxel/prednisone doesn’t achieve better efficacy compared to a control 
group receiving only standard docetaxel/prednisone (224).  
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Another survivin ASO under development is SPC3042 (or EZN-3042), which is a 
16-mer locked nucleic acid ASO that binds to exon 4 of the survivin transcript (225). In 
lung carcinoma A549 and Calu-6 xenograft models, SPC3042 induces 60% down-
regulation of survivin mRNA and 37-45% tumor growth inhibition (TGI) as single 
treatment and 83% TGI as combination treatment with paclitaxel (226). However, recent 
data from a Phase I study has reported dose-limiting grade 3 toxicity of SPC3042 as 
single treatment in children with relapsed acute lymphoblastic leukemia (ALL), although 
2 out of 5 patients are detected with decreased survivin expression. And the study was 
terminated due to the severe side effect without further clinical development (227). 
 
 
3.4.3 Dominant Negative Survivin (DNS) 
 
DNS is a single amino acid mutant form of survivin protein. DNS is designed to 
form heterodimer with wild-type survivin and then interfere with the survivin biological 
function. Study has shown that delivering DNS plasmid DNA or DNS protein into cancer 
cell in vitro or tumor tissue in vivo can induce wide-spread apoptosis and tumor growth 
inhibition. One of the well-studied DNSs is the T34A survivin, of which Thr34 is 
replaced with alanine. T34A DNS is also referred as “phosphorylation-dead mutation 
survivin”, since the phosphorylation of survivin by CDK/p34cdc2-cyclcin B1 on Thr34 is 
critical for its stability and anti-apoptotic function. T34A survivin triggers mitochondria 
apoptosis pathway, promotes p53-associated apoptosis and enhances the anti-cancer 
efficacy of chemotherapy agents like cisplatin and doxorubicin (228). Transfection of 
T34A survivin plasmid into YUSAC2 melanoma cells prevented tumor formation upon 
s.c. injection in mice model and induction of T34A in established melanoma tumors leads 
to 60-70% tumor growth inhibition (229). Fusing an HIV-derived TAT peptide sequence 
into T34A survivin greatly increases the cell permeability and protein transduction 
efficiency. The TAT-T34A survivin enters YUSAC2 or WM793 melanoma cells within 
30 min and leads to caspase-3 activation and cell detachment. Intraperitoneal (i.p.) 
injection of TAT-T34A survivin results in rapid tumor accumulation in 1 hr with 
induction of apoptosis and aberrant nuclei formation (230). 
 
Besides, the replacement of Cys84 on wild-type survivin with alanine generates 
C84A survivin and disrupts the zinc chelating of BIR domain on survivin then abolishes 
the anti-apoptosis effect of survivin protein. When C84A survivin coded plasmid is intra-
tumorally injected together with a costimulatory of T cells, B7-1, mouse EL-4 thymic 
lymphoma tumor growth has been significantly inhibited. And the combination treatment 
generates higher antitumor cytotoxic T-lymphocyte (CTL) activity comparing with the 
single treatment groups (231). When survivin C84A mutant is fused with a 9 N-terminal 
arginine residues (R9, cell-permeable peptide carrier), the formed SurR9-C84A protein 
shows dual actions. In normal cells, it protects differentiated SK-N-SH human 
neuroblastoma cells from activated T-cell neurotoxicity (232) and increases the 
proliferation of differentiated SK-N-SH and HCN-2 neurons (233). In cancerous cells, it 
sensitizes prostate cancer cells to TNF-α and induces tumor-specific intrinsic and 
extrinsic apoptosis in colon cancer cells (234). Interestingly, researchers have studied that 
the adenovirus transduction of double point mutant survivin (TC34,84AA) into 
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hepatocellular cancer cells exerts stronger cytotoxicity effect and this form of survivin 
mutant is more sensitive to the ubiquitin-mediated degradation (235). 
 
 
3.5 Conclusion 
 
Despite extensive efforts since the discovery of survivin in 1997, only a few 
survivin antagonists are available for clinical test. Given the fact that survivin is 
preferentially distributed in cancer cells rather than normal tissues, survivin antagonists 
usually are well-tolerated and inherently show low toxicities (153, 155, 202). However, 
inadequate anti-tumor efficacy leads to the major failure in clinical trials of survivin 
antagonists. Two categories of factors contribute to the observed efficacy limits. On one 
hand, the degradation and unspecific delivery of biological agents include antisense 
oligonucleotides (e.g., LY2181308 and SPC3042) (225, 236, 237), ribozymes (29, 30) 
and small interfering RNAs (238, 239) restricted their internalization into tumor cells. On 
the other hand, the high degree of co-overexpression of survivin with drug-resistant 
markers like ABC transporter proteins hindered the efficacy of some survivin antagonists 
(153, 240). For example, the tumor cell uptake of YM155, the most potent survivin gene 
promoter inhibitor (203, 205, 207), is impeded by P-glycoprotein (Pgp) drug efflux pump 
(241), which is practically co-overexpressed with survivin in drug-resistant breast cancer, 
renal cell carcinoma and acute myeloid leukemia patients (242-244). Therefore, the 
development of new survivin inhibitors that can effectively overcome multidrug 
resistance with good pharmacokinetic properties is highly needed. 
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CHAPTER 4.    DISCOVERY OF NOVEL SMAC MIMETIC AS SELECTIVE 
SURVIVIN INHIBITOR* 
 
 
4.1 Introduction 
 
The family of inhibitor of apoptosis proteins (IAP) bind to caspases, block the 
assembling of pro-apoptotic protein signaling complexes, and thereby prevent the 
activation of caspase proteolytic cleavages and the subsequent triggering of apoptosis. 
There are eight IAP proteins identified in human: NAIP, cIAP1, cIAP2, XIAP, ML-IAP, 
ILP2, survivin, and apollon (172, 245, 246). As overexpression of IAPs frequently occurs 
in cancer cells and has been linked to tumor progression, treatment failure, and poor 
prognosis, IAPs are considered to be promising therapeutic targets in either directly 
eliciting cell death or lowering the threshold for cell death induction of current anticancer 
therapeutics (245, 247, 248).  
 
Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP 
binding protein with low pI) molecules released from mitochondria antagonize the IAPs 
and can protect caspases from IAP inhibition (245, 247-250). Smac interacts with IAPs 
mainly via its N-terminal AVPI binding motif. A proven strategy for inhibiting IAPs is to 
disrupt the interaction between an IAP and Smac by developing Smac mimetics (249). 
Smac-mimicking IAP antagonists can induce apoptosis in tumor cells and effectively 
inhibit tumor growth in mice (251-256). They can also inactivate nuclear factor κB (NF-
κB) and produce secretion of tumor necrosis factor α (TNF-α) (248, 255). Several Smac 
mimetics have entered late stage preclinical development or human clinical testing as 
novel cancer therapeutics (251-256). For example, Birinapant (TL32711), now in Phase 
II study, can effectively suppress cIAP1 and XIAP at well-tolerated doses and promises 
antitumor activity either as a single agent or in combination with standard-of-care 
chemotherapeutic drugs in adult patients with advanced solid tumors or lymphoma(257). 
However, no IAP inhibitors have been approved by the FDA as of today, and there are 
limitations with many existing IAP inhibitors. For example, YM155 is a well-known 
survivin inhibitor that has gone through clinical trials, but it has been shown to be a 
substrate for the P-glycoprotein (Pgp) drug efflux pump (241), suggesting that it could 
suffer from multidrug resistance (MDR) in its eventual clinical use. Thus, exploring 
novel scaffolds to develop potent and selective IAP antagonists is still much needed. 
Since all IAP proteins share the signature baculoviral IAP repeat (BIR) domain (245), 
which interacts with Smac, shape-based virtual screening will be helpful in identifying 
potential small-molecule Smac mimetics for regulating apoptosis in cancer cells.  
 
In this chapter, we describe our efforts to identify novel small-molecule Smac 
mimetics through an integrated virtual screening and biological validation approach.  
 
 
* Modified with permission. Wang J, Li W. Discovery of novel second mitochondria-
derived activator of caspase mimetics as selective inhibitor of apoptosis protein 
inhibitors. J Pharmacol Exp Ther. 2014;349: 319-329. 
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Their efficiency in inhibiting IAPs, especially XIAP and survivin (BIRC5), and inducing 
apoptosis in cancer cells was further validated in serial biological studies both in vitro 
and in vivo. These compounds represent novel scaffolds for IAP inhibition and can be 
further optimized to serve as a potential targeted agent for various types of cancers.  
 
 
4.2 Methods 
 
 
4.2.1 Shape-based Virtual Screening 
 
The University of Cincinnati’s Drug Discovery Center (UC DDC) Library 
(contains 362,910 compounds) was used to conduct the shape-based virtual screening. 
All structures were first prepared using the LigPrep module in Maestro Suite 2012 
(Schrodinger, LLC, New York, NY) to generate conformers and charged states. We used 
the phase_shape program in Canvas (version1.4, Schrodinger, LLC, New York, NY). 
Conformers with a shape similarity below 0.7 were filtered out, and hits with a similarity 
value above this threshold were selected for subsequent molecular docking process.  
 
 
4.2.2 Molecule Docking 
 
Crystal structures of Smac bound to XIAP BIR3 domain (PDB ID: 1G73 (249) 
and 1TW6 (258)) were processed with the Protein Preparation Wizard, and the grid of 
AVPI binding site was defined by Glide (version 5.7, Schrodinger, LLC, New York, 
NY). 1000 hits with top-ranked similarity value were docked into the AVPI binding site 
in each separate complex. The best docking complexes were subject to restricted 
molecular dynamics to release any strains by using the Macromodel module with OPLS-
2005 force field. The ligand and its surrounding residues within 15 Å were allowed to 
move freely, while residues outside the 15-Å radius were kept rigid. 
 
 
4.2.3 Cell Culture and Reagents 
 
Human melanoma A375 cell line and human prostate PC-3 and DU145 cell lines 
were acquired from American Type Culture Collection (Manassas, VA). Human 
melanoma M14 cell line was kindly provided by Dr. Robert Clarke (Georgetown 
University, Washington, DC). Human keratinocyte Hacat cell line was a gift from Dr. 
Andrzej T. Slominski (University of Tennessee Health Science Center, Memphis, TN). 
Human dermal fibroblast adult cells (HDFa) cells were purchased from Life 
Technologies (Thermo Fisher Scientific Inc., Waltham, MA). All cell lines were 
authenticated prior to use for this study. Cancer cells were cultured in DMEM (for 
melanoma cells) or RPMI 1640 (for prostate cancer cells) medium (Mediatech, Inc., 
Manassas, VA), supplemented by 10% fetal bovine serum (FBS, Atlanta Biologicals, 
Lawrenceville, GA), 1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis, MO) 
and 5 μg/mL bovine insulin (Sigma-Aldrich, St. Louis, MO). Hacat cells were cultured in 
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10% FBS supplemented DMEM medium. HDFa cells were maintained in supplemented 
Gibco® Medium 106 (M-106-500, Life Technologies). Compounds were dissolved in 
dimethyl sulfoxide (DMSO, Sigma-Aldrich, and St. Louis, MO) to make a stock solution 
of 10 mM. Compound solutions were freshly prepared by diluting stocks with cell culture 
medium before use (final solution contained less than 0.5% DMSO). Proteasome 
inhibitor MG-132 was purchased from Enzo Life Sciences, Inc. (Farmingdale, NY).  
 
 
4.2.4 Cell Viability Assay 
 
Resources of cell line and culture reagent can be found in Supplemental 
Information Method. The anti-proliferation effect against cancer cells of all UC 
compounds was first screened in vitro by using the MTS assay as described previously 
(127, 129, 259). Then the IC50 values of selected hits were tested through the 
sulforhodamine B (SRB) assay as reported before (129).  
 
 
4.2.5 siRNA Silencing Survivin or XIAP Expression 
 
SignalsSilence® survivin or XIAP siRNA and fluorescein conjugated control 
siRNA were purchased from Cell Signaling Technology, Inc. (#6351, #6446, #6201, 
Danvers, MA). They were transfected into pre-seeded A375 or PC-3 cells by mixing with 
Lipofectamin® RNAiMAX reagent (Invitrogen, Thermo Fisher Scientific Inc., Waltham, 
MA) at the final concentration of 100 nM in serum-free medium. 24 hr after the 
transfection, cells were treated with compound solution to determine the changes of cell 
viability.  
 
 
4.2.6 Caspase Functional Assay 
 
The caspase activity of cancer cells treated by DMSO control or compound 
solution after 24-h or 48-h incubation was analyzed using Caspase-Glo® 3/7 and Caspase-
Glo® 9 assay kits from Promega Corporation (Madison, WI) as per manufacturer’s 
instructions. The readings of relative luminescence unit (RLU) were normalized by the 
cell viability results from the same well determined by compatible CytoTox-FlourTM 
Cytotoxicity assay kit (Promega, Madison, WI). 
 
 
4.2.7 Western Blotting 
 
After treatment for the indicated time, A375, PC-3, and DU145 cells were lysed 
to determine by Western blotting the relevant IAP family protein levels. Primary rabbit 
antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA): anti-
cIAP1 (#7065), anti-cIAP2 (#3130), anti-survivin (#2808), anti-XIAP (#2045), anti-livin 
(#2978), or anti-GAPDH (#3683). Then anti-rabbit IgG HRP-conjugated secondary 
antibody (Cell Signaling, #7071) was used to detect the target protein level Lane 
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intensities were quantified with ImageJ software (US National Institutes of Health, 
Bethesda, MD). 
 
 
4.2.8 Flow Cytometry Analysis 
 
Flow cytometry analysis was performed as described previously (129). Briefly, 
A375 cells (n = 3) were synchronized through 24 h starvation in growth media containing 
only 0.1% FBS. Then the cells were treated with 0, 1, or 4 μM UC-112 in full growth 
media (10% FBS) for another 24 h. Then the cell-phase distribution was determined on a 
BD LSR-II cytometer (BD Biosciences, San Jose, CA) with 10,000 cells scored, and data 
were processed using Modfit 2.0 program (Verity Software House, Topsham, ME). 
 
 
4.2.9 Human Melanoma A375 Tumor Xenograft Model and Treatment 
 
We first estimated the acute maximum tolerable dose (MTD) for compound UC-
112. Progressively increasing injection doses via intra-peritoneal (i.p.) injection route to 
BXD mice (n = 3) determined the estimated MTD to be above 200 mg/kg with one-week 
continuous treatment. To ensure a large safety margin during the three-week treatment 
and considering the practical doses in clinical, we scaled down the dose to 20 mg/kg and 
40 mg/kg in the xenograft model study. 
 
Seven- to 8-week-old male nude mice were purchased from Charles River 
Laboratories International, Inc. (Wilmington, MA). Right before use, A375 cells were 
suspended in ice-cold phenol red-free and FBS-free DMEM medium and mixed with 
high concentration Matrigel (BD Biosciences, San Jose, CA) at a ratio of 1:1. 100 μL of 
this mixture containing 3 × 106 A375 cells was injected subcutaneously to the left-side 
dorsal flank of each mouse. One week after the inoculation, the mice were randomized 
into four groups (n = 7), and treatments started. UC-112 compound was suspended in 
sterile PBS buffer and administered through intraperitoneally (i.p.) injection once per 
day, 5 days per week, for 3 continuous weeks. Vehicle control group was i.p. injected 
with the same volume (100 μL) of PBS buffer at the same dosing frequency. At the end 
of the experiments, mice were euthanized, and tumor tissues were isolated and weighed 
separately. Then one small piece (around 50 mg) from each tumor was cut and stored in 
liquid nitrogen immediately. The rest of the tumor tissue was fixed in 10% buffered 
formalin phosphate solution for more than 1 week before pathology staining analysis.  
 
Tumor volume and body weight of each mouse were evaluated 3 times a week. 
We calculated the tumor volume with the formula a × b2 × 0.5, where a and b represented 
the larger and smaller tumor diameters. Data were presented as mean ± SD for each 
group and plotted as a function of time. Tumor growth inhibition (TGI) ratio (%) was 
calculated as 100 - 100 × [(T - T0)/(C - C0)], where T, T0, C, and C0 were the mean tumor 
volume for the specific group on the last day of treatment, mean tumor volume of the 
same group on the first day of treatment, mean tumor volume for the vehicle control 
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group on the last day of treatment, and mean tumor volume for the vehicle control group 
on the first day of treatment, respectively.  
 
 
4.2.10 Pathology Analysis 
 
Tumor tissues fixed in formalin buffer for more than 1 week were stained with 
hematoxylin and eosin. All the slides were scanned to create a digital replica of the entire 
tissue on a glass microscopic slide by using the ScanScopeXT at 0.25 pixel/μm.  
 
 
4.2.11 TUNEL Assay 
 
To evaluate the nuclear DNA fragmentation within the A375 tumor tissue, 
Terminal deoxynucleotidyltranferase (TdT)-mediated dUTP nick end labeling (TUNEL) 
assay was performed using the DeadEndTM Fluorometric TUNEL system (Promega, 
Madison, WI) following the manufacturer's protocols. Briefly, the formalin-fixed and 
paraffin-embedded tumor sections were deparaffinized and rehydrated before 100 μL of 
20 μg/mL proteinase K solution was added to premeabilize the tumor sections. After pre-
equilibration in room temperature for 10 minutes, tumor sections were incubated with 
nucleotide mix and rTdT enzyme at 37°C for one hour. The reaction was stopped with 
saline-sodium citrate (SSC) buffer and the tumor sections were washed with PBS to 
remove the excess reagents. These slides were mounted in VECTASHIELD® + DAPI (H-
1500, Vector Labs, Burlingame, CA) to stain nuclei. Finally, coverslips were added and 
the slides were analyzed immediately under a fluorescence microscope (EVOS® FL Cell 
Imaging System, Thermo Fisher Scientific Inc., NY). 
 
 
4.2.12 Statistical Analysis 
 
Data were analyzed using Prism Software 5.0 (GraphPad Software, Inc., San 
Diego, CA). The statistical significance (P value) was evaluated by one-way ANOVA 
followed by nonparametric Dunnett’s test for in vitro apoptosis detection and in vivo 
xenograft study. Every treated group was compared to the vehicle group separately. 
 
 
4.3 Results and Discussion 
 
 
4.3.1 Identification of Initial Hits from Virtual Screening 
 
We started the study with shape-based virtual screening using the phase shape 
program in Canvas. It initiates finding trial alignments based on the principle of the 
distribution of atom triplets, then refines the top alignments to maximize the volume 
overlap(260). The 3D structure of Smac N-terminus AVPI tetrapeptide (PDB ID: 1G73 
(249)) in its bioactive conformation was selected as the query template to screen 
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molecules within the prepared compound library that could achieve similar 
conformations to that of the active AVPI peptide. In our study, the highest shape-
similarity score of UC library compounds reached 0.81; over 800 compounds had scores 
over 0.75. Figure 4-1 illustrates the alignments generated from the similarity screening 
where template ligand AVPI peptide overlapped well with representative hit compounds 
UC-222 and UC-112.  
 
To validate the theoretical interaction between the shape-based screening hits and 
IAP protein, we docked the top 1000 hits into the Smac AVPI binding pocket in two 
widely used crystal complexes of Smac-XIAP (X chromosome-linked IAP) BIR3 domain 
(PDB ID:1G73 (249) and 1TW6 (258)) . We selected two widely used Smac-XIAP 
complexes at this step because XIAP is the most characterized IAP and a direct inhibitor 
of initiator caspase-9 (245, 261). Apoptotic resistance was found to correlate with 
expression levels of XIAP in human prostate, melanoma, and non-small cell lung cancer 
cells (247). In addition, the ability of XIAP to inhibit apoptosis has been shown to allow 
melanoma cells to escape endoplasmic reticulum (ER) stress-mediated cell death (261). 
Hit compounds with best docking scores in either of the crystal structures were examined 
for their drug-like properties. Fifty hits from each of the two crystal structures (100 hits in 
total and their binding poses on the AVPI pocket are shown in Figure 4-2) were selected 
and combined to produce 71 unique final hits for subsequent in vitro assay against a 
panel of cancer cells.  
 
 
4.3.2 Validation of Virtual Screening Using In Vitro Anti-proliferation Assay 
 
Here we selected four well-established cancer cell lines (two human melanoma 
and two human prostate cancer) to first screen the hit compounds anti-proliferation 
potency. Those cell lines had been used widely to evaluate the efficacy of IAP inhibitors 
both in vitro and in vivo (254, 255, 262). We first performed a two-concentration quick 
screening assay for the 71 unique hits identified in the previous step. Hits that displayed 
more than a 10% growth inhibition at a concentration of 3 μM or 10 μM on either of 
A375 or M14 melanoma cells after 48 h incubation are listed in the column diagram 
(Figure 4-3). Compounds UC-274, UC-476, UC-112, and UC-222 (Table 4-1, upper 
panel) achieved more than 50% growth inhibition in A375 or M14 cells at low micro-
molar concentration.  
 
We subsequently determined the IC50 values for these four UC compounds and 
embelin (a reference IAP inhibitor (246, 254) serving as a positive control) on an 
expanded panel of human melanoma (A375 and M14) and prostate cancer (PC-3 and 
DU145) cell lines (Table 4-1, lower panel). Embelin is a potent and non-peptidic small 
molecular XIAP inhibitor with good in vivo antitumor and anti-inflammation activity. 
Among the four, UC-112 was the most active compound: its IC50 was as low as 0.7 μM 
against PC-3 cell line. All four UC compounds had comparable or better anti-
proliferation activity than did embelin (Table 4-1).  
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Figure 4-1. In silico similarity alignments of template ligand, Smac N-terminus 
tetrapeptide AVPI (blue stick), with representative UC compounds (UC-222 in 
brown tube; UC-112 in yellow tube) 
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Figure 4-2. In silico predicted binding poses of 50 hits selected for in vitro activity 
evaluation docked into AVPI binding sides in different XIAP BIR3-Smac complexes  
PDB IDs: A, 1G73; B, 1TW6; hits were displayed with grey thin sticks and AVPI was 
presented with green tube stick. 
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Figure 4-3. Cell growth inhibition percentages of XIAP inhibitor hits on human 
melanoma A375 and M14 cells at 4 μM or 10 μM after 48 h incubation determined 
by MTS assay (n =4) 
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Table 4-1. Growth inhibitory percentages of UC compounds at a concentration 
of 3 μM or 10 μM (MTS assay, n = 4) and IC50 (μM) values of UC compounds in 
comparison with embelin against cancer cell proliferation (SRB assay, n = 4) 
 
  Growth 
inhibition 
of A375 cell 
(%) 
Growth 
inhibition 
of M14 cell 
(%) 
IC50 (μM) 
Com-
pound 
ID 
Struc-
ture 
3 
μM 
10 
μM 
3 
μM 
10 
μM 
A37
5 
M14 PC-
3 
DU145 AVG
* 
UC-
274 
 12.8 
± 3.5 
73.7 
± 2.4 
39.9 
± 3.3 
70.2 
± 1.1 
13.4 
± 0.7 
12.3 
± 0.4 
15.1 
± 0.3 
17.3 ± 
2.9 
14.5 
± 1.1 
UC-
476 
 16.7 
± 2.3 
84.0 
± 1.6 
20.6 
± 2.0 
85.3 
± 3.8 
10.4 
± 0.2 
10.2 
± 0.2 
12.8 
± 2.1 
11.4 ± 
2.2 
11.2 
± 0.6 
UC-
112 
 50.7 
± 5.1 
65.0 
± 3.4 
81.1 
± 1.7 
99.6 
± 0.6 
1.6 ± 
0.1 
2.5 ± 
0.3 
0.7 ± 
0.1 
3.4 ± 
0.8 
2.1 ± 
0.6 
UC-
222 
 67.0 
± 1.6 
94.6 
± 1.0 
73.7 
± 2.0 
99.2 
± 0.7 
2.7 ± 
0.4 
3.5 ± 
0.1 
2.3 ± 
0.2 
4.5 ± 
1.7 
3.3 ± 
0.5 
Embe-
lin 
 ND ND ND ND 14.3 
± 3.2 
20.7 
± 5.4 
13.0 
± 1.8 
23.2 ± 
3.7 
17.8 
± 2.5 
 
ND: not determined. Data are shown as mean ± SEM. AVG*: average IC50 value was 
calculated using the data across all four tested cell lines of the same compound. 
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We also investigated the cell toxicity of these UC compounds on two non-
cancerous cell lines (Table 4-2). Compared with its average IC50 value in the tested 
cancer cell lines, UC-112 has around 2.5 folds higher IC50 values on Hacat or HDFa cells. 
The IC50 values of UC-222 have increased 8 to 12 folds in the tested non-cancerous cells, 
compared with the average  IC50 on the cancer cell lines.  
 
 
4.3.3 Hit Compounds Increased Caspase Activities Significantly Better than 
Embelin 
 
The Smac N-terminus IAP binding motif interacts with the IAPs and protects 
caspase function either directly or indirectly. Because the overexpression of IAPs in 
cancer cells result in the suppression of caspase functions, the capability of raising 
caspase activities is often used to measure the potency of IAP inhibitors (250-252). 
Embelin was reported to increase caspase activity in PC-3 cells at a concentration of 40 
μM after 42-h incubation (254). However, our pilot study showed that four most potent 
UC compounds at the concentration of 40 μM would kill most of the cancer cells, 
therefore making the measurement of caspase level below the assay detection limit. For 
this reason, we used much lower concentrations for UC compounds and performed the 
caspase functional Glo-assay (Figure 4-4A to D). All UC compounds effectively 
increased the caspase-3/7 (the executor caspases) and caspase-9 (the initiator caspase) 
levels on A375 and PC-3 cells in a time-dependent manner (Figure 4-4). In addition, UC-
222 at a concentration of 10 μM and UC-112 at a concentration of 4 μM (10 μM of UC-
112 was too high for this assay due to its higher potency) had significantly stronger (P < 
0.01) caspase activation potency compared to embelin at 4 times or 10 times higher 
concentration (40 μM). 
 
 
4.3.4 Western Blotting Analyses of IAPs Level Change in Cancer Cells 
 
Having established that the four UC hit compounds  can potently increase the 
caspase activities, we asked the question whether these compounds produced their effects 
by directly inhibiting IAPs, since they were screened in silico as Smac N-terminus AVPI 
mimetic molecules. To answer this question, we studied the changes of IAP levels in 
cancer cells when they were treated by the two most potent UC compounds, UC-112 and 
UC-222, or the reference IAP inhibitor embelin. While there were no significant changes 
of XIAP, cIAP1, cIAP2, or survivin expression at short time incubation (3 h, data not 
shown), when the incubation time was increased to 24 h, UC-112 at concentrations of 4 
μM or 10 μM (Figure 4-5A)  significantly suppressed survivin level  on A375, PC-3, and 
DU145 cell lines in a dose-dependent manner. UC-112 potently decreased survivin level 
(94% and 97% at 4 μM and 10 μM, respectively) in A375 cells while its inhibition of the 
other major IAPs (i.e., XIAP, cIAP1, cIAP2), which also interact with Smac, was much 
weaker. At the same time point (24 h), UC-222 at concentrations of 4 μM or 10 μM 
decreased the level of cIAP2 on PC-3 cells and XIAP on DU145 cells but only had very 
mild effects on the survivin level in either cell line (Figure 4-5A).  
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Table 4-2. IC50 (μM) values of UC compounds in comparison with embelin 
against normal cells proliferation (SRB assay, n = 4) 
 
Cell line 
type 
Cell line 
name 
UC-274 UC-476 UC-112 UC-222 Embelin 
Cancer 
cell lines 
AVG* 14.5 ± 1.1 11.2 ± 0.6 2.1 ± 0.6 3.3 ± 0.5 17.8 ± 2.5 
Non-
cancerous 
cell lines 
Hacat > 100 6.2 ± 1.8 5.6 ± 1.5 36.0 ± 2.3 43.6 ± 3.7 
HDFa 42.8 ± 6.4 11.4 ± 2.5 5.2 ± 0.2 29.5 ± 7.1 3.1 ± 0.7 
 
Data are shown as mean ± SEM. AVG*: average IC50 value on four cancer cell lines 
(A375, M14, PC-3, DU145). 
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Figure 4-4. Relative in vitro caspase activity of human melanoma A375 or human 
prostate cancer PC-3 cells after treatment with UC compounds or embelin at 
different concentrations (n = 4) 
Testing concentrations (4 μM or 10 μM) of UC compounds were selected in reference to 
their in vitro anti-proliferation potency. All the relative light unit (RLU) data were 
normalized according to the cell viability results read from the same well in a 96-well 
plate. A, caspase-3/7 in A375 cells. B, caspase-3/7 in PC-3 cells. C, caspase-9 in A375 
cells (48 hr incubation). D, caspase-9 in PC-3 cells (48 hr incubation). **P < 0.01 
compared to corresponding results of embelin group. 
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Figure 4-5. Compounds UC-112 and UC-222 down-regulate the IAP levels in vitro 
A, Western blotting analysis using cell lysates of A375, PC-3, or DU145 cells that have 
been treated by compounds at concentrations of 4 or 10 μM for 24 h. B, at concentration 
of 40 μM, Western blotting analysis showed that UC-112 and UC-222 can effectively 
induce degradation of XIAP and survivin, after 8-h or 24-h incubation. C, Silencing 
survivin or XIAP gene in A375 or PC-3 cells increased the IC50 values of UC-112. 
Treatment started at 24 hr after the siRNA transfection. The cell viability after 48 hr 
treatment was determined using MTS assay (n = 4). D, comparison between compound 
UC-112 and YM155 regarding the potency of reduced survivin level in A375 or PC-3 
cells. Photographs show representative data from three independent experiments. E, MTS 
assay (n = 4) revealed that UC-112 overcomes Pgp-mediated multidrug resistance much 
better than does YM155.  
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In comparison, the inhibition effects of embelin at low concentrations (4 μM 
and10 μM) on the IAP levels were not clear in these cell lines (Figure 4-5A). When we 
increased its concentration to 40 μM, embelin could inhibit XIAP expression in PC-3 
cells with an 8-h incubation (Figure 4-5B), consistent with literature report (254). In 
contrast, UC-112 at 40 μM only moderately decreased the level of XIAP but substantially 
down-regulated level of survivin in A375 cells (Figure 4-5B). UC-222 at this 
concentration (40 μM) was most potent in decreasing XIAP levels in A375 and DU145 
cells but PC-3 cells were more resistant to the UC-222 treatment. Thus, UC-112 
demonstrated selective inhibition against survivin among the IAPs tested (Figure 4-6).   
 
To validate whether the toxicity of UC-112 on cancer cells results from its down-
regulation effects on IAP levels, we silenced the gene of survivin or XIAP by transfecting 
A375 and PC-3 cells with specific siRNAs. Then the anti-proliferation efficacy of UC-
112 on these transfected cancer cells was determined with MTS assay and the data was 
shown in Figure 4-7. Compared to the results from the non-transfected (blank group) or 
non-specific siRNA transfected cells, IC50 values of UC-112 increased 7 to 10 folds when 
either XIAP or survivin expression was silenced.  
 
Survivin is a unique and smallest member of inhibitor of apoptosis proteins 
(IAPs). It is highly expressed in most types of cancer but has very low or undetectable 
expression in differentiated normal tissues (161, 194, 263-266). Consistent with this 
differential expression, survivin inhibitors have been shown to have broad efficacy in 
many types of cancer and low toxicity (157, 166). Additionally, survivin expression has 
been well correlated with tumor progression, resistance to existing therapies, and poor 
patient survival (231, 263, 267, 268). Survivin is involved in a myriad of oncogenic 
pathways and is considered to be a nodal protein. Recent studies have also revealed that 
high levels of survivin positively correlate with the over-activation of known oncogenic 
pathways (HIF-1α (157, 231), HSP90 (158, 159), PI3K/AKT (160, 161), ERK (162), Bcl-2 
(269, 270) and RAS pathways (163, 164)) but negatively correlate with tumor suppressor 
genes (p53, PTEN (165-167)). Together, these characteristics make selective inhibition of 
survivin an ideal target for novel cancer drug discovery. 
 
Encouraged by the results that compound UC-112 is a relatively potent inhibitor 
of survivin, we quantified the potency of the compound by incubating A375 and PC-3 
cells with serially diluted UC-112 solutions (from 4 μM to 10 nM). We also selected 
YM155 (204, 206, 207, 262), a highly efficient survivin promoter inhibitor as the 
experiment’s positive control. Results (Figure 4-5D, Figure 4-6B) showed that UC-112 
significantly down-regulated survivin levels (> 50% compared to control group) on A375 
cells at a concentration of 400 nM in 24 h, while a higher concentration (1 μM) or longer 
treatment time (48 h) (data not shown) was needed in PC-3 cells. YM155 showed to be a 
more potent survivin inhibitor and strongly inhibited the expression of survivin at 
concentration as low as 40 nM in A375 cells or 100 nM in PC-3 cells, consistent with 
data in published reports(204, 207). No significant change in XIAP levels was observed 
in either cell line treated with either UC-112 or YM155 at any concentrations tested. This 
observation confirmed that compound UC-112 could selectively decrease the survivin 
protein level over the levels of other IAP family proteins including the XIAP. Although  
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Figure 4-6. Lane density quantification data of western blotting analysis results 
(A375 cells) in (A) Figure 4-5A and (B) Figure 4-5C 
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Figure 4-7. IC50 values of UC-112 increased in survivin or XIAP gene silenced 
A375 and PC-3 cells 
A, western blotting showed that siRNA transfection specifically silenced the expression 
of survivin or XIAP in A375 and PC-3 cells. B, IC50 values of UC-112 tested on different 
siRNA transfected cells in MTS assay (n = 4). 
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YM155 is extremely potent in binding and inhibiting the survivin promoter, its main 
drawback is that it is a substrate for the Pgp drug efflux pump (271). In fact, when tested 
in Pgp overexpressed M14/MDR1 melanoma cells, UC-112 have comparable IC50 values 
in the resistant M14/MDR1 and the sensitive M14 parental cells (Figure 4-5E and Table 
4-3, small resistance index is desirable to overcome drug resistance), displaying a small 
resistance index value around 2. In contrast, the resistance index of YM155 was larger 
than 2900, consistent with the finding that it is a Pgp substrate.  
 
 
4.3.5 Proteasome Inhibitor MG132 Rescued the Down-regulated Survivin Levels in 
Cancer Cells Treated by UC-112 
 
Although the degradation mechanisms of survivin still need to be clearly 
delineated, XIAP-associated factor 1 (XAF1) was reported to activate E3 activity in 
XIAP and directly led to survivin degradation through ubiquitination (172). To further 
understand the possible mechanism leading to survivin down-regulation by UC-112, we 
hypothesized that this compound involved the ubiquitin-related degradation process of 
survivin. To test this hypothesis, we determined whether the addition of a pan-
proteasome inhibitor, MG132, would counteract the ubiquitin-mediated degradation 
process and rescue survivin from the action of UC-112.  As shown in Figure 4-8A, co-
incubation of pan-proteasome inhibitor MG132 (10 μM) with UC-112 for 24 h 
effectively rescued the survivin levels in PC-3 and DU145 cells. MG132 at 10 μM in this 
study was unable to rescue survivin in A375 cells because these cells are more sensitive 
to the survivin down-regulation effect resulted from UC-112 treatment. However, if 
A375 cells were pretreated with higher concentrations of MG132 (20 μM or 50 μM) for 6 
h followed by incubation with UC-112 for another 24 h after washing away MG132, the 
survivin level could be rescued from UC-112 treatment (Figure 4-8B). The results 
suggest that UC-112 may produce its survivin inhibition effect, at least in part, via the 
ubiquitin-mediated degradation of survivin.     
 
 
4.3.6 UC-112 Arrested A375 Melanoma Cells in G1 Phase 
 
It is well established that survivin plays complex and critical roles during cell 
mitosis as a chromosomal passenger protein to promote chromosome segregation and 
cytokinesis in the G2/M phase of the cell cycle (194, 264, 267). Survivin as a cytoplasmic 
protein is dominantly expressed in the G2/M phase, followed by a rapid degradation via 
the ubiquitin-proteasome pathway during G1 (161, 170, 264, 267). Therefore, the survival 
of cancer cells in the G2/M phase is highly dependent on the presence of survivin, while 
cells in the G1 phase are insensitive to survivin expressions. If UC-112 potently degrades 
survivin in cancer cells, then we would expect that cells in the G2/M phase will collapse 
while the less survivin-dependent cells in the G1 phase will remain, leading to an overall 
G1 phase accumulation upon UC-112 treatment. To test this hypothesis, we performed 
cell cycle analysis to determine how UC-112 would influence the cell cycle distribution.  
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Table 4-3. UC-112 overcomes Pgp-mediated drug resistance much better than 
YM155 (n = 4) 
 
 IC50  
Compound ID M14 (nM) M14/MDR1 (nM) Resistant Index 
UC-112 780 ± 32 1798 ± 140 2.3 
YM155 3.4 ± 0.5 >10,000 >2,941 
Colchicine 5.0 ± 0.5 345 ± 12 69 
 
Resistant Index was calculated by dividing the IC50 in resistant cells by the IC50 in the 
sensitive parental cells. Higher RI values suggests stronger drug resistance 
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Figure 4-8. Proteasome inhibitor MG132 can rescue survivin inhibition by UC-
112 
A, Western blotting analysis after co-incubation of MG132 (10 μM) with UC-112 for 24 
h in A375, PC-3, and DU145 cells. B, A375 cells were pretreated by high doses of 
MG132 (20 μM or 50 μM) for 6 h and washed once by blank cell culture medium. Then 
UC-112 was added for following 24 h incubation. Photographs showed representative 
data from three independent experiments. C, cell cycle analysis of A375 cells incubated 
with 1 μM or 4 μM UC-112 for 24 h (n = 3). 
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The results (Figure 4-8C) of flow cytometry analysis showed that incubation with 
1 μM UC-112 for 24 h caused A375 cells to accumulate in the S phase, with a concurrent 
reduction of cells in the G2/M phase. When the concentration of UC-112 increased to 4 
μM, a large percentage of A375 cells (76 ± 2% in treatment vs. 51 ± 1% in vehicle 
control) accumulated in the G0/G1 phase with escalated sub-G1 events, which indicated 
induction of cell apoptosis. The percentage of cells remaining in the G2/M phase was 
decreased (13 ± 1% in treatment vs. 21 ± 2% in vehicle control). In this study, UC-112 
blocked the A375 cell cycle in G1 phase in a dose-dependent manner. This observation is 
consistent with the proposed mechanisms of action for UC-112 as described above, 
providing additional evidence that UC-112 targets survivin degradation, a post-
translational modification process. In contrast, down-regulation of survivin gene 
expression by YM155 was a cell cycle-independent event without G1 cell arrest in a wide 
panel of cancer cells (272). Thus, unlike YM155, UC-112 down-regulated the survivin 
levels in cancer cells more likely by promoting the ubiquitin-mediated degradation of 
survivin rather than by altering the expression of survivin at the transcription level. 
 
 
4.3.7 UC-112 Inhibited Tumor Growth in a Melanoma Xenograft Model In Vivo 
 
To further investigate the therapeutic potential of compound UC-112, we 
evaluated its anti-tumor efficacy in an A375 xenograft mouse model. We first estimated 
the maximum tolerable dose (MTD) in mice. UC-112 was well tolerated in mice up to 
200 mg/kg which was the highest dose we tested. The very low toxicity displayed by UC-
112 is consistent with the above evidence suggesting that UC-112 is a selective survivin 
inhibitor, because survivin is highly expressed in tumor cells but minimally expressed in 
normal tissues (157, 263, 266). Considering realistic doses that are normally used 
clinically, we decreased the dose of UC-112 to 10% (20 mg/kg) and 20% (40 mg/kg) in 
subsequent in vivo efficacy studies. After 3 weeks of continuous treatment, UC-112 was 
highly effective in inhibiting melanoma tumor growth in the A375 xenograft model in a 
dose-dependent pattern (Figure 4-9A and Figure 4-10) without causing  (>10%) body 
weight loss in nude mice (Figure 4-9B). Treatment with UC-112 at 20 mg/kg achieved 
65.59 ± 19.56% tumor growth inhibition (TGI) compared to vehicle control group, while 
the dose at 40 mg/kg almost completely inhibited tumor growth (TGI was 95.23 ± 
3.11%). The average tumor weight in the UC-112 40-mg/kg treatment group was only 
13.56% of that in the vehicle control group (Figure 4-9C). To determine whether the 
potential mechanisms of action for UC-112 observed in vitro will remain in vivo, we 
compared the IAP protein expressions between the control and treatment tumors. As 
shown in Figure 4-9D, UC-112 significantly reduced both survivin and XIAP levels in 
the lysates of fresh tumors isolated at the end of the treatment, confirming the in vivo  
efficacy of UC-112 was at least in part through the strong inhibition of IAPs. 
Hematoxylin and eosin staining showed that UC-112 induced extensive tumor cell death 
in these A375 melanoma tumors (Figure 4-9E). Furthermore, TUNEL assay which 
measured nuclear DNA fragmentation (Figure 4-9F) clearly showed the dose-dependent 
increasing of apoptosis in tumor sections of UC-112 treatment groups. All these results 
are consistent with our in vitro observations that UC-112 could efficiently inhibit tumor 
cell proliferation by down-regulating the level of IAPs, especially survivin protein.  
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Figure 4-9. UC-112 (20 mg/kg and 40 mg/kg) strongly suppress melanoma tumor 
growth in an A375 xenograft mouse model (n = 7, i.p. injection 5 days per week) 
A, tumor volume growth curve. B, mice body weight versus time plot. C, tumor weight 
comparison bar graph. **P < 0.01, ***P < 0.001 compared to the corresponded results of 
vehicle group. D, Western blotting analysis of survivin and XIAP levels in fresh tumor 
lysates. Each lane represents tumor tissue lysate from a single mouse. E, representative 
immunohistochemistry images for H&E staining of A375 tumor tissue sections. The scale 
bar (yellow) in each image represents 200 μm. Photographs show representative data 
from three independent experiments. F, representative fluorescence microscope images 
for TUNEL assay of A375 tumor tissue sections. The scale bar (white) in each image 
represents 100 μm. 
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Figure 4-10. Tumor images of in vivo anti-tumor efficacy evaluation of UC-112 (20 
mg/kg and 40 mg/kg) on A375 xenograft nude mice model (n = 7, i.p. injection five 
days per week for three continuous weeks) 
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CHAPTER 5.    ANTI-CANCER EFFICACY, PHYSIO-CHEMICAL PROPERTY 
AND TARGET VALIDATION STUDIES OF OPTIMIZED UC-112 ANALOGS* 
 
 
5.1 Introduction 
 
We recently discovered that UC-112, [5-((benzyloxy)methyl)-7-(pyrrolidin-1-
ylmethyl)quinolin-8-ol], is a potent, selective survivin inhibitor (273). UC-112 inhibits 
tumor cell growth in several cancer cell lines in vitro and suppresses melanoma tumor 
growth in vivo (273). Mechanistic studies indicated that UC-112 selectively inhibits 
survivin expression and induces strong cancer cell apoptosis. By performing targeted 
structural modifications, a series of novel UC-112 analogs were obtained. Biological 
evaluation of these new analogs revealed their excellent anti-proliferative activity against 
several cancer cell lines including multidrug-resistant phenotypes. Mechanism of action 
studies confirmed that these new UC-112 analogs maintained their mechanisms of 
actions by selectively down-regulating the level of survivin among other IAP family 
proteins. Preliminary in vivo evaluation for the most active compound MX106 
demonstrated its efficacy against human melanoma tumor growth.  
 
 
5.2 Materials and Methods 
 
 
5.2.1 Cell Culture and Cell Viability Assay 
 
The anti-proliferative effect of UC-112 and its analogs were tested in human 
melanoma (A375, M14 and M14/LCC6MDR1) and human prostate cancer (PC-3) cell 
lines. All the cell lines were purchased from ATCC (American Type Culture Collection, 
Manassas, VA). The cancer cells were cultured using the supplemented cell culture 
medium as described before (259) at 37oC in a humidified atmosphere containing 5% 
CO2. 5000 cells in logarithm growing phase were seeded overnight into each well of a 
96-well plate. Then the cells were continuously incubated with sequential diluted 
compound solution (10 nM to 100 μM, 100 μl per well) in cell culture medium. After 48 
h treatment, the cell viability was determined in MTS assay and IC50 was calculated (n = 
4) as described before (127, 273). 
 
 
5.2.2 NCI-60 Screening 
 
Four compounds including the parental compound UC-112 were submitted to 
National Cancer Institute for its NCI-60 cell line screening, initially tested at one 
 
* Modified with permission. Xiao M, Wang J, Lin Z, Lu Y, Li Z, White S, Miller D, Li 
W. Design, synthesis and structure-activity relationship studies of novel survivin 
inhibitors with potent anti-proliferative properties. PLOS ONE. DOI: 
10.1371/journal.pone.0129807  
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concentration (10 μM), and subsequently selected for full five concentration testing 
following the standard protocols disclosed by NCI (274). In brief, cells were plated into 
96 well micro-titer plates 24 h prior to the treatment of compound solution for 48 h, then 
the cell viability was read out through absorbance of sulforhodamine B (SRB) staining.   
 
 
5.2.3 Western Blotting  
 
Lysates of A375 cells treated by the compound solution for 24 h were used to 
determine the change of IAP protein levels through western blotting. Primary rabbit 
antibodies against survivin, XIAP, cIAP1, cIAP2, livin, p53 and GAPDH were purchased 
from Cell Signaling Technology, Inc. (Danvers, MA) and used according to manufacture 
instructions as reported previously (273). Protein lane intensities were quantified by 
ImageJ software (US National Institutes of Health, Bethesda, MD). 
 
 
5.2.4 DARTS Assay  
 
Drug affinity responsive target stability (DARTS) assay was performed to identify 
the protein targets of UC-112 analogs in A375 or M14 cell lysates following the 
protocols described in Dr. Jing Huang’s publications (275, 276). In brief, A375 or M14 
lysates were prepared in nondenaturing M-PER lysis buffer (Thermo Fisher Scientific, 
Waltham, MA) with protease and phosphatase inhibitors. Then TNC (Tris, NaCl, CaCl2) 
buffer was added into cell lysates before the total protein concentration of lysate being 
determined by BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA). Next the 
lysates were split into two groups: one group was added with compound of interest 
solution, the other group was added with same amount of vehicle (DMSO). The samples 
were mixed thoroughly and incubated at room temperature for 1 h. Then 10 mg/mL 
pronase stock solution was added into both compound treated or vehicle control groups to 
achieve the final dilution of 1:100, 1:300, 1:1000 and 1:3000. One aliquot of each group 
was kept as un-digested control. The proteolysis was performed at room temperature for 
30 min before ice cold protease inhibitor stock being added into the mixture. Then SDS 
loading buffer was added into all the samples and heated to 70 ?C for 10 min. Finally, the 
results were analyzed by SDS-PAGE and immunoblotting. 
 
 
5.2.5 Molecular Modeling 
 
The molecular docking studies were performed following similar procedure as 
described before (273, 277) in Schrodinger Molecular Modeling Suite 2014 (Schrodinger 
Inc., Portland, OR). All the ligands were prepared to generate various conformation 
before being docked into the Smac AVPI binding site of a human survivin crystal 
structure (Protein Data Bank entry: 3UIH). Molecular dynamic calculation was done after 
the docking to minimize the energy of potential ligand binding poses. Results were 
visualized using the Maestro interface of the Schrodinger software. 
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5.2.6 Liver Microsomal Stability Study 
 
Liver microsomal metabolic stability was conducted by incubating the 
compounds of interest (0.5 μM) in a total reaction volume of 1 mL containing 1 mg/mL 
microsomal in reaction buffer [0.2 M of phosphate buffer solution (pH 7.4), 1.3 mM 
nicotinamide adenine dinucleotide phosphate (NADP+), 3.3 mM glucose-6-phosphate, 
and 0.4 U/mL glucose-6-phosphate dehydrogenase] shaking at 37°C 100 rpm. The 
NADPH regenerating system (solution A and B) was obtained from BD Biosciences 
(Bedford, MA). Aliquots (100 μL) from the reaction mixtures were sampled at 0, 5, 10, 
20, 30, 60, 90 and 120 min. Ice cold acetonitrile (150 μL) containing 200 nM of the 
internal standard was added to quench the reaction and to precipitate the proteins. 
Samples operated under similar condition using heat-denatured microsomal were used as 
controls. After centrifugation at 13,000g for 15 min, the supernatant was submitted for 
LC-MS/MS analysis. 
 
 
5.2.7 Plasma Protein Bounding Study 
 
Plasma (human and rat) protein binding was analyzed using a rapid equilibrium 
dialysis (RED) device (Thermo Fisher Scientific, Waltham, MA) containing dialysis 
membrane with molecular weight cut-off at 8,000 Daltons. 50 μM test compound was 
sparkled into the plasma chamber. Then dialysis was performed at 37 °C with 100 rpm 
shaking for 4 h as per manufacturer’s recommendation. At the end of dialysis, 50 μL 
aliquot from both plasma chamber and buffer saline chamber was removed and quenched 
with equal volume of ice cold acetonitrile with internal standard in -20 °C for 20 min. 
After centrifugation at 13,000g for 15 min, the supernatant was submitted for LC-MS/MS 
analysis. Free drug percentage was calculated as peak area of test compound in dialysate 
buffer divided by peak area of test compound in dialysate plasma. 
 
 
5.2.8 In Vivo Anti-tumor Efficacy Test 
 
3 × 106 A375 cells were implanted into the left-side dorsal flank of each nude 
mouse (n = 5) to establish the human melanoma A375 tumor xenograft model as 
described previously (129, 273). Compound MX106 were first dissolved in DMSO then 
diluted by 2% methylcellulose PBS buffer. The proportion of DMSO in final solution 
was kept at lower than 5%. Mice body weight and the size of tumor were closely 
monitored during the 3 week continuous treatment (i.p. injection, one dose per day five 
days per week). At the end point of the treatment, mice were sacrificed after anesthesia.  
 
 
5.2.9 TUNEL Assay 
 
A375 tumor tissues collected from the in vivo efficacy study in the above were 
fixed in formalin phosphate buffer for one week. Then the tissues were processed to get 
paraffin embedded sections. TUNEL assay was performed using DeadEndTM 
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Fluorometric kit (Promega Corporation, Madison, WI) following manufacturer’s 
instructions. By the end of the experiment, VECTASHIELD® Hard SetTM mounting 
medium with DAPI (Vector Lab, Inc., Burlingame, CA) was used to mount the tumor 
slides and stain the nuclei. The final slides were analyzed immediately under a 
fluorescence microscope (EVOS® FL Cell Imaging System, Thermo Fisher Scientific 
Inc., NY). 
 
 
5.3 Results and Discussion 
 
 
5.3.1 UC-112 Analogs Could Overcome Multidrug Resistance 
 
The co-existing of survivin and drug resistant marker in tumor tissue has hindered 
the in vivo anti-cancer activity of survivin inhibitors. In order to determine whether the 
new analogs we made can overcome multidrug resistance (MDR), we compared the 
activity of those analogs against multidrug-resistant melanoma cells (M14/LCCMDR1) 
and their parental sensitive cancer cells (M14). This pair of cell line is well validated and 
widely used to assess whether the drugs can overcome Pgp-mediated MDR (278-280). 
Our three best compounds MX86, MX35 and MX106 together with the most successful 
small molecule survivin inhibitor YM155 were tested on both the MDR melanoma cells 
and their parental cells (Table 5-1). The resistance index is calculated by dividing the 
IC50 value of the resistant cell line by IC50 value of the sensitive parental cell line. So the 
smaller this value, the better resistance overcoming effect obtained. As this table shows, 
compounds MX86, MX35 and MX106 all have very small resistance indexes (1.8, 1.9 
and 2.3 respectively). Their activity in the resistant cell line is comparable with that in the 
parental cell line. For existing survivin inhibitor, YM155, although it is very potent in 
parental cell line (IC50 at 3 nM), its activity in resistant cell line is considerably lower 
(IC50 is higher than 10 μΜ, resistance index is higher than 2941). This data indicate that 
the new UC-112 analogs can circumvent Pgp-mediated multi-drug resistance and are 
distinct from that of YM-155. 
 
 
5.3.2 UC-112 Analogs Showed Good Anti-proliferation Effects with Selectivity in 
NCI-60 Cell Line Screening 
 
UC-112 and three potent analogs MX86, MX106 and MX35 were submitted to 
NCI for its one-concentration (10 μM) screening against the NCI-60 cell lines. All four 
compounds showed good activity and were selected for the subsequent five doses testing 
to determine their growth inhibition potency (GI50) in the NCI-60 cell lines. As shown in 
Figure 5-1, structure modification from UC-112 to our best compound MX106 has 
improved the average GI50 by nearly four times (2.2 μM for UC-112 vs. 0.5 μM for 
MX106).  
 
The heat map in Figure 5-2 summarizes the compound growth inhibition pattern 
which is characterized by the GI50 mean values from NCI-60 screening. UC-112 and its 
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Table 5-1. In vitro anti-proliferation activities of UC-112 analogs determined by 
MTS assay (n = 4) 
 
    IC50 ± SEM(μM)  
Structure ID X R1 A375 PC-3 M14 M14/LCC
6MDR1 
Resistance 
Index 
 
UC-112 O H 1.9 ± 
0.6 
1.6 ± 
1.0 
2.1 ± 
0.3 
3.2 ± 0.5 1.5 
MX35 S H 1.4 ± 
0.3 
1.1 ± 
0.1 
1.4 ± 
0.2 
2.9 ± 0.6 2.1 
MX86 O Br 0.9 ± 
0.2 
0.7 ± 
0.3 
1.0 ± 
0.2 
1.8 ± 0.6 1.8 
MX106 O i-
Pr 
0.9 ± 
0.1 
0.7 ± 
0.1 
0.8 ± 
0.2 
1.8 ± 0.4 2.3 
    YM155 0.003
± 
0.002 
0.005 
± 
0.002 
0.003 
± 
0.001 
> 10 > 2941 
 
Resistance Index was calculated through dividing IC50 value in resistant cell line 
(M14/LCC6MDR1) by IC50 in sensitive cell line (M14) for each compound. 
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Figure 5-1. Average GI50 data for UC-112, compound MX35, MX86 and MX106 
tested in NCI-60 anti-proliferative screening 
Data is shown with mean ± SD as bar graph. 
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new analogs showed interesting selective growth inhibition behavior within the NCI 60 
cell lines. The GI50 value of compound MX106 in renal cancer cell line UO-31 was as 
low as 52.5 nM. Interestingly, two other cell lines, HCT-15 (colon cancer) and 
NCI/ADR-RES (ovarian cancer), were also particularly sensitive to the treatment of  
UC-112 and its analogs, with lowest GI50 value (highest activity) for compound MX106 
at 46.8 nM and 50.1 nM, respectively. Since colorectal adenocarcinoma HCT-15 cells 
intrinsically expresses moderate levels of Pgp, multidrug-resistance-associated protein 
(MRP) and lung-resistance-associated protein (LRP) (281), and ovarian cancer 
NCI/ADR-RES cells are naturally over-expressing MDR1 and resistant to various 
chemotherapies including doxorubicin (282), these data have supported our findings that 
UC-112 and its analogs could effectively overcome the multidrug resistance in vitro.  
 
 
5.3.3 Mechanism of Action Studies 
 
In our recently report (273), UC-112 exerted its tumor killing effect by selectively 
inhibiting the expression of survivin. In order to determine whether the new UC-112 
analogs maintained the same mechanism of action, we performed the western blotting 
assay for MX106 in A375 and PC-3 cells (Figure 5-3A). Compound MX106 dose-
dependently suppressed survivin level in these two cancer cell lines, while the levels of 
other IAPs were minimally affected. The presence of compound MX106 at 300 nM for 
24 h reduced survivin levels over 50% in both A375 and PC-3 cells (lane density was 
quantified by ImageJ software, data not shown). Interestingly, A375 is a p53 wild type 
cancer cell, whereas PC-3 is a p53 null cancer cell. As shown in Figure 5-3B, UC-112 
and MX106 reduced the level of survivin in both A375 and PC-3 cells, which indicated 
the survivin down-regulation effects of UC-112 and MX106 is not p53 status dependent. 
 
Next, we have conducted DARTS assay which is designed on the fact that the 
protease susceptibility of the target protein will decrease upon ligand binding. DARTS 
methodology is developed for general identifying protein-ligand interactions and has 
been proved to be universally applicable without acquiring the modification of ligand or 
targeted protein (275, 276). A375 and M14 cell lysates were pre-incubated with 1 μM 
MX106 before proteolysis with pronase at gradient concentrations. Immunoblotting 
results in Figure 5-4 revealed that incubation with MX106 protected the survivin protein 
from the digestion of pronase, comparing with untreated samples. Non-target proteins 
like GAPDH were non-differentiated digested by pronase with or without the presence of 
MX106. Furthermore, pronase digestion of XIAP, cIAP1 and cIAP2 proteins was not 
protected by the pre-incubation of MX106 in our study. The observation indicated the 
existing of some specific interaction between MX106 and survivin protein, which made 
the later more resistant to pronase digestion in A375 and M14 cell lysates. 
 
 
5.3.4 Molecular Modeling Study 
 
To understand the observed improvement in potency of compound MX106 over 
its parental compound UC-112, we developed a molecular model and performed the 
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Figure 5-2. Heat map showing the GI50 values (nM) for UC-112 and three analogs 
in the NCI-60 screening 
High intensity (blue) cells indicate high activity and low intensity (red) cells indicate low 
activity. Average GI50 values were calculated for each compound, separately. 
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Figure 5-3. Western blotting analysis of MX106 in A375 and PC-3 cell lines 
A, representative images of western blotting analysis of A375 or PC-3 cells treated with 
gradient increasing concentrations of MX106 for 24 h. B, representative images of 
western blotting analysis of A375 or PC-3 cells treated with 1 μM UC-112 or MX106 for 
2 h or 20 h.  
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Figure 5-4. Representative DARTS results for pronase-digested A375 or M14 cell 
lysates 
Immunoblotting showed protection of the target protein, survivin, by the incubation with 
MX106, whereas digestion of the non-target proteins like GAPDH was unchanged. 
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molecular docking study using the complex of human survivin-Smac AVPI (PDB entry: 
3UIH). As shown in Figure 5-5A, UC-112 displayed several interesting interactions with 
the survivin protein BIR domain: (1) two hydrogen bonding interactions between the 
A/B-ring of UC-112 and residue Asp71; (2) one hydrogen bonding interaction between  
the D-ring nitrogen and residue Glu68; and (3) an π- π stacking interaction between the 
A/B-ring of UC-112 and residue Typ67 (Figure 5-5A). Examination of this proposed 
binding pose clearly suggests that the un-substituted phenyl ring of UC-112 failed to 
occupy a hydrophobic groove (cycled with green dash line in Figure 5-5A), and a 
properly sized, non-polar para-substitution (e.g., an isopropyl moiety as in compound 
MX106) to this ring would fill this groove and also provide excellent overlap with the 
bioactive AVPI peptide (Figure 5-5B). The binding mode is consistent with our 
experimental results. Further refinement to this model, and ultimately an X-ray crystal 
structure will greatly facilitate the future optimization of this scaffold. 
 
 
5.3.5 In Vivo Anti-tumor Efficacy Assessment 
 
Since our in vitro study showed that compound MX106 has the highest anti-
proliferative potency in this series of UC-112 analogs, we selected MX106 to test its in 
vivo efficacy against tumor growth in a human melanoma A375 xenograft model through 
i.p injection. As shown in the Figure 5-6A and B, compound MX106 inhibited the 
growth of A375 xenograft tumor in a dose-dependent manner during the three weeks of 
continuous treatment group is 53% and 79% slower than the vehicle control group, 
respectively. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay, which measured the nuclear DNA fragmentation, showed that a high dose (40 
mg/kg) of compound MX106 treatment caused the widely-spread cell apoptosis inside 
the tumor tissues (Figure 5-6C). 
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Figure 5-5. Potential binding pose of UC-112 and compound MX106 in the Smac 
N-terminus tetra-peptide AVPI binding site of survivin crystal structure (PDB 
entry: 3UIH) . 
The surface of AVPI binding site in survivin was colored according to residue charge 
(blue for positive while red for negative). A, UC-112 (green tube) formed hydrogen 
bonds with residue Asp71 and Glu68 on the survivin protein BIR domain. B, compound 
MX106 (orange tube) displayed similar binding pose with UC-112 but had better 
occupied the grove toward the N-terminus of survivin protein. And this pose was 
overlapping well with the binding mode of native ligand, Smac AVPI (green stick). 
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Figure 5-6. In vivo anti-tumor efficacy of compound MX106  
A and B, MX106 effectively inhibited the growth of A375 xenograft tumor after three 
weeks continuous treatment (i.p. injection) in a dose-dependent manner (A) without 
causing obvious decrease of mice body weight (B). C, Representative images of TUNEL 
assay using the formalin-fixed tumor sections. 
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CHAPTER 6.    SUMMARY AND FUTURE DIRECTION 
 
In the combination project, since one of the major hallmarks for tubulin inhibitors 
is their ability to strongly arrest cells in the G2/M phase, we hypothesized the 
combination of vemurafenib and a tubulin inhibitor would synergistically arrest 
melanoma cells, leading to enhanced apoptosis, and overcome acquired resistance. In this 
study we selected novel tubulin inhibitors, ABI-231 and ABI-274, to investigate its 
combination with vemurafenib against melanoma tumors. We developed vemurafenib-
resistant human melanoma cell line A375RF21 and MDA-MB-435 VemR. Results 
showed that the combination of ABI compound and vemurafenib had strong synergy in 
vitro. We confirmed that the synergy is unlikely through enhanced inhibition of tubulin 
polymerization or diminished of p-ERK activation. Instead, our experimental results 
revealed that this combined treatment overcomes the acquired vemurafenib-resistance 
through enhanced apoptosis induction produced by synergistic G1 and G2/M cell-cycle 
arrest and substantially impaired the survival signaling pathway related to AKT 
phosphorylation. We showed that the strong synergy observed in vitro clearly translated 
to significant efficacy in vivo when tested in a vemurafenib-resistant xenograft model. 
Further immunohistochemistry analyses on tissue sections confirmed the strong 
inhibition of tumor proliferation and the diminished activity of pAKT. The in vivo studies 
presented here show an effective combination treatment in tumor cells that are already 
vemurafenib-resistant by using A375RF21 xenograft models. It is conceivable that if we 
used the combination before tumor cells became resistant to vemurafenib, tumor 
regression may be more enhanced and we could significantly delay or even prevent the 
development of resistant tumor cells. This could translate into at least a substantially 
longer progression-free time in patients, and/or enhanced disease regression. Collectively, 
our study offers the first direct evidence and a rationale for combining a potent tubulin 
inhibitor with an inhibitor targeting the RAF/MEK/ERK pathway for greatly improved 
therapy for melanoma patients. To further conduct this project, we need to address three 
types of questions: 1) can we find a better methodology other than CI values to precisely 
evaluate the combination effect test in vitro; 2) can we establish more BRAF inhibition 
resistant models with known and clinical relevant mechanisms; 3) can we deal with the 
tumor heterogeneity, which is extremely important in control of acquired resistance to 
small molecule cancer therapy, through rational designed combination treatment. 
 
In the survivin inhibitor project, using shape-based virtual screening combined 
with biological activity evaluation, we identified four Smac mimetic hits with higher or 
comparable anti-proliferation potency compared with embelin. The overall hypothesis is, 
theses hit compounds can mimic the function of Smac, which is the endogenous inhibitor 
of IAPs including survivin, and thus trigger the programmed apoptosis in cancer cells. 
The four identified hits significantly activated caspase-3/7 and caspase-9 function in 
human melanoma A375 and prostate cancer PC-3 cell lines. Compounds UC-112 and 
UC-222 strongly suppressed XIAP and survivin levels in vitro and had scaffolds 
amicable for modification to further improve their potency. In particular, compound UC-
112 showed good selectivity in decreasing the level of survivin (BIRC5) in a dose-
dependent manner, possibly through the ubiquitin-mediated degradation pathways, and it 
also has the potential to overcome Pgp-mediated multidrug-resistance which is a 
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limitation for many of the existing IAP inhibitors. More excitingly, UC-112 displayed 
very low toxicity, showed potent efficacy of tumor growth inhibition in an A375 
melanoma xenograft model, and maintained its mechanisms of actions in vivo. This 
integrated chemical biology study provided promising lead compounds amicable for 
further structural optimization in order to develop new selective IAP inhibitors as 
potential therapeutic agents for resistant cancers, either as a single agent or in 
combinations with existing drugs. Novel analogs which are structurally modified from 
the lead compound UC-112 have showed excellent anti-proliferative activities and could 
also effectively overcome Pgp-mediated multiple drug resistance. The most potent 
compound MX106 has selectively down-regulated the level of survivin as the parent 
compound UC-112 in a p53 status independent manner. And compound MX106 greatly 
inhibited the growth of A375 xenograft tumor in vivo. These findings are encouraging but 
target validation work is essential to further direct the future study of this project. In other 
words, we need to know why the level of survivin protein is decreased after the treatment 
of UC-112 and its analogs. Considering the regulation mechanisms of survivin, we 
should investigate whether the compounds are promoting degradation or inhibiting the 
expression of survivin. Meanwhile, the off-target effect of this series of compounds need 
to be properly evaluate although in the xenograft models, i.p. injection for three 
continued weeks at doses up to 40 mg/kg did not significantly affect the nude mice body 
weight.  
 
 
  
 91 
LIST OF REFERENCES 
 
 
1.  Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, et al. A 
phase II multicenter study of ipilimumab with or without dacarbazine in 
chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 
2011;29: 489-498. 
2.  Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. 
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N 
Engl J Med. 2012;366: 707-714. 
3.  Al-Lazikani B, Workman P. Unpicking the combination lock for mutant BRAF 
and RAS melanomas. Cancer Discov. 2013;3: 14-19. 
4.  Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining Targeted 
Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and 
Challenges. J Clin Oncol. 2014;32: 2248-2254. 
5.  Nijenhuis CM, Haanen JB, Schellens JH, Beijnen JH. Is combination therapy the 
next step to overcome resistance and reduce toxicities in melanoma? Cancer Treat 
Rev. 2013;39: 305-312. 
6.  Voskoboynik M, Arkenau HT. Combination therapies for the treatment of 
advanced melanoma: a review of current evidence. Biochem Res Int. 2014;2014: 
307059. 
7.  Wang J, Miller DD, Li W. Emerging Drug Combination Approaches in 
Melanoma Therapy. InTech, 2015. ISBN: 978-953-51-2036-0, DOI: 
10.5772/59360 
8.  Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. 
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic 
mutations of B-RAF. Cell. 2004;116: 855-867. 
9.  Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective 
inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl 
Acad Sci U S A. 2008;105: 3041-3046. 
10.  King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, et al. 
Dabrafenib; preclinical characterization, increased efficacy when combined with 
trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One. 
2013;8: e67583. 
11.  Solit DB, Rosen N. Towards a unified model of RAF inhibitor resistance. Cancer 
Discov. 2014;4: 27-30. 
12.  Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU. 
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a 
mouse model of human melanoma. Oncoimmunology. 2012;1: 609-617. 
13.  Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for 
BRAF-mutant metastatic melanoma. Clin Cancer Res. 2014;20: 2035-2043. 
14.  Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Zhang XD, 
et al. Antiproliferative effects of continued mitogen-activated protein kinase 
pathway inhibition following acquired resistance to BRAF and/or MEK inhibition 
in melanoma. Mol Cancer Ther. 2013;12: 1332-1342. 
 92 
15.  Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. BRAF 
inhibitor activity in V600R metastatic melanoma. European Journal of Cancer. 
2013;49: 1073-1079. 
16.  Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, et al. BRAF 
inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife. 
2013;2: e00969. 
17.  Roesch A. Tumor heterogeneity and plasticity as elusive drivers for resistance to 
MAPK pathway inhibition in melanoma. Oncogene. 2014. 
18.  Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra- 
and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and 
metastatic melanoma. PLoS One. 2012;7: e29336. 
19.  Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 
pathway inhibitors. Oncogene. 2013;32: 1207-1215. 
20.  Tentori L, Lacal PM, Graziani G. Challenging resistance mechanisms to therapies 
for metastatic melanoma. Trends Pharmacol Sci. 2013;34: 656-666. 
21.  Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. 
Tumour micro-environment elicits innate resistance to RAF inhibitors through 
HGF secretion. Nature. 2012;487: 500-504. 
22.  Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et 
al. COT drives resistance to RAF inhibition through MAP kinase pathway 
reactivation. Nature. 2010;468: 968-972. 
23.  Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. 
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor 
genomic profiling. J Clin Oncol. 2011;29: 3085-3096. 
24.  Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors 
transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. 
Nature. 2010;464: 427-430. 
25.  Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H. 
Acquired resistance to BRAF inhibition can confer cross-resistance to combined 
BRAF/MEK inhibition. J Invest Dermatol. 2012;132: 1850-1859. 
26.  Carlino MS, Todd JR, Gowrishankar K, Mijatov B, Pupo GM, Fung C, et al. 
Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant 
melanoma. Mol Oncol. 2014;8: 544-554. 
27.  Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, et 
al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant 
melanoma cells by reactivating MEK and ERK signaling. Sci Signal. 2014;7: 
ra30. 
28.  Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, et al. Resistance to 
selective BRAF inhibition can be mediated by modest upstream pathway 
activation. Cancer Res. 2012;72: 969-978. 
29.  Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, 
et al. Tumor genetic analyses of patients with metastatic melanoma treated with 
the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013;19: 4868-
4878. 
 93 
30.  Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, et al. 
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF 
V600E-mutated melanomas. Mol Cancer Ther. 2008;7: 2876-2883. 
31.  Choi J, Landrette SF, Wang T, Evans P, Bacchiocchi A, Bjornson R, et al. 
Identification of PLX4032-resistance mechanisms and implications for novel 
RAF inhibitors. Pigment Cell Melanoma Res. 2014;27: 253-262. 
32.  Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, et al. 
Overexpression of ATP-binding cassette transporter ABCG2 as a potential 
mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant 
cancer cells. Biochem Pharmacol. 2013;85: 325-334. 
33.  Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved 
survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 
2012;367: 107-114. 
34.  Wright CJ, McCormack PL. Trametinib: first global approval. Drugs. 2013;73: 
1245-1254. 
35.  Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, et al. Reversing melanoma 
cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR 
pathway. PLoS One. 2011;6: e28973. 
36.  Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II 
study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-
mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. 
J Clin Oncol. 2013;31: 482-489. 
37.  Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. 
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. 
N Engl J Med. 2012;367: 1694-1703. 
38.  Goldinger SM, Zimmer L, Schulz C, Ugurel S, Hoeller C, Kaehler KC, et al. 
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK 
inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European 
Journal of Cancer. 2014;50: 406-410. 
39.  Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et 
al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired 
resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or 
MEK mutations. Mol Cancer Ther. 2012;11: 909-920. 
40.  Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, et al. 
Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF 
inhibitor-resistant melanoma. Cancer Res. 2013;73: 7043-7055. 
41.  Lee CI, Menzies AM, Haydu LE, Azer M, Clements A, Kefford RF, et al. 
Features and management of pyrexia with combined dabrafenib and trametinib in 
metastatic melanoma. Melanoma Res. 2014. 
42.  Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, et al. 
Combination of vemurafenib and cobimetinib in patients with advanced 
BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15: 954-
965. 
  
 94 
43.  Kefford R, Miller WH, Tan DSW, Sullivan RJ, Long G, Dienstmann R, et al. 
Preliminary results from a phase Ib/II, open-label, dose-escalation study of the 
oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor 
MEK162 in BRAF V600-dependent advanced solid tumors. Journal of Clinical 
Oncology. 2013;31. 
44.  Dummer R, Robert C, Nyakas M, McArthur GA, Kudchadkar RR, Gomez-Roca 
C, et al. Initial results from a phase I, open-label, dose escalation study of the oral 
BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or 
metastatic melanoma. Journal of Clinical Oncology. 2013;31. 
45.  Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-
talks. Oncogene. 2008;27: 5527-5541. 
46.  Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla 
AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase 
switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. 
Cancer Cell. 2010;18: 683-695. 
47.  Lasithiotakis KG, Sinnberg TW, Schittek B, Flaherty KT, Kulms D, Maczey E, et 
al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces 
cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol. 
2008;128: 2013-2023. 
48.  Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, et al. The 
farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces 
sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol. 2011;131: 
468-479. 
49.  Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination 
small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in 
a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18: 
4345-4355. 
50.  Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, et al. 
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in 
melanoma. Mol Cancer. 2014;13: 83. 
51.  Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, et al. Sensitivity 
to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF 
and wildtype PTEN status. Mol Cancer. 2012;11: 75. 
52.  Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, et al. 
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to 
effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad 
Sci U S A. 2013;110: 4015-4020. 
53.  Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome 
PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. 
Cancer Res. 2011;71: 5067-5074. 
54.  Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, et 
al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR 
and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer 
Res. 2012;18: 2316-2325. 
  
 95 
55.  Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. 
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression 
and a More Favorable Tumor Microenvironment in Patients with Metastatic 
Melanoma. Clinical Cancer Research. 2013;19: 1225-1231. 
56.  Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes 
transcriptional up-regulation of interleukin 8 and vascular endothelial growth 
factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol 
Cancer Ther. 2003;2: 753-763. 
57.  Ghosh S, Maity P. Augmented antitumor effects of combination therapy with 
VEGF antibody and cisplatin on murine B16F10 melanoma cells. Int 
Immunopharmacol. 2007;7: 1598-1608. 
58.  Sini P, Samarzija I, Baffert F, Littlewood-Evans A, Schnell C, Theuer A, et al. 
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) 
blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize 
tumor cells to platinum-based chemotherapeutics. Cancer Res. 2008;68: 1581-
1592. 
59.  Terheyden P, Hofmann MA, Weininger M, Brocker EB, Becker JC. Anti-vascular 
endothelial growth factor antibody bevacizumab in conjunction with 
chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol. 2007;133: 
897-901. 
60.  Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible 
and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 
2014;508: 118-122. 
61.  Motl S. Bevacizumab in combination chemotherapy for colorectal and other 
cancers. Am J Health Syst Pharm. 2005;62: 1021-1032. 
62.  Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, 
et al. Bevacizumab plus fotemustine as first-line treatment in metastatic 
melanoma patients: clinical activity and modulation of angiogenesis and 
lymphangiogenesis factors. Clin Cancer Res. 2010;16: 5862-5872. 
63.  Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT, 
3rd, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-
paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV 
melanoma : a North Central Cancer Treatment Group study, N0775. Cancer. 
2013;119: 586-592. 
64.  Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, et al. Vascular 
endothelial growth factor blockade reduces intratumoral regulatory T cells and 
enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin 
Cancer Res. 2006;12: 6808-6816. 
65.  Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, et al. A 
phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in 
patients with metastatic melanoma. Cancer Chemother Pharmacol. 2007;59: 165-
174. 
66.  Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, 
Hellberg C. Identification of a subset of pericytes that respond to combination 
therapy targeting PDGF and VEGF signaling. Int J Cancer. 2007;121: 2606-2614. 
 96 
67.  O'Reilly T, Lane HA, Wood JM, Schnell C, Littlewood-Evans A, Brueggen J, et 
al. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic 
BL16/BL6 murine melanoma model. Cancer Chemother Pharmacol. 2011;67: 
193-200. 
68.  Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, et 
al. Bevacizumab and everolimus in the treatment of patients with metastatic 
melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. 
Cancer. 2010;116: 4122-4129. 
69.  Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, et al. Phase II 
study evaluating the efficacy, safety, and pharmacodynamic correlative study of 
dual antiangiogenic inhibition using bevacizumab in combination with sorafenib 
in patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 
2014;74: 77-84. 
70.  Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, et al. Dual 
VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and 
pharmacodynamic biomarkers. Cancer Biol Ther. 2014;15: 975-981. 
71.  Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, et 
al. ERK1/2 is highly phosphorylated in melanoma metastases and protects 
melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol. 2007;127: 
2207-2215. 
72.  Ivanov VN, Hei TK. Combined treatment with EGFR inhibitors and arsenite 
upregulated apoptosis in human EGFR-positive melanomas: a role of suppression 
of the PI3K-AKT pathway. Oncogene. 2005;24: 616-626. 
73.  Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, et al. 
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin 
and temozolomide. J Invest Dermatol. 2009;129: 1500-1515. 
74.  Keuling AM, Andrew SE, Tron VA. Inhibition of p38 MAPK enhances ABT-
737-induced cell death in melanoma cell lines: novel regulation of PUMA. 
Pigment Cell Melanoma Res. 2010;23: 430-440. 
75.  Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper 
ZA, et al. Clinical profiling of BCL-2 family members in the setting of BRAF 
inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. 
PLoS One. 2014;9: e101286. 
76.  Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcala A, Chen YE, et al. 
Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses 
melanoma viability and tumor growth. Clin Cancer Res. 2013;19: 4383-4391. 
77.  Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, et al. MEK 
inhibition affects STAT3 signaling and invasion in human melanoma cell lines. 
Oncogene. 2014;33: 1850-1861. 
78.  Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of 
BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 
2012;2: 344-355. 
79.  Woodard J, Platanias LC. AMP-activated kinase (AMPK)-generated signals in 
malignant melanoma cell growth and survival. Biochem Biophys Res Commun. 
2010;398: 135-139. 
 97 
80.  Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, et al. 
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in 
melanoma cell lines with distinct driver mutations. J Transl Med. 2011;9: 76. 
81.  Sagoo MS, Harbour JW, Stebbing J, Bowcock AM. Combined PKC and MEK 
inhibition for treating metastatic uveal melanoma. Oncogene. 2014. 
82.  Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The protein kinase C 
inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS 
One. 2012;7: e29622. 
83.  Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, et al. Combined PKC and 
MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. 
Oncogene. 2013. 
84.  Wang J, Chen J, Miller DD, Li W. Synergistic combination of novel tubulin 
inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in 
BRAFV600E melanoma. Mol Cancer Ther. 2014;13: 16-26. 
85.  Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, et al. 
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted 
inhibition of Hsp90 with ganetespib. Mol Cancer Ther. 2014;13: 353-363. 
86.  Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, et al. The 
CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting 
from MAPK Reactivation and Cyclin D1 Upregulation. Mol Cancer Ther. 2014. 
87.  Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. 
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl 
J Med. 2010;363: 711-723. 
88.  Srivastava N, McDermott D. Update on benefit of immunotherapy and targeted 
therapy in melanoma: the changing landscape. Cancer Manag Res. 2014;6: 279-
289. 
89.  Riley JL. Combination checkpoint blockade--taking melanoma immunotherapy to 
the next level. N Engl J Med. 2013;369: 187-189. 
90.  Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of 
ipilimumab in melanoma and first data on new combination therapies. Curr Opin 
Oncol. 2013;25: 166-172. 
91.  Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et 
al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N 
Engl J Med. 2012;366: 2443-2454. 
92.  Shah DJ, Dronca RS. Latest advances in chemotherapeutic, targeted, and immune 
approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014;89: 
504-519. 
93.  Perez-Gracia JL, Labiano S, Rodriguez-Ruiz ME, Sanmamed MF, Melero I. 
Orchestrating immune check-point blockade for cancer immunotherapy in 
combinations. Curr Opin Immunol. 2014;27: 89-97. 
94.  Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety 
and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J 
Med. 2012;366: 2455-2465. 
95.  Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination 
blockade expands infiltrating T cells and reduces regulatory T and myeloid cells 
within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107: 4275-4280. 
 98 
96.  Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et 
al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369: 
122-133. 
97.  Kudchadkar RR, Gibney GT, Weber J, Chen A, Smith K, Merek S. A phase IB 
study of ipilimumab with peginterferon alfa-2b in patients with unresectable 
melanoma. Journal of Clinical Oncology. 2013;31. 
98.  Hodi FS, Lee SJ, McDermott DF, Rao UNM, Butterfield LH, Tarhini AA, et al. 
Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) 
versus ipi alone in metastatic melanoma: E1608. Journal of Clinical Oncology. 
2013;31. 
99.  Kwong ML, Neyns B, Yang JC. Adoptive T-cell transfer therapy and oncogene-
targeted therapy for melanoma: the search for synergy. Clin Cancer Res. 2013;19: 
5292-5299. 
100.  Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. 
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human 
Metastatic Melanoma. Clinical Cancer Research. 2012;18: 1386-1394. 
101.  Donia M, Fagone P, Nicoletti F, Andersen RS, Hogdall E, Straten PT, et al. 
BRAF inhibition improves tumor recognition by the immune system: Potential 
implications for combinatorial therapies against melanoma involving adoptive T-
cell transfer. Oncoimmunology. 2012;1: 1476-1483. 
102.  Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition 
increases tumor infiltration by T cells and enhances the antitumor activity of 
adoptive immunotherapy in mice. Clin Cancer Res. 2013;19: 393-403. 
103.  Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK 
in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that 
is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19: 598-609. 
104.  Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, et al. 
MEK inhibition, alone or in combination with BRAF inhibition, affects multiple 
functions of isolated normal human lymphocytes and dendritic cells. Cancer 
Immunol Res. 2014;2: 351-360. 
105.  Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with 
combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368: 1365-
1366. 
106.  Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, et al. 
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits 
V600E-positive melanomas. Pigment Cell Melanoma Res. 2010;23: 820-827. 
107.  Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 
(PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity 
in preclinical melanoma models. Cancer Res. 2010;70: 5518-5527. 
108.  Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. 
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of 
BRAF-mutant colorectal cancer. Cancer Res. 2012;72: 779-789. 
109.  Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 
pathway inhibitors. Oncogene. 2012. 
 99 
110.  Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of 
a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 
2010;467: 596-599. 
111.  Flaherty KT. Targeting metastatic melanoma. Annu Rev Med. 2012;63: 171-183. 
112.  Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-
exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-
RAF inhibitor resistance. Nat Commun. 2012;3: 724. 
113.  Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, et al. 
Elevated CRAF as a potential mechanism of acquired resistance to BRAF 
inhibition in melanoma. Cancer Res. 2008;68: 4853-4861. 
114.  Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire 
resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 
2010;468: 973-977. 
115.  Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-
Duvaz D, et al. Inhibiting EGF Receptor or SRC Family Kinase Signaling 
Overcomes BRAF Inhibitor Resistance in Melanoma. Cancer Discov. 2013;3: 
158-167. 
116.  Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, et al. 
Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl 
Med. 2010;2: 35ra41. 
117.  Balzano D, Santaguida S, Musacchio A, Villa F. A general framework for 
inhibitor resistance in protein kinases. Chem Biol. 2011;18: 966-975. 
118.  Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to 
tyrosine kinase targeted therapy. Mol Cancer. 2010;9: 75. 
119.  Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread 
potential for growth-factor-driven resistance to anticancer kinase inhibitors. 
Nature. 2012;487: 505-509. 
120.  Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. 
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced 
BRAF(V600E). Nature. 2011;480: 387-390. 
121.  Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J. Single agent versus 
combination chemotherapy for metastatic breast cancer. Cochrane Database Syst 
Rev. 2005: CD003372. 
122.  Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. 
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 
2012;366: 2189-2197. 
123.  Pannu V, Karna P, Sajja HK, Shukla D, Aneja R. Synergistic antimicrotubule 
therapy for prostate cancer. Biochem Pharmacol. 2011;81: 478-487. 
124.  Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, et al. Clinical 
responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy 
stratified by gene mutations in patients with metastatic melanoma. Cancer. 2012. 
125.  Chen J, Li CM, Wang J, Ahn S, Wang Z, Lu Y, et al. Synthesis and 
antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting 
tubulin polymerization. Bioorg Med Chem. 2011;19: 4782-4795. 
 100 
126.  Chen J, Wang Z, Li CM, Lu Y, Vaddady PK, Meibohm B, et al. Discovery of 
novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin 
as potential anticancer agents. J Med Chem. 2010;53: 7414-7427. 
127.  Chen J, Ahn S, Wang J, Lu Y, Dalton JT, Miller DD, et al. Discovery of novel 2-
aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as 
antiproliferative agents. J Med Chem. 2012;55: 7285-7289. 
128.  Li CM, Lu Y, Chen J, Costello TA, Narayanan R, Dalton MN, et al. Orally 
bioavailable tubulin antagonists for paclitaxel-refractory cancer. Pharm Res. 
2012;29: 3053-3063. 
129.  Wang Z, Chen J, Wang J, Ahn S, Li CM, Lu Y, et al. Novel tubulin 
polymerization inhibitors overcome multidrug resistance and reduce melanoma 
lung metastasis. Pharm Res. 2012;29: 3040-3052. 
130.  Chou TC. Drug combination studies and their synergy quantification using the 
Chou-Talalay method. Cancer Res. 2010;70: 440-446. 
131.  Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, et al. 
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF 
and MEK inhibitors in melanoma. Cell Rep. 2013;4: 1090-1099. 
132.  Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the 
first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11: 
873-886. 
133.  Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, et al. The 
HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through 
diverse mechanisms. Clin Cancer Res. 2012;18: 2502-2514. 
134.  Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, et al. 
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell 
immunotherapy. Cancer Res. 2012;72: 3928-3937. 
135.  Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway 
in cancer therapy. Expert Opin Ther Targets. 2012;16: 121-130. 
136.  Liu R, Liu D, Xing M. The Akt inhibitor MK2206 synergizes, but perifosine 
antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor 
AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab. 
2012;97: E173-182. 
137.  Krishnegowda G, Prakasha Gowda AS, Tagaram HR, Carroll KF, Irby RB, 
Sharma AK, et al. Synthesis and biological evaluation of a novel class of isatin 
analogs as dual inhibitors of tubulin polymerization and Akt pathway. Bioorg 
Med Chem. 2011;19: 6006-6014. 
138.  Viola G, Bortolozzi R, Hamel E, Moro S, Brun P, Castagliuolo I, et al. MG-2477, 
a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR 
pathway and delayed apoptosis in A549 cells. Biochem Pharmacol. 2012;83: 16-
26. 
139.  Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, et al. S9, a novel 
anticancer agent, exerts its anti-proliferative activity by interfering with both 
PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS One. 2009;4: 
e4881. 
140.  Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene. 
2003;22: 9075-9086. 
 101 
141.  Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, 
et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase 
inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and 
tumor regression when combined with docetaxel. Clin Cancer Res. 2008;14: 230-
239. 
142.  Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, 
expressed in cancer and lymphoma. Nat Med. 1997;3: 917-921. 
143.  Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer 
therapy. Cancer Treat Rev. 2009;35: 553-562. 
144.  Sun C, Nettesheim D, Liu Z, Olejniczak ET. Solution structure of human survivin 
and its binding interface with Smac/Diablo. Biochemistry. 2005;44: 11-17. 
145.  Wendt MD, Sun C, Kunzer A, Sauer D, Sarris K, Hoff E, et al. Discovery of a 
novel small molecule binding site of human survivin. Bioorg Med Chem Lett. 
2007;17: 3122-3129. 
146.  Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat 
Rev Cancer. 2008;8: 61-70. 
147.  Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-
family protein survivin inhibits caspase activity and apoptosis induced by Fas 
(CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58: 5315-5320. 
148.  Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. 
Expression of survivin is correlated with cancer cell apoptosis and is involved in 
the development of human pancreatic duct cell tumors. Cancer. 2001;92: 271-278. 
149.  Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, et al. 
Expression of survivin correlates with apoptosis, proliferation, and angiogenesis 
during human colorectal tumorigenesis. Cancer. 2001;91: 2026-2032. 
150.  Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013;332: 225-228. 
151.  Bates DJ, Lewis LD. Manipulating the apoptotic pathway: potential therapeutics 
for cancer patients. Br J Clin Pharmacol. 2013;76: 381-395. 
152.  Athanasoula K, Gogas H, Polonifi K, Vaiopoulos AG, Polyzos A, Mantzourani 
M. Survivin beyond physiology: orchestration of multistep carcinogenesis and 
therapeutic potentials. Cancer Lett. 2014;347: 175-182. 
153.  Singh N, Subramanian K, Kanwar RK, Cheung CH, Kanwar JR. Clinical aspects 
for survivin: a crucial molecule for targeting drug-resistant cancers. Drug Discov 
Today. 2014. 
154.  Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al. Survivin - 
biology and potential as a therapeutic target in oncology. Onco Targets Ther. 
2013;6: 1453-1462. 
155.  Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CH. Treat cancers by 
targeting survivin: just a dream or future reality? Cancer Treat Rev. 2013;39: 802-
811. 
156.  Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert 
Opin Ther Targets. 2008;12: 463-476. 
157.  Mamori S, Asakura T, Ohkawa K, Tajiri H. Survivin expression in early 
hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic 
culture condition. World J Gastroenterol. 2007;13: 5306-5311. 
 102 
158.  Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, et al. 
Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A. 2003;100: 
13791-13796. 
159.  Cheung CH, Chen HH, Cheng LT, Lyu KW, Kanwar JR, Chang JY. Targeting 
Hsp90 with small molecule inhibitors induces the over-expression of the anti-
apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. 
Mol Cancer. 2010;9: 77. 
160.  Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between 
epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal 
pathways increases resistance to apoptosis by up-regulating survivin gene 
expression. J Biol Chem. 2006;281: 25903-25914. 
161.  Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, et al. 
Survivin expression is regulated by coexpression of human epidermal growth 
factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-
kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005;65: 
11018-11025. 
162.  Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, et 
al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting 
survivin overcomes imatinib resistance and increases imatinib sensitivity in 
imatinib-responsive CML cells. Blood. 2006;107: 1555-1563. 
163.  Okuya M, Kurosawa H, Kikuchi J, Furukawa Y, Matsui H, Aki D, et al. Up-
regulation of survivin by the E2A-HLF chimera is indispensable for the survival 
of t(17;19)-positive leukemia cells. J Biol Chem. 2010;285: 1850-1860. 
164.  Sommer KW, Rodgarkia-Dara CJ, Schreiner C, Holzmann K, Krupitza G, Cerni 
C. Oncogenic c-H-ras deregulates survivin expression: an improvement for 
survival. FEBS Lett. 2007;581: 4921-4926. 
165.  Nabilsi NH, Broaddus RR, Loose DS. DNA methylation inhibits p53-mediated 
survivin repression. Oncogene. 2009;28: 2046-2050. 
166.  Erkanli S, Kayaselcuk F, Kuscu E, Bagis T, Bolat F, Haberal A, et al. Expression 
of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous 
endometrium. Int J Gynecol Cancer. 2006;16: 1412-1418. 
167.  Guha M, Plescia J, Leav I, Li J, Languino LR, Altieri DC. Endogenous tumor 
suppression mediated by PTEN involves survivin gene silencing. Cancer Res. 
2009;69: 4954-4958. 
168.  Ku JH, Godoy G, Amiel GE, Lerner SP. Urine survivin as a diagnostic biomarker 
for bladder cancer: a systematic review. BJU Int. 2012;110: 630-636. 
169.  Santa Cruz Guindalini R, Mathias Machado MC, Garicochea B. Monitoring 
survivin expression in cancer: implications for prognosis and therapy. Mol Diagn 
Ther. 2013;17: 331-342. 
170.  Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-
proteasome pathway regulates survivin degradation in a cell cycle-dependent 
manner. J Cell Sci. 2000;113 Pt 23: 4363-4371. 
171.  White-Gilbertson S, Kurtz DT, Voelkel-Johnson C. The role of protein synthesis 
in cell cycling and cancer. Mol Oncol. 2009;3: 402-408. 
 103 
172.  Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. 
Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)-XAF1 
complex. J Biol Chem. 2007;282: 26202-26209. 
173.  Esteve PO, Chin HG, Pradhan S. Human maintenance DNA (cytosine-5)-
methyltransferase and p53 modulate expression of p53-repressed promoters. Proc 
Natl Acad Sci U S A. 2005;102: 1000-1005. 
174.  Wang Z, Fukuda S, Pelus LM. Survivin regulates the p53 tumor suppressor gene 
family. Oncogene. 2004;23: 8146-8153. 
175.  Vegran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. 
Association of p53 gene alterations with the expression of antiapoptotic survivin 
splice variants in breast cancer. Oncogene. 2007;26: 290-297. 
176.  Xu R, Zhang P, Huang J, Ge S, Lu J, Qian G. Sp1 and Sp3 regulate basal 
transcription of the survivin gene. Biochem Biophys Res Commun. 2007;356: 
286-292. 
177.  Chen Y, Wang X, Li W, Zhang H, Zhao C, Li Y, et al. Sp1 upregulates survivin 
expression in adenocarcinoma of lung cell line A549. Anat Rec (Hoboken). 
2011;294: 774-780. 
178.  Obexer P, Hagenbuchner J, Unterkircher T, Sachsenmaier N, Seifarth C, Bock G, 
et al. Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human 
neuroblastoma cells to DNA damage-induced apoptosis. Mol Biol Cell. 2009;20: 
2041-2048. 
179.  Hagenbuchner J, Kuznetsov AV, Obexer P, Ausserlechner MJ. BIRC5/Survivin 
enhances aerobic glycolysis and drug resistance by altered regulation of the 
mitochondrial fusion/fission machinery. Oncogene. 2013;32: 4748-4757. 
180.  Kramer OH, Baus D, Knauer SK, Stein S, Jager E, Stauber RH, et al. Acetylation 
of Stat1 modulates NF-kappaB activity. Genes Dev. 2006;20: 473-485. 
181.  Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, 
Koca C, et al. Signal transducer and activator of transcription-3, inflammation, 
and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009;1171: 59-
76. 
182.  Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012;149: 
1192-1205. 
183.  Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. Regulation of 
survivin expression by IGF-1/mTOR signaling. Oncogene. 2007;26: 2678-2684. 
184.  O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, et al. Regulation of 
apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad 
Sci U S A. 2000;97: 13103-13107. 
185.  Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein 
kinase A regulates cytoprotection. Mol Cell. 2007;27: 17-28. 
186.  Chu Y, Yao PY, Wang W, Wang D, Wang Z, Zhang L, et al. Aurora B kinase 
activation requires survivin priming phosphorylation by PLK1. J Mol Cell Biol. 
2011;3: 260-267. 
187.  Wang H, Holloway MP, Ma L, Cooper ZA, Riolo M, Samkari A, et al. 
Acetylation directs survivin nuclear localization to repress STAT3 oncogenic 
activity. J Biol Chem. 2010;285: 36129-36137. 
 104 
188.  Riolo MT, Cooper ZA, Holloway MP, Cheng Y, Bianchi C, Yakirevich E, et al. 
Histone deacetylase 6 (HDAC6) deacetylates survivin for its nuclear export in 
breast cancer. J Biol Chem. 2012;287: 10885-10893. 
189.  Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr 
Opin Cell Biol. 2006;18: 616-622. 
190.  Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the 
(aurora) ABCs of mitosis. Trends Cell Biol. 2001;11: 49-54. 
191.  Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, et al. An anti-apoptotic 
protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 
2001;40: 1117-1123. 
192.  Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is 
essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. 
J Biol Chem. 2003;278: 23130-23140. 
193.  Oikawa T, Unno Y, Matsuno K, Sawada J, Ogo N, Tanaka K, et al. Identification 
of a small-molecule inhibitor of the interaction between Survivin and 
Smac/DIABLO. Biochem Biophys Res Commun. 2010;393: 253-258. 
194.  Du J, Kelly AE, Funabiki H, Patel DJ. Structural basis for recognition of H3T3ph 
and Smac/DIABLO N-terminal peptides by human Survivin. Structure. 2012;20: 
185-195. 
195.  Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL, et al. 
Silencing survivin gene expression promotes apoptosis of human breast cancer 
cells through a caspase-independent pathway. J Cell Biochem. 2008;105: 381-
390. 
196.  Kelly AE, Sampath SC, Maniar TA, Woo EM, Chait BT, Funabiki H. 
Chromosomal enrichment and activation of the aurora B pathway are coupled to 
spatially regulate spindle assembly. Dev Cell. 2007;12: 31-43. 
197.  Kelly AE, Ghenoiu C, Xue JZ, Zierhut C, Kimura H, Funabiki H. Survivin reads 
phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. 
Science. 2010;330: 235-239. 
198.  Jiang G, Ren B, Xu L, Song S, Zhu C, Ye F. Survivin may enhance DNA double-
strand break repair capability by up-regulating Ku70 in human KB cells. 
Anticancer Res. 2009;29: 223-228. 
199.  Hu S, Qu Y, Xu X, Xu Q, Geng J, Xu J. Nuclear survivin and its relationship to 
DNA damage repair genes in non-small cell lung cancer investigated using tissue 
array. PLoS One. 2013;8: e74161. 
200.  Chang YJ, Li LT, Chen HA, Hung CS, Wei PL. Silencing survivin activates 
autophagy as an alternative survival pathway in HCC cells. Tumour Biol. 
2014;35: 9957-9966. 
201.  Niu TK, Cheng Y, Ren X, Yang JM. Interaction of Beclin 1 with survivin 
regulates sensitivity of human glioma cells to TRAIL-induced apoptosis. FEBS 
Lett. 2010;584: 3519-3524. 
202.  Rauch A, Hennig D, Schafer C, Wirth M, Marx C, Heinzel T, et al. Survivin and 
YM155: how faithful is the liaison? Biochim Biophys Acta. 2014;1845: 202-220. 
  
 105 
203.  Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, et al. Multicenter 
phase II trial of YM155, a small-molecule suppressor of survivin, in patients with 
advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27: 4481-
4486. 
204.  Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, et al. 
YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and 
tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer 
Drugs. 2011;22: 454-462. 
205.  Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, et al. 
Phase I study of YM155, a novel survivin suppressant, in patients with advanced 
solid tumors. Clin Cancer Res. 2009;15: 3872-3880. 
206.  Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, et al. 
Antitumor activity of YM155, a selective small-molecule survivin suppressant, 
alone and in combination with docetaxel in human malignant melanoma models. 
Clin Cancer Res. 2011;17: 5423-5431. 
207.  Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. YM155, 
a novel small-molecule survivin suppressant, induces regression of established 
human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67: 
8014-8021. 
208.  Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F. A novel small molecule 
FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-
independent manner, shows superior antitumor activity. PLoS One. 2012;7: 
e45571. 
209.  Zhao J, Ling X, Cao S, Liu X, Wan S, Jiang T, et al. Antitumor activity of FL118, 
a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its 
primary structure and steric configuration. Mol Pharm. 2014;11: 457-467. 
210.  Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with 
anticancer activity. IDrugs. 2008;11: 204-214. 
211.  Khanna N, Dalby R, Tan M, Arnold S, Stern J, Frazer N. Phase I/II clinical safety 
studies of terameprocol vaginal ointment. Gynecol Oncol. 2007;107: 554-562. 
212.  Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Supko JG, et al. 
Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro 
Oncol. 2012;14: 511-517. 
213.  Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, et al. 
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J 
Natl Cancer Inst. 2006;98: 1068-1077. 
214.  Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, et al. Rational 
design of shepherdin, a novel anticancer agent. Cancer Cell. 2005;7: 457-468. 
215.  Meli M, Pennati M, Curto M, Daidone MG, Plescia J, Toba S, et al. Small-
molecule targeting of heat shock protein 90 chaperone function: rational 
identification of a new anticancer lead. J Med Chem. 2006;49: 7721-7730. 
216.  Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of 
survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. 
Cancer Res. 2003;63: 230-235. 
  
 106 
217.  Pennati M, Campbell AJ, Curto M, Binda M, Cheng Y, Wang LZ, et al. 
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase 
inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 
2005;4: 1328-1337. 
218.  Villerbu N, Gaben AM, Redeuilh G, Mester J. Cellular effects of purvalanol A: a 
specific inhibitor of cyclin-dependent kinase activities. Int J Cancer. 2002;97: 
761-769. 
219.  Iizuka D, Ogura A, Kuwabara M, Inanami O. Purvalanol A induces apoptosis and 
downregulation of antiapoptotic proteins through abrogation of phosphorylation 
of JAK2/STAT3 and RNA polymerase II. Anticancer Drugs. 2008;19: 565-572. 
220.  Lee HG, Baek JW, Shin SJ, Kwon SH, Cha SD, Park WJ, et al. Antitumor effects 
of flavopiridol on human uterine leiomyoma in vitro and in a xenograft model. 
Reprod Sci. 2014;21: 1153-1160. 
221.  Jain SK, Bharate SB, Vishwakarma RA. Cyclin-dependent kinase inhibition by 
flavoalkaloids. Mini Rev Med Chem. 2012;12: 632-649. 
222.  Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK. 
Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer 
Ther. 2011;10: 221-232. 
223.  Talbot DC, Ranson M, Davies J, Lahn M, Callies S, Andre V, et al. Tumor 
survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-
of-concept, first-in-human dose study. Clin Cancer Res. 2010;16: 6150-6158. 
224.  Wiechno P, Somer BG, Mellado B, Chlosta PL, Cervera Grau JM, Castellano D, 
et al. A randomised phase 2 study combining LY2181308 sodium (survivin 
antisense oligonucleotide) with first-line docetaxel/prednisone in patients with 
castration-resistant prostate cancer. Eur Urol. 2014;65: 516-520. 
225.  Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, et al. 
SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther. 2008;7: 2736-
2745. 
226.  Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM, Horak ID. Down-
modulation of survivin expression and inhibition of tumor growth in vivo by 
EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides 
Nucleotides Nucleic Acids. 2010;29: 97-112. 
227.  Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, et 
al. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid 
(mRNA) antagonist, administered in combination with chemotherapy in children 
with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic 
advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr 
Hematol Oncol. 2014;36: 458-463. 
228.  Aspe JR, Wall NR. Survivin-T34A: molecular mechanism and therapeutic 
potential. Onco Targets Ther. 2010;3: 247-254. 
229.  Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor 
growth in vivo by survivin targeting. Proc Natl Acad Sci U S A. 2001;98: 635-
640. 
230.  Yan H, Thomas J, Liu T, Raj D, London N, Tandeski T, et al. Induction of 
melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable 
Survivin antagonist. Oncogene. 2006;25: 6968-6974. 
 107 
231.  Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of 
survivin antagonists on growth of established tumors and B7-1 immunogene 
therapy. J Natl Cancer Inst. 2001;93: 1541-1552. 
232.  Baratchi S, Kanwar RK, Kanwar JR. Novel survivin mutant protects 
differentiated SK-N-SH human neuroblastoma cells from activated T-cell 
neurotoxicity. J Neuroimmunol. 2011;233: 18-28. 
233.  Baratchi S, Kanwar RK, Cheung CH, Kanwar JR. Proliferative and protective 
effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol. 2010;227: 
120-132. 
234.  Roy K, Kanwar RK, Krishnakumar S, Cheung CH, Kanwar JR. Competitive 
inhibition of survivin using a cell-permeable recombinant protein induces cancer-
specific apoptosis in colon cancer model. Int J Nanomedicine. 2015;10: 1019-
1043. 
235.  Zhang R, Wang T, Li KN, Qin WW, Chen R, Wang K, et al. A survivin double 
point mutant has potent inhibitory effect on the growth of hepatocellular cancer 
cells. Cancer Biol Ther. 2008;7: 547-554. 
236.  Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, et al. 
Pleiotropic cell-division defects and apoptosis induced by interference with 
survivin function. Nat Cell Biol. 1999;1: 461-466. 
237.  Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted 
agents: highlights of the 2008 American society of clinical oncology meeting. J 
Hematol Oncol. 2008;1: 20. 
238.  Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, et al. Silencing 
of survivin gene by small interfering RNAs produces supra-additive growth 
suppression in combination with 17-allylamino-17-demethoxygeldanamycin in 
human prostate cancer cells. Mol Cancer Ther. 2006;5: 179-186. 
239.  Zhen HN, Li LW, Zhang W, Fei Z, Shi CH, Yang TT, et al. Short hairpin RNA 
targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J 
Oncol. 2007;31: 1111-1117. 
240.  Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer 
treatments: perspectives for new therapeutic interventions. Drug Resist Updat. 
2002;5: 65-72. 
241.  Iwai M, Minematsu T, Li Q, Iwatsubo T, Usui T. Utility of P-glycoprotein and 
organic cation transporter 1 double-transfected LLC-PK1 cells for studying the 
interaction of YM155 monobromide, novel small-molecule survivin suppressant, 
with P-glycoprotein. Drug Metab Dispos. 2011;39: 2314-2320. 
242.  Guenova ML, Balatzenko GN, Nikolova VR, Spassov BV, Konstantinov SM. An 
anti-apoptotic pattern correlates with multidrug resistance in acute myeloid 
leukemia patients: a comparative study of active caspase-3, cleaved PARPs, Bcl-
2, Survivin and MDR1 gene. Hematology. 2010;15: 135-143. 
243.  Baytekin F, Tuna B, Mungan U, Aslan G, Yorukoglu K. Significance of P-
glycoprotein, p53, and survivin expression in renal cell carcinoma. Urol Oncol. 
2011;29: 502-507. 
244.  Imai Y, Yamagishi H, Ono Y, Ueda Y. Versatile inhibitory effects of the 
flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette 
transporters that characterize stem cells. Clin Transl Med. 2012;1: 24. 
 108 
245.  Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. 
Nat Rev Drug Discov. 2012;11: 109-124. 
246.  Wu H, Panakanti R, Li F, Mahato RI. XIAP gene expression protects beta-cells 
and human islets from apoptotic cell death. Mol Pharm. 2010;7: 1655-1666. 
247.  Tian F, Lee SW. X-linked inhibitor of apoptosis protein as a therapeutic target in 
metastatic melanoma. J Invest Dermatol. 2010;130: 2169-2172. 
248.  Wang S. Design of small-molecule Smac mimetics as IAP antagonists. Curr Top 
Microbiol Immunol. 2011;348: 89-113. 
249.  Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP 
recognition by Smac/DIABLO. Nature. 2000;408: 1008-1012. 
250.  de Almagro MC, Vucic D. The inhibitor of apoptosis (IAP) proteins are critical 
regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol. 
2012;34: 200-211. 
251.  Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, et al. Discovery of 
a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and 
clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012;55: 
4101-4113. 
252.  Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a 
novel, bivalent Smac mimetic that induces apoptosis and tumor regression by 
concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008;68: 
9384-9393. 
253.  Nikolovska-Coleska Z, Meagher JL, Jiang S, Kawamoto SA, Gao W, Yi H, et al. 
Design and characterization of bivalent Smac-based peptides as antagonists of 
XIAP and development and validation of a fluorescence polarization assay for 
XIAP containing both BIR2 and BIR3 domains. Anal Biochem. 2008;374: 87-98. 
254.  Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, et al. Discovery of 
embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through 
structure-based computational screening of a traditional herbal medicine three-
dimensional structure database. J Med Chem. 2004;47: 2430-2440. 
255.  Peng Y, Sun H, Lu J, Liu L, Cai Q, Shen R, et al. Bivalent Smac mimetics with a 
diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel 
anticancer agents. J Med Chem. 2012;55: 106-114. 
256.  Sun H, Nikolovska-Coleska Z, Lu J, Meagher JL, Yang CY, Qiu S, et al. Design, 
synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent 
Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in 
XIAP. J Am Chem Soc. 2007;129: 15279-15294. 
257.  Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, et al. The novel 
SMAC mimetic birinapant exhibits potent activity against human melanoma cells. 
Clin Cancer Res. 2013;19: 1784-1794. 
258.  Vucic D, Franklin MC, Wallweber HJ, Das K, Eckelman BP, Shin H, et al. 
Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: 
implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J. 
2005;385: 11-20. 
259.  Xiao M, Ahn S, Wang J, Chen J, Miller DD, Dalton JT, et al. Discovery of 4-
Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent 
antiproliferative properties. J Med Chem. 2013;56: 3318-3329. 
 109 
260.  Sastry GM, Dixon SL, Sherman W. Rapid shape-based ligand alignment and 
virtual screening method based on atom/feature-pair similarities and volume 
overlap scoring. J Chem Inf Model. 2011;51: 2455-2466. 
261.  Hiscutt EL, Hill DS, Martin S, Kerr R, Harbottle A, Birch-Machin M, et al. 
Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of 
endoplasmic reticulum stress-induced apoptosis for melanoma therapy. J Invest 
Dermatol. 2010;130: 2250-2258. 
262.  Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF. YM-155 
potentiates the effect of ABT-737 in malignant human glioma cells via survivin 
and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther. 
2013;12: 326-338. 
263.  Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 
2010;430: 199-205. 
264.  Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the 
cell-signalling perspective. Drug Discov Today. 2011;16: 485-494. 
265.  Pavlyukov MS, Antipova NV, Balashova MV, Vinogradova TV, Kopantzev EP, 
Shakhparonov MI. Survivin monomer plays an essential role in apoptosis 
regulation. J Biol Chem. 2011;286: 23296-23307. 
266.  Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal 
adult tissues. Mol Cancer Ther. 2006;5: 1087-1098. 
267.  McKenzie JA, Grossman D. Role of the apoptotic and mitotic regulator survivin 
in melanoma. Anticancer Res. 2012;32: 397-404. 
268.  Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, et al. 
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung 
cancer cells by targeting survivin. Mol Cancer Ther. 2012;11: 204-213. 
269.  Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Lin Q, et al. Expression of survivin 
and bax/bcl-2 in peroxisome proliferator activated receptor-gamma ligands 
induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol. 2005;16: 
455-459. 
270.  Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, et al. TW-37, a 
small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in 
pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res. 
2009;69: 2757-2765. 
271.  Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted 
BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low 
ABCB1 expression. European Journal of Cancer. 2012;48: 763-771. 
272.  Cheng Q, Ling X, Haller A, Nakahara T, Yamanaka K, Kita A, et al. Suppression 
of survivin promoter activity by YM155 involves disruption of Sp1-DNA 
interaction in the survivin core promoter. Int J Biochem Mol Biol. 2012;3: 179-
197. 
273.  Wang J, Li W. Discovery of novel second mitochondria-derived activator of 
caspase mimetics as selective inhibitor of apoptosis protein inhibitors. J 
Pharmacol Exp Ther. 2014;349: 319-329. 
274.  Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat 
Rev Cancer. 2006;6: 813-823. 
 110 
275.  Lomenick B, Jung G, Wohlschlegel JA, Huang J. Target identification using drug 
affinity responsive target stability (DARTS). Curr Protoc Chem Biol. 2011;3: 
163-180. 
276.  Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target 
identification using drug affinity responsive target stability (DARTS). Proc Natl 
Acad Sci U S A. 2009;106: 21984-21989. 
277.  Lu Y, Chen J, Wang J, Li CM, Ahn S, Barrett CM, et al. Design, synthesis, and 
biological evaluation of stable colchicine binding site tubulin inhibitors as 
potential anticancer agents. J. Med. Chem. 2014;57: 7355-7366. 
278.  Leonessa F, Green D, Licht T, Wright A, Wingate-Legette K, Lippman J, et al. 
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast 
cancer. Br J Cancer. 1996;73: 154-161. 
279.  Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and 
silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003;304: 
1258-1267. 
280.  Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, et al. 
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug 
resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009;69: 
3918-3926. 
281.  Uchiyama-Kokubu N, Watanabe T. Establishment and characterization of 
adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with 
multidrug resistance. Anticancer Drugs. 2001;12: 769-779. 
282.  angthong S, Ha H, Teerawattananon T, Ngamrojanavanich N, Neamati N, 
Muangsin N. Overcoming doxorubicin-resistance in the NCI/ADR-RES model 
cancer cell line by novel anthracene-9,10-dione derivatives. Bioorg Med Chem 
Lett. 2013;23: 6156-6160. 
 
 
 
 111 
VITA 
 
 
 Jin Wang was born in Anhui Province, China in 1988. She attended the Sun Yat-
sen University from Year 2005 to 2009 and received a Bachelor of Science degree in 
pharmacy. Then she joined the graduate program in the Department of Pharmaceutical 
Sciences, the University of Tennessee Health Science Center, from where she will 
receive her Ph.D degree under the supervision of Professor Dr. Wei Li. 
 
 
